Details of Drug-Metabolizing Enzyme (DME)

General Information of DME (ID: DME0001)
DME Name	Cytochrome P450 3A4 (CYP3A4), Homo sapiens
Synonyms	Cytochrome P450 family 3 subfamily A member 4; Quinine 3-monooxygenase; 1,4-cineole 2-exo-monooxygenase; 1,8-cineole 2-exo-monooxygenase; Albendazole monooxygenase (sulfoxide-forming); Albendazole sulfoxidase; CYP3A3; CYP3A4; CYPIIIA3; CYPIIIA4; Cholesterol 25-hydroxylase; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase
Gene Name	CYP3A4
UniProt ID	CP3A4_HUMAN
Gene ID	1576
EC Number	EC: 1.14.14.55 (Click to Show/Hide the Complete EC Tree) Oxidoreductase Oxygen paired donor oxidoreductase Flavin/flavoprotein donor oxidoreductase EC: 1.14.14.55
Lineage	Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Interactome (loading-time for this interactome depdends on the speed of web connection)
Interactions between Microbiome and DME (MICBIO) Jump to Detailed Interactome Data
Interactions between Xenobiotics and DME (XEOTIC) Jump to Detailed Interactome Data
Interactions between Host Protein and DME (HOSPPI) Jump to Detailed Interactome Data

Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME
Sequence	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA
Structure	1W0F ; 1W0G ; 2J0D ; 2V0M ; 3NXU ; 3TJS ; 3UA1 ; 4D6Z ; 4D75
Pathway	Bile secretion (hsa04976 )
	Chemical carcinogenesis (hsa05204 )
	Drug metabolism - cytochrome P450 (hsa00982 )
	Drug metabolism - other enzymes (hsa00983 )
	Linoleic acid metabolism (hsa00591 )
	Metabolic pathways (hsa01100 )
	Metabolism of xenobiotics by cytochrome P450 (hsa00980 )
	Retinol metabolism (hsa00830 )
	Steroid hormone biosynthesis (hsa00140 )
Function	This enzyme is involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids. It exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta- estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position and plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone. It also metabolizes testosterone to less biologically active 2beta- and 6beta- hydroxytestosterones. It catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) and the epoxidation of double bonds of PUFA with a preference for the last double bond. It metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15- epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs) and plays a role in the metabolism of retinoids.In addition, it displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate- limiting step for the biosynthesis of all-trans-retinoic acid (atRA) and further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance. It is also responsible for oxidative metabolism of xenobiotics. It metabolizes the majority of the administered drugs; catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole and hydroxylates antimalarial drug quinine.

Full List of Drug(s) Metabolized by This DME
Drugs Approved by FDA			Click to Show/Hide the Full List of Drugs: 719 Drugs
Cobicistat	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[1]
Darolutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[2]
Bupropion	Drug Info	Approved	Nicotine dependence	ICD11: 6C4A	[3]
Tamoxifen citrate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[4]
Yn-968D1	Drug Info	Approved	Breast cancer	ICD11: 2C60-2C6Y	[5]
Erlotinib hydrochloride	Drug Info	Approved	Lung cancer	ICD11: 2C25	[6]
Alosetron hydrochloride	Drug Info	Approved	Irritable bowel syndrome	ICD11: DD91	[7]
Arbidol	Drug Info	Approved	Virus infection	ICD11: 1A24-1D9Z	[8]
Fostemsavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60-1C62	[9]
Fostemsavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60-1C62	[10]
Idelalisib	Drug Info	Approved	Chronic lymphocytic leukaemia	ICD11: 2A82	[11]
Warfarin sodium	Drug Info	Approved	Atrial fibrillation	ICD11: BC81	[12]
Estradiol acetate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[13]
Estradiol cypionate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[13]
Estradiol valerate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[13]
Estrone	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[14]
Nicotine	Drug Info	Approved	Nicotine dependence	ICD11: 6C4A	[15]
Apremilast	Drug Info	Approved	Psoriasis vulgaris	ICD11: EA90	[16]
Atazanavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[17]
Cocaine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[18]
Palbociclib	Drug Info	Approved	Breast cancer	ICD11: 2C60	[19]
Pimavanserin	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[20]
Apalutamide	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[21]
Capmatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[22]
Capmatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[23]
Dronabinol	Drug Info	Approved	Anorexia nervosa	ICD11: 6B80	[24]
Ozanimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[25]
Betamethasone	Drug Info	Approved	Inflammation	ICD11: 1A00-CA43	[26]
Bortezomib	Drug Info	Approved	Breast cancer	ICD11: 2C60	[27]
Daclatasvir dihydrochloride	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[28]
Delavirdine mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[29]
Diclofenac sodium	Drug Info	Approved	Osteoarthritis	ICD11: FA00	[30]
Hydrocodone	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[31]
Prednisolone	Drug Info	Approved	Multiple myeloma	ICD11: 2A83	[32]
Prednisone	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[32]
Amlodipine besylate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[33]
Amlodipine maleate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[33]
Galantamine hydrobromide	Drug Info	Approved	Alzheimer disease	ICD11: 8A20	[34]
Ibrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[35]
Ketoconazole	Drug Info	Approved	Dermatophytosis	ICD11: 1F28	[36]
Loxoprofen gel	Drug Info	Approved	Inflammation	ICD11: 1A00-CA43	[37]
Metoclopramide hydrochloride	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[38]
Montelukast sodium	Drug Info	Approved	Asthma	ICD11: CA23	[24]
Naloxone	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[39]
Primaquine	Drug Info	Approved	Malaria	ICD11: 1F40	[40]
Progesterone	Drug Info	Approved	Premature labour	ICD11: JB00	[41]
Rosiglitazone	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[42]
Acalabrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[43]
Almogran	Drug Info	Approved	Migraine	ICD11: 8A80	[44]
Almogran	Drug Info	Approved	Migraine	ICD11: 8A80	[45], [46]
Crizotinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[47]
Imatinib mesylate	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[48]
Lidocaine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[49]
Linagliptin	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[50]
Linagliptin	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[51]
Metronidazole	Drug Info	Approved	Amebiasis	ICD11: 1A36	[52]
Temsirolimus	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[53]
Valdecoxib	Drug Info	Approved	Osteoarthritis	ICD11: FA00	[54]
Brivaracetam	Drug Info	Approved	Focal seizure	ICD11: 8A68	[55]
Cannabidiol	Drug Info	Approved	Lennox-Gastaut syndrome	ICD11: 8A62	[56]
Capsaicin	Drug Info	Approved	Herpes zoster	ICD11: 1E91	[57]
Ciclosporin	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[58]
Ciclosporin	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[59]
Clomipramine hydrochloride	Drug Info	Approved	Obsessive-compulsive disorder	ICD11: 6B20	[60]
Doravirine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[61]
Doxazosin	Drug Info	Approved	Essential hypertension	ICD11: BA00	[62]
Ethinyl estradiol	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[63]
Fedratinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[64], [65]
Ifosfamide	Drug Info	Approved	Lung cancer	ICD11: 2C25	[24]
Irbesartan	Drug Info	Approved	Essential hypertension	ICD11: BA00	[66]
Lapatinib ditosylate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[67]
Lenvatinib mesylate	Drug Info	Approved	Thyroid cancer	ICD11: 2D10	[68]
Mycophenolate mofetil	Drug Info	Approved	Crohn disease	ICD11: DD70	[69]
Pitavastatin	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[70]
Silodosin	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[71]
Siponimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[72]
Sunitinib malate	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[6]
Sunitinib malate	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[73]
Tacrolimus	Drug Info	Approved	Ulcerative colitis	ICD11: DD71	[18]
Terbinafine hydrochloride	Drug Info	Approved	Pityriasis versicolor	ICD11: 1F2D	[24]
Ticlopidine	Drug Info	Approved	Cerebral stroke	ICD11: 8B11	[24]
Tipranavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[74]
Tretinoin	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[75]
Almotriptan malate	Drug Info	Approved	Migraine	ICD11: 8A80	[45]
Aprepitant	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[76]
Asenapine maleate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[77]
Brentuximab vedotin	Drug Info	Approved	Anaplastic large cell lymphoma	ICD11: 2A90	[78]
Bupivacaine hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[79]
Cabazitaxel	Drug Info	Approved	Breast cancer	ICD11: 2C60	[80]
Clomipramine	Drug Info	Approved	Depression	ICD11: 6A70-6A7Z	[81]
Clomipramine	Drug Info	Approved	Depression	ICD11: 6A70-6A7Z	[82]
Colchicine	Drug Info	Approved	Uncontrolled gout	ICD11: FA25	[83]
Conjugated estrogens	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[84]
Cyclobenzaprine	Drug Info	Approved	Depression	ICD11: 6A71	[85]
Daunorubicin	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[86]
Disulfiram	Drug Info	Approved	Alcohol dependence	ICD11: 6C40	[87]
Enzalutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[88]
Enzalutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[89]
Guanfacine hydrochloride	Drug Info	Approved	Attention deficit hyperactivity disorder	ICD11: 6A05	[90]
Methyltestosterone	Drug Info	Approved	Breast cancer	ICD11: 2C60	[91]
Mirabegron	Drug Info	Approved	Overactive bladder	ICD11: GC50	[92]
Norethindrone	Drug Info	Approved	Solid tumour/cancer	ICD11: 2A00-2F9Z	[93]
Oxycodone hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[94]
Oxymorphone	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[95]
Pioglitazone hydrochloride	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[96]
Pravastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[97]
Ranolazine	Drug Info	Approved	Angina pectoris	ICD11: BA40	[98]
Rivaroxaban	Drug Info	Approved	Deep vein thrombosis	ICD11: BD71	[99]
Sirolimus	Drug Info	Approved	Lymphangioleiomyomatosis	ICD11: CB07	[18]
Tacrine hydrochloride	Drug Info	Approved	Alzheimer disease	ICD11: 8A20	[44]
Topiramate	Drug Info	Approved	Focal seizure	ICD11: 8A68	[100]
Trabectedin	Drug Info	Approved	Leiomyosarcoma	ICD11: 2B58	[101]
Albendazole	Drug Info	Approved	Giardiasis	ICD11: 1A31	[40]
Alpelisib	Drug Info	Approved	Breast cancer	ICD11: 2C60	[102]
Apomorphine	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[103]
Beclomethasone dipropionate	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[104]
Beclomethasone dipropionate	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[105]
Chenodeoxycholic acid	Drug Info	Approved	Cholelithiasis	ICD11: DC11	[106]
Clomiphene citrate	Drug Info	Approved	Female infertility	ICD11: GA31	[107]
Copanlisib	Drug Info	Approved	Follicular lymphoma	ICD11: 2A80	[108]
Deflazacort	Drug Info	Approved	Muscular dystrophy	ICD11: 8C70	[109]
Dehydroepiandrosterone	Drug Info	Approved	Dyspareunia	ICD11: GA12	[41]
Deoxycholic acid	Drug Info	Approved	Obesity	ICD11: 5B81	[110]
Edoxaban	Drug Info	Approved	Atrial fibrillation	ICD11: BC81	[111]
Etonogestrel	Drug Info	Approved	Contraception	ICD11: JA65	[112]
Halothane	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[113]
Hydrocodone bitartrate	Drug Info	Approved	Neuropathic pain	ICD11: 8E43	[114]
Hydrocortisone	Drug Info	Approved	Uncontrolled gout	ICD11: FA25	[115]
Indinavir sulfate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[24]
Ketamine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[116]
Levocetirizine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[117]
Medrysone	Drug Info	Approved	Eyelid inflammation	ICD11: 9A02	[118]
Meperidine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[119]
Methylprednisolone	Drug Info	Approved	Lymphoblastic Lymphoma	ICD11: 2A70	[120]
Nilotinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[121]
Osimertinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[122]
Osimertinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[123]
Panobinostat lactate	Drug Info	Approved	Multiple myeloma	ICD11: 2A83	[124]
Perampanel	Drug Info	Approved	Focal seizure	ICD11: 8A68	[125]
Ponesimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[126]
Ponesimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[127]
Quinine sulfate	Drug Info	Approved	Malaria	ICD11: 1F40	[128]
Regorafenib	Drug Info	Approved	Colon cancer	ICD11: 2B90	[129]
Regorafenib	Drug Info	Approved	Colon cancer	ICD11: 2B90	[130]
Remdesivir	Drug Info	Approved	Coronavirus Disease 2019 (COVID-19)	ICD11: 1D6Y	[131]
Tamsulosin	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[132]
Tamsulosin	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[133]
Telithromycin	Drug Info	Approved	Bronchitis	ICD11: CA20	[134]
Teniposide	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[135]
Tepotinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[136]
Tepotinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[137]
Ticagrelor	Drug Info	Approved	Cerebral stroke	ICD11: 8B11	[138]
Tucatinib	Drug Info	Approved	HER2-positive breast cancer	ICD11: 2C60-2C6Y	[139]
Alfentanil	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[140]
Aliskiren	Drug Info	Approved	Essential hypertension	ICD11: BA00	[141]
Alitretinoin	Drug Info	Approved	Kaposi sarcoma	ICD11: 2B57	[142]
Arteether	Drug Info	Approved	Malaria	ICD11: 1F40-1F45	[143]
Axitinib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[144]
Benzphetamine	Drug Info	Approved	Obesity	ICD11: 5B81	[145]
Brexpiprazole	Drug Info	Approved	Bipolar disorder	ICD11: 6A60	[146]
Caffeine	Drug Info	Approved	Orthostatic hypotension	ICD11: BA21	[147]
Carvedilol	Drug Info	Approved	Congestive heart failure	ICD11: BD10	[148]
Cisapride	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[149]
Dextromethorphan hydrobromide	Drug Info	Approved	Atherosclerosis	ICD11: BA80	[150]
Diazepam	Drug Info	Approved	Epilepsy	ICD11: 8A60	[151]
Diethylstilbestrol	Drug Info	Approved	Vaginitis	ICD11: GA02	[152]
Digitoxin	Drug Info	Approved	Congestive heart failure	ICD11: BD10	[153]
Dihydroergotamine	Drug Info	Approved	Migraine	ICD11: 8A80	[31]
Diphenylpyraline	Drug Info	Approved	Allergy	ICD11: 4A80	[154]
Doxepin hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[155]
Drospirenone	Drug Info	Approved	Contraception	ICD11: JA65	[156]
Eliglustat tartrate	Drug Info	Approved	Gaucher disease	ICD11: 5C56	[24]
Ergocalciferol	Drug Info	Approved	Hypoparathyroidism	ICD11: 5A50	[157]
Finasteride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[18]
Fluoxymesterone	Drug Info	Approved	Breast cancer	ICD11: 2C60	[158]
Flutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[159]
Gilteritinib	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[160]
Gilteritinib	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[161]
Haloperidol decanoate	Drug Info	Approved	Agitation/aggression	ICD11: 6D86	[162]
Lansoprazole	Drug Info	Approved	Duodenal ulcer	ICD11: DA63	[163]
Lasofoxifene	Drug Info	Approved	Osteoporosis	ICD11: FB83	[164]
Lasofoxifene	Drug Info	Approved	Osteoporosis	ICD11: FB83	[165]
Levonorgestrel	Drug Info	Approved	Menorrhagia	ICD11: GA20	[166]
Levonorgestrel	Drug Info	Approved	Menorrhagia	ICD11: GA20	[167]
Lorcaserin	Drug Info	Approved	Obesity	ICD11: 5B81	[168]
Macitentan	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[169]
Nateglinide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[170]
Nevirapine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[171]
Norethindrone acetate	Drug Info	Approved	Menorrhagia	ICD11: GA20	[93]
Olaparib	Drug Info	Approved	Ovarian cancer	ICD11: 2C73	[172]
Ondansetron	Drug Info	Approved	Gastritis	ICD11: DA42	[173]
Pomalidomide	Drug Info	Approved	Breast cancer	ICD11: 2C60	[174]
Propafenone hydrochloride	Drug Info	Approved	Ventricular tachyarrhythmia	ICD11: BC71	[175]
Propranolol hydrochloride	Drug Info	Approved	Migraine	ICD11: 8A80	[176]
Repaglinide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[170]
Rifabutin	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[177]
Rofecoxib	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[24]
Rotigotine	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[178]
SR141716A	Drug Info	Approved	Obesity	ICD11: 5B80-5B81	[179]
Tivozanib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[180]
Tolcapone	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[181]
Toremifene citrate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[182]
Trazodone hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[183]
Trimethoprim	Drug Info	Approved	Infectious cystitis	ICD11: GC00	[18]
Verapamil hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[24]
Vilanterol	Drug Info	Approved	Asthma	ICD11: CA23	[184]
Ziprasidone	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[185]
Amitriptyline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[186]
Amprenavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[187]
Artemether	Drug Info	Approved	Malaria	ICD11: 1F40	[188]
Avanafil	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[189]
Baricitinib	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[190]
Baricitinib	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[191]
Belinostat	Drug Info	Approved	Anaplastic large cell lymphoma	ICD11: 2A90	[192]
Betrixaban	Drug Info	Approved	Venous thromboembolism	ICD11: BD72	[193]
Brigatinib	Drug Info	Approved	Anaplastic large cell lymphoma	ICD11: 2A90	[194]
Bromfenac	Drug Info	Approved	Cataract	ICD11: 9B10	[195]
Buspirone	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[196]
Carbamazepine	Drug Info	Approved	Epilepsy	ICD11: 8A60	[197]
Cenobamate	Drug Info	Approved	Focal seizure	ICD11: 8A68	[198]
Cevimeline hydrochloride	Drug Info	Approved	Sjogren syndrome	ICD11: 4A43	[199]
Cinacalcet hydrochloride	Drug Info	Approved	Hyperparathyroidism	ICD11: 5A51	[200]
Clobazam	Drug Info	Approved	Lennox-Gastaut syndrome	ICD11: 8A62	[201]
Codeine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[202]
Cortisone acetate	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[203]
Cyclophosphamide	Drug Info	Approved	Multiple myeloma	ICD11: 2A83	[204]
Dabrafenib mesylate	Drug Info	Approved	Melanoma	ICD11: 2C30	[205]
Darifenacin hydrobromide	Drug Info	Approved	Overactive bladder	ICD11: GC50	[206]
Dasatinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[207]
Desvenlafaxine	Drug Info	Approved	Major depressive disorder	ICD11: 6A70-6A7Z	[208]
Desvenlafaxine	Drug Info	Approved	Major depressive disorder	ICD11: 6A70-6A7Z	[209], []
Desvenlafaxine succinate	Drug Info	Approved	Depression	ICD11: 6A71	[210]
Diltiazem hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[211]
Dolutegravir sodium	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[212]
Donepezil hydrochloride	Drug Info	Approved	Alzheimer disease	ICD11: 8A20	[213]
Doxorubicin	Drug Info	Approved	Breast cancer	ICD11: 2C60	[214]
Dronedarone hydrochloride	Drug Info	Approved	Atrial fibrillation	ICD11: BC81	[215]
Efavirenz	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[216]
Erdafitinib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[217]
Exjade	Drug Info	Approved	Hyperphosphatemia	ICD11: 5C64	[218]
Felbamate	Drug Info	Approved	Epilepsy	ICD11: 8A60	[219]
Fluoxetine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[220]
Flurazepam	Drug Info	Approved	Insomnia	ICD11: 7A00	[221]
Fluvastatin sodium	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[222]
Histamine	Drug Info	Approved	Allergy	ICD11: 4A80	[223]
Ibuprofen	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[224]
Imipramine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[225]
Infigratinib	Drug Info	Approved	Discovery agent	ICD: N.A.	[226], [227]
Infigratinib	Drug Info	Approved	Discovery agent	ICD: N.A.	[226]
Isotretinoin	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[228]
Isotretinoin	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[229]
Isradipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[18]
Isradipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[230]
Istradefylline	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[231]
Ivermectin	Drug Info	Approved	Onchocerciasis	ICD11: 1F6A	[232]
Ivosidenib	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[233]
Ivosidenib	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[234]
Leflunomide	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[235]
Leflunomide	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[236]
Lesinurad	Drug Info	Approved	Uncontrolled gout	ICD11: FA25	[237]
Letermovir	Drug Info	Approved	Cytomegalovirus infection	ICD11: 1D82	[238]
Levomepromazine	Drug Info	Approved	Insomnia	ICD11: 7A00	[239]
Lurasidone	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[240]
Metoprolol succinate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[241]
Metoprolol tartrate	Drug Info	Approved	Angina pectoris	ICD11: BA40	[242]
Midazolam hydrochloride	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[243]
Mometasone furoate	Drug Info	Approved	Allergy	ICD11: 4A80	[118]
Morphine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[244]
Nefazodone	Drug Info	Approved	Depression	ICD11: 6A71	[245]
Neratinib	Drug Info	Approved	Breast cancer	ICD11: 2C60	[246]
Pexidartinib	Drug Info	Approved	Neurofibromatosis	ICD11: LD2D	[247]
Phenytoin	Drug Info	Approved	Epilepsy	ICD11: 8A60	[248]
Prazepam	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[249]
Promazine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[250]
Propoxyphene Hydrochloride	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[251]
Quinidine	Drug Info	Approved	Ventricular tachyarrhythmia	ICD11: BC71	[252]
Rilpivirine hydrochloride	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[253]
Ropivacaine hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[254]
Rucaparib	Drug Info	Approved	Ovarian cancer	ICD11: 2C73	[255]
Simvastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[256]
Simvastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[257]
Sulfinpyrazone	Drug Info	Approved	Uncontrolled gout	ICD11: FA25	[258]
Suvorexant	Drug Info	Approved	Insomnia	ICD11: 7A00	[259]
Tofacitinib citrate	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[260]
Vismodegib	Drug Info	Approved	Melanoma	ICD11: 2C30	[261]
Zanubrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[262]
Zanubrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[263]
Zileuton	Drug Info	Approved	Asthma	ICD11: CA23	[24]
Zolpidem tartrate	Drug Info	Approved	Insomnia	ICD11: 7A00	[264]
Alectinib hydrochloride	Drug Info	Approved	Lung cancer	ICD11: 2C25	[265]
Amiodarone hydrochloride	Drug Info	Approved	Ventricular tachyarrhythmia	ICD11: BC71	[36]
Anastrozole	Drug Info	Approved	Breast cancer	ICD11: 2C60	[266]
Argatroban	Drug Info	Approved	Thrombosis	ICD11: DB61	[267]
Atorvastatin calcium	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[24]
Azelastine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[268]
Bedaquiline fumarate	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[269]
Betamethasone valerate	Drug Info	Approved	Psoriasis vulgaris	ICD11: EA90	[270]
Budesonide	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[271]
Buprenorphine hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[272]
Cabozantinib	Drug Info	Approved	Thyroid cancer	ICD11: 2D10	[273]
Chlorpromazine hydrochloride	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[274]
Citalopram hydrobromide	Drug Info	Approved	Depression	ICD11: 6A71	[275]
Clarithromycin	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[276]
Clofazimine	Drug Info	Approved	Crohn disease	ICD11: DD70	[18]
Clonidine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[277]
Clozapine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[278]
Delamanid	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[279]
Dofetilide	Drug Info	Approved	Atrial fibrillation	ICD11: BC81	[280]
Dolasetron mesylate	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[281]
Doxapram hydrochloride	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[282]
Entrectinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[283]
Eszopiclone	Drug Info	Approved	Insomnia	ICD11: 7A00	[24]
Ethosuximide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[284]
Etravirine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[285]
Everolimus	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[286]
Exemestane	Drug Info	Approved	Breast cancer	ICD11: 2C60	[287]
Famciclovir	Drug Info	Approved	Genital herpes	ICD11: 1A94	[288]
Fentanyl citrate	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[289]
Fingolimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[290]
Fingolimod hydrochloride	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[290]
Flunisolide	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[291]
Fosphenytoin sodium	Drug Info	Approved	Epilepsy	ICD11: 8A60	[292]
Fostamatinib	Drug Info	Approved	Thrombocytopenia	ICD11: 3B64	[293]
Gemfibrozil	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[294]
Glipizide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[295]
Indapamide	Drug Info	Approved	Essential hypertension	ICD11: BA00	[296]
Intedanib	Drug Info	Approved	Idiopathic pulmonary fibrosis	ICD11: CB03	[297]
Isosorbide dinitrate	Drug Info	Approved	Anal fissure	ICD11: DB50	[298]
Isosorbide mononitrate	Drug Info	Approved	Angina pectoris	ICD11: BA40	[298]
Ivabradine hydrochloride	Drug Info	Approved	Acute coronary syndrome	ICD11: BA4Z	[299]
Ixabepilone	Drug Info	Approved	Breast cancer	ICD11: 2C60	[300]
Levobupivacaine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[301]
Levorphanol	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[302]
Levothyroxine sodium	Drug Info	Approved	Hypothyroidism	ICD11: 5A00	[303]
Loxapine succinate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[304]
Lurbinectedin	Drug Info	Approved	Lung cancer	ICD11: 2C25	[305]
Mifepristone	Drug Info	Approved	Cushing syndrome	ICD11: 5A70	[306]
Mirtazapine	Drug Info	Approved	Depression	ICD11: 6A71	[307]
Nalmefene	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[308]
Naloxegol oxalate	Drug Info	Approved	Opioid-induced constipation	ICD11: DB32	[309]
Nisoldipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[18]
Omeprazole	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[24]
Ospemifene	Drug Info	Approved	Dyspareunia	ICD11: GA12	[310]
Oxycodone	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[311]
Paroxetine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[312]
Pazopanib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[313]
Perphenazine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[314]
Phenprocoumon	Drug Info	Approved	Thrombosis	ICD11: DB61	[315]
Pimozide	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[316]
Ponatinib hydrochloride	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[317]
Pralsetinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[318]
Propofol	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[319]
Quetiapine fumarate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[320]
Rabeprazole sodium	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[321]
Raloxifene	Drug Info	Approved	Osteoporosis	ICD11: FB83	[322]
Ritonavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[323]
Ropinirole hydrochloride	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[324]
Saquinavir mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[325]
Solifenacin succinate	Drug Info	Approved	Overactive bladder	ICD11: GC50	[326]
Sulfamethoxazole	Drug Info	Approved	Infectious cystitis	ICD11: GC00	[327]
Tandospirone	Drug Info	Approved	Anxiety disorder	ICD11: 6B00-6B0Z	[328]
Tasimelteon	Drug Info	Approved	Insomnia	ICD11: 7A00	[329]
Telaprevir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[330]
Theophylline	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[331]
Thioridazine	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[332]
Thiotepa	Drug Info	Approved	Breast cancer	ICD11: 2C60	[333]
Tramadol hydrochloride	Drug Info	Approved	Neuropathic pain	ICD11: 8E43	[334]
Triazolam	Drug Info	Approved	Insomnia	ICD11: 7A00	[335]
Vemurafenib	Drug Info	Approved	Melanoma	ICD11: 2C30	[336]
Venlafaxine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[24]
VESNARINONE	Drug Info	Approved	Cardiac failure	ICD11: BD10-BD1Z	[337]
Vilazodone hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[338]
Vortioxetine hydrobromide	Drug Info	Approved	Depression	ICD11: 6A71	[339]
Zafirlukast	Drug Info	Approved	Asthma	ICD11: CA23	[340]
Acetaminophen	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[341]
Alfuzosin hydrochloride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[342]
Alprazolam	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[343]
Apixaban	Drug Info	Approved	Deep vein thrombosis	ICD11: BD71	[344]
Aripiprazole lauroxil	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[345]
Avapritinib	Drug Info	Approved	Gastrointestinal stromal tumour	ICD11: 2B5B	[346]
Avapritinib	Drug Info	Approved	Gastrointestinal stromal tumour	ICD11: 2B5B	[347]
Binimetinib	Drug Info	Approved	Melanoma	ICD11: 2C30	[348]
Calcitriol	Drug Info	Approved	Congenital alopecia	ICD11: LC30	[349]
Canagliflozin	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[350]
Chlordiazepoxide	Drug Info	Approved	Anxiety disorder	ICD11: 6B00-6B0Z	[351]
Chlorpheniramine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[53]
Ciclesonide	Drug Info	Approved	Asthma	ICD11: CA23	[352]
Cisplatin	Drug Info	Approved	Lung cancer	ICD11: 2C25	[353]
Clonazepam	Drug Info	Approved	Epilepsy	ICD11: 8A60	[145]
Dapagliflozin	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[354]
Darunavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[355]
Desloratadine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[356]
Dexamethasone sodium phosphate	Drug Info	Approved	Ataxia-telangiectasia	ICD11: 4A01	[357]
Dexlansoprazole	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[358]
Digoxin	Drug Info	Approved	Cardiac arrhythmia	ICD11: BC65	[359]
Docetaxel	Drug Info	Approved	Breast cancer	ICD11: 2C60	[360]
Dutasteride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[361]
Dutasteride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[362]
Eravacycline	Drug Info	Approved	Methicillin-resistant staphylococcus infection	ICD11: 1D01	[363]
Estazolam	Drug Info	Approved	Insomnia	ICD11: 7A00	[364]
Etoposide	Drug Info	Approved	Lung cancer	ICD11: 2C25	[365]
Ezetimibe	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[366]
Fedratinib hydrochloride	Drug Info	Approved	Myelofibrosis	ICD11: 2A22	[367]
Fenofibrate	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[294]
Fesoterodine	Drug Info	Approved	Overactive bladder	ICD11: GC50	[368]
Gefitinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[369]
Grepafloxacin	Drug Info	Approved	Bronchitis	ICD11: CA20	[370]
Iloperidone	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[371]
Irinotecan hydrochloride	Drug Info	Approved	Colon cancer	ICD11: 2B90	[372]
Itraconazole	Drug Info	Approved	Blastomycosis	ICD11: 1F22	[373]
Lenvatinib	Drug Info	Approved	Thyroid cancer	ICD11: 2D10	[374]
Levallorphan	Drug Info	Approved	Narcotic depression	ICD11: 6A70-6A7Z	[302]
Levomethadyl acetate hydrochloride	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[375]
Levomilnacipran	Drug Info	Approved	Depression	ICD11: 6A71	[376]
Loperamide hydrochloride	Drug Info	Approved	Irritable bowel syndrome	ICD11: DD91	[377]
Losartan potassium	Drug Info	Approved	Essential hypertension	ICD11: BA00	[18]
Lovastatin	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[378]
Macimorelin	Drug Info	Approved	Growth hormone deficiency	ICD11: 5A60-5A61	[379]
Medroxyprogesterone acetate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[380]
Methadone	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[381]
Mexiletine hydrochloride	Drug Info	Approved	Ventricular tachyarrhythmia	ICD11: BC71	[382]
Midostaurin	Drug Info	Approved	Mastocytosis	ICD11: 2A21	[383]
Mycophenolic acid	Drug Info	Approved	Crohn disease	ICD11: DD70	[384], [385]
Mycophenolic acid	Drug Info	Approved	Crohn disease	ICD11: DD70	[386]
Nelfinavir mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[24]
Nimodipine	Drug Info	Approved	Cerebral vasospasm	ICD11: BA85	[18]
Olopatadine	Drug Info	Approved	Conjunctivitis	ICD11: 9A60	[387]
Paclitaxel	Drug Info	Approved	Ovarian cancer	ICD11: 2C73	[388]
Paclitaxel	Drug Info	Approved	Ovarian cancer	ICD11: 2C73	[389]
Palonosetron hydrochloride	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[390]
Pantoprazole sodium	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[391]
Pergolide mesylate	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[178]
Phenelzine	Drug Info	Approved	Depression	ICD11: 6A71	[392]
Phenobarbital	Drug Info	Approved	Epilepsy	ICD11: 8A60	[393]
Pinacidil	Drug Info	Approved	Essential hypertension	ICD11: BA00	[394]
Pitavastatin calcium	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[395]
Pitolisant	Drug Info	Approved	Excessive daytime sleepiness	ICD11: MG42	[396]
Rifampin	Drug Info	Approved	Tuberculosis	ICD11: 1B10-1B14	[397]
Riociguat	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[398]
Ruxolitinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[399]
Ruxolitinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[400]
Ruxolitinib phosphate	Drug Info	Approved	Myelofibrosis	ICD11: 2A22	[401]
Safinamide	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[402]
Safinamide mesylate	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[403], [404]
Salbutamol	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[18]
Selinexor	Drug Info	Approved	Multiple myeloma	ICD11: 2A83	[405]
Sitagliptin	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[406]
Sonidegib phosphate	Drug Info	Approved	Basal cell carcinoma	ICD11: 2C32	[407]
Sorafenib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[408]
Sulfadiazine	Drug Info	Approved	Toxoplasmosis	ICD11: 1F57	[18]
Tapinarof	Drug Info	Approved	Discovery agent	ICD: N.A.	[409]
Taxol	Drug Info	Approved	Breast cancer	ICD11: 2C60-2C6Y	[410]
Timolol maleate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[411]
Tolterodine tartrate	Drug Info	Approved	Overactive bladder	ICD11: GC50	[412]
Troglitazone	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[413]
Vinorelbine tartrate	Drug Info	Approved	Lung cancer	ICD11: 2C25	[414]
Voriconazole	Drug Info	Approved	Candidiasis	ICD11: 1F23	[415]
Zaleplon	Drug Info	Approved	Insomnia	ICD11: 7A00	[416]
Zidovudine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[417]
Abemaciclib	Drug Info	Approved	Breast cancer	ICD11: 2C60	[418]
Abiraterone acetate	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[419]
Alogliptin	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[420]
Ambrisentan	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[421]
Armodafinil	Drug Info	Approved	Obstructive sleep apnea	ICD11: 7A41	[422]
Atenolol	Drug Info	Approved	Essential hypertension	ICD11: BA00	[423]
Azilsartan	Drug Info	Approved	Hypertension	ICD11: BA00-BA04	[424], [425]
Bicalutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[426]
Boceprevir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[427]
Bosentan	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[428]
Bromocriptine mesylate	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[429]
Busulfan	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[430]
Cabergoline	Drug Info	Approved	Hyperprolactinaemia	ICD11: 5A60	[178]
Cariprazine hydrochloride	Drug Info	Approved	Bipolar disorder	ICD11: 6A60	[431]
Celecoxib	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[432]
Cerivastatin sodium	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[24]
Cilostazol	Drug Info	Approved	Arteriosclerosis obliterans	ICD11: BD40	[433]
Clindamycin	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[434]
Clofibrate	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[294]
Clopidogrel bisulfate	Drug Info	Approved	Acute coronary syndrome	ICD11: BA4Z	[24]
Cyproterone	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[435]
Cytarabine	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[436]
Dapsone	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[437]
Difluprednate	Drug Info	Approved	Anterior uveitis	ICD11: 9A96	[438]
Dydrogesterone	Drug Info	Approved	Menorrhagia	ICD11: GA20	[439]
Eletriptan hydrobromide	Drug Info	Approved	Migraine	ICD11: 8A80	[24]
Elvitegravir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[440]
Enalapril	Drug Info	Approved	Essential hypertension	ICD11: BA00	[18]
Eplerenone	Drug Info	Approved	Ventricular dysfunction	ICD11: BD13	[441]
Ergotamine tartrate	Drug Info	Approved	Migraine	ICD11: 8A80	[442]
Escitalopram	Drug Info	Approved	Depression	ICD11: 6A71	[275]
Estramustine	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[443]
Estropipate	Drug Info	Approved	Hypogonadism	ICD11: 5A61	[444]
Ethynodiol diacetate	Drug Info	Approved	Contraception	ICD11: JA65	[445]
Flibanserin	Drug Info	Approved	Inhibited sexual desire	ICD11: HA00	[446]
Fluconazole	Drug Info	Approved	Candidiasis	ICD11: 1F23	[447]
Fludrocortisone	Drug Info	Approved	Hyponatraemia	ICD11: 5C72	[18]
Fluorometholone	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[118]
Fosamprenavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[448]
Granisetron hydrochloride	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[449]
Hydromorphone	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[450]
Icatibant	Drug Info	Approved	Hereditary angioedema	ICD11: 4A00	[451]
Iclaprim	Drug Info	Approved	Methicillin-resistant staphylococcus infection	ICD11: 1D01	[452]
Isavuconazole	Drug Info	Approved	Allergic bronchopulmonary aspergillosis	ICD11: CA82	[453]
Ivacaftor	Drug Info	Approved	Cystic fibrosis	ICD11: CA25	[454]
Lacosamide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[455]
Levomethadyl Acetate	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[456]
Levomethadyl Acetate	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[457]
Lomitapide mesylate	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[458]
Lopinavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[459]
Loratadine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[18]
Loteprednol etabonate	Drug Info	Approved	Conjunctivitis	ICD11: 9A60	[460]
Mebendazole	Drug Info	Approved	Ascariasis	ICD11: 1F62	[461]
Mefloquine hydrochloride	Drug Info	Approved	Malaria	ICD11: 1F40	[462]
Megestrol acetate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[463]
Mephenytoin	Drug Info	Approved	Epilepsy	ICD11: 8A60	[464]
Mitotane	Drug Info	Approved	Adrenocortical carcinoma	ICD11: 2D11	[465]
Moxidectin	Drug Info	Approved	Onchocerciasis	ICD11: 1F6A	[466]
Nicardipine hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[467]
Nifedipine	Drug Info	Approved	Angina pectoris	ICD11: BA40	[468]
Orphenadrine citrate	Drug Info	Approved	Myalgia	ICD11: FB56	[469]
Oxazepam	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[470]
OZ277	Drug Info	Approved	Malaria	ICD11: 1F40-1F45	[471]
Paliperidone	Drug Info	Approved	Bipolar disorder	ICD11: 6A60	[472]
Pentamidine isethionate	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[40]
Phentermine	Drug Info	Approved	Obesity	ICD11: 5B81	[473]
Prasugrel hydrochloride	Drug Info	Approved	Acute coronary syndrome	ICD11: BA4Z	[474]
Pretomanid	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[475]
Pyrazinamide	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[476]
Quazepam	Drug Info	Approved	Insomnia	ICD11: 7A00	[477]
Rosuvastatin	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[478]
Salmeterol xinafoate	Drug Info	Approved	Asthma	ICD11: CA23	[479]
Secnidazole	Drug Info	Approved	Amebiasis	ICD11: 1A36	[480]
Selegiline	Drug Info	Approved	Major depressive disorder	ICD11: 6A70-6A7Z	[481]
Selegiline hydrochloride	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[482]
Selexipag	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[483]
Sertraline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[312]
Sibutramine	Drug Info	Approved	Obesity	ICD11: 5B81	[484]
Sildenafil citrate	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[24]
Stiripentol	Drug Info	Approved	Epilepsy	ICD11: 8A60	[485]
Sulindac	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[486]
Tazemetostat	Drug Info	Approved	Follicular lymphoma	ICD11: 2A80	[487]
Temazepam	Drug Info	Approved	Insomnia	ICD11: 7A00	[488]
Tetracycline	Drug Info	Approved	Spotted fever	ICD11: 1C31	[489]
Tiagabine	Drug Info	Approved	Epilepsy	ICD11: 8A60	[490]
Tinidazole	Drug Info	Approved	Protozoan infection	ICD11: 1F5Z	[491]
Tiotropium	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[492]
Tiotropium Bromide	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[492]
Tolvaptan	Drug Info	Approved	Hyponatraemia	ICD11: 5C72	[493]
Triclabendazole	Drug Info	Approved	Fascioliasis	ICD11: 1F82	[494]
Ulipristal	Drug Info	Approved	Contraception	ICD11: JA65	[495]
Vandetanib	Drug Info	Approved	Thyroid cancer	ICD11: 2D10	[496]
Vorapaxar sulfate	Drug Info	Approved	Myocardial infarction	ICD11: BA41	[497]
Voxelotor	Drug Info	Approved	Sickle-cell anaemia	ICD11: 3A51	[367]
Zonisamide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[498]
Avacopan	Drug Info	Approved	Discovery agent	ICD: N.A.	[499]
Aztreonam	Drug Info	Approved	Cystic fibrosis	ICD11: CA25	[500]
Baloxavir marboxil	Drug Info	Approved	Influenza virus infection	ICD11: 1E30	[501]
Baloxavir marboxil	Drug Info	Approved	Influenza virus infection	ICD11: 1E30	[502]
Bexarotene	Drug Info	Approved	Anaplastic large cell lymphoma	ICD11: 2A90	[18]
Bimatoprost	Drug Info	Approved	Glaucoma	ICD11: 9C61	[503]
Bisoprolol	Drug Info	Approved	Essential hypertension	ICD11: BA00	[504]
Bosutinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[6]
Brinzolamide	Drug Info	Approved	Glaucoma	ICD11: 9C61	[18]
Chloroquine	Drug Info	Approved	Malaria	ICD11: 1F40	[505]
Chloroquine	Drug Info	Approved	Malaria	ICD11: 1F40	[506]
Chlorzoxazone	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[18]
Clevidipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[507]
Clotrimazole	Drug Info	Approved	Candidiasis	ICD11: 1F23	[508]
Conivaptan hydrochloride	Drug Info	Approved	Hyponatraemia	ICD11: 5C72	[509]
Dacomitinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[510]
Dantrolene sodium	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[18]
Desipramine	Drug Info	Approved	Attention deficit hyperactivity disorder	ICD11: 6A05	[225]
Dihydroergocristine	Drug Info	Approved	Alcohol dependence	ICD11: 6C40	[511]
Dirithromycin	Drug Info	Approved	Bronchitis	ICD11: CA20	[512]
Disopyramide phosphate	Drug Info	Approved	Ventricular tachyarrhythmia	ICD11: BC71	[513]
Dorzolamide hydrochloride	Drug Info	Approved	Glaucoma	ICD11: 9C61	[18]
Elbasvir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[514]
Enasidenib	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[515]
Encorafenib	Drug Info	Approved	Melanoma	ICD11: 2C30	[516]
Epinastine	Drug Info	Approved	Conjunctivitis	ICD11: 9A60	[517]
Erythromycin stearate	Drug Info	Approved	Acute upper respiratory infection	ICD11: CA07	[518]
Ethchlorvynol	Drug Info	Approved	Insomnia	ICD11: 7A00	[519]
Felodipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[520]
Fluprednisolone	Drug Info	Approved	Asthma	ICD11: CA23	[521]
Fluticasone furoate	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[118]
Fluticasone propionate	Drug Info	Approved	Asthma	ICD11: CA23	[522]
Fluticasone propionate	Drug Info	Approved	Asthma	ICD11: CA23	[523]
Fosinopril	Drug Info	Approved	Hypertension	ICD11: BA00-BA04	[524]
Fulvestrant	Drug Info	Approved	Breast cancer	ICD11: 2C60	[525]
GDC-0199	Drug Info	Approved	Solid tumour/cancer	ICD11: 2A00-2F9Z	[526]
GS-7340	Drug Info	Approved	Hepatitis B virus infection	ICD11: 1E50-1E51	[527]
Halcinonide	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[528]
Halofantrine	Drug Info	Approved	Malaria	ICD11: 1F40	[529]
Hydroxyamphetamine	Drug Info	Approved	Horner syndrome	ICD11: 8D8A	[530]
Hydroxychloroquine sulfate	Drug Info	Approved	Malaria	ICD11: 1F40	[531]
Hydroxyprogesterone caproate	Drug Info	Approved	Uterine cancer	ICD11: 2C76	[532]
Hydroxyzine	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[533]
Ibudilast	Drug Info	Approved	Castleman's disease	ICD11: 4B2Y	[534]
Imiquimod	Drug Info	Approved	Basal cell carcinoma	ICD11: 2C32	[18]
Indacaterol maleate	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[535]
Isavuconazonium	Drug Info	Approved	Allergic bronchopulmonary aspergillosis	ICD11: CA82	[536]
Lefamulin	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[537]
Lenacapavir	Drug Info	Approved	Discovery agent	ICD: N.A.	[538]
Lenacapavir	Drug Info	Approved	Discovery agent	ICD: N.A.	[539]
Letrozole	Drug Info	Approved	Breast cancer	ICD11: 2C60	[540]
Lonafarnib	Drug Info	Approved	Progeria	ICD11: LD2B	[541], [542]
Lonafarnib	Drug Info	Approved	Progeria	ICD11: LD2B	[541]
Lorlatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[543]
Lumefantrine	Drug Info	Approved	Malaria	ICD11: 1F40	[544]
Meloxicam	Drug Info	Approved	Osteoarthritis	ICD11: FA00	[545]
Methylergometrine	Drug Info	Approved	Migraine	ICD11: 8A80	[442]
Methysergide	Drug Info	Approved	Migraine	ICD11: 8A80	[546]
Mitapivat	Drug Info	Approved	Discovery agent	ICD: N.A.	[547]
Modafinil	Drug Info	Approved	Narcolepsy	ICD11: 7A20	[18]
Nebivolol hydrochloride	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[548]
Norgestimate	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[549]
Nortriptyline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[550]
Omidenepag isopropyl	Drug Info	Approved	Discovery agent	ICD: N.A.	[551]
Orlistat	Drug Info	Approved	Obesity	ICD11: 5B80-5B81	[552]
Oxybutynin chloride	Drug Info	Approved	Overactive bladder	ICD11: GC50	[553]
Paramethasone	Drug Info	Approved	Allergy	ICD11: 4A80	[118]
Pemigatinib	Drug Info	Approved	Hepatocellular carcinoma	ICD11: 2C12	[554]
Pemigatinib	Drug Info	Approved	Hepatocellular carcinoma	ICD11: 2C12	[555]
Pemigatinib	Drug Info	Approved	Hepatocellular carcinoma	ICD11: 2C12	[556]
Pemigatinib	Drug Info	Approved	Hepatocellular carcinoma	ICD11: 2C12	[557]
Permethrin	Drug Info	Approved	Scabies	ICD11: 1G04	[558]
Pimecrolimus	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[559]
Posaconazole	Drug Info	Approved	Candidiasis	ICD11: 1F23	[560]
Praziquantel	Drug Info	Approved	Schistosomiasis	ICD11: 1F86	[561]
Prednicarbate	Drug Info	Approved	Ascariasis	ICD11: 1F62	[562]
Rifampicin	Drug Info	Approved	Osteoporosis	ICD11: FB83	[563]
Rifapentine	Drug Info	Approved	Pulmonary tuberculosis	ICD11: 1B10	[564]
Rifaximin	Drug Info	Approved	Hepatic encephalopathy	ICD11: DB99	[565]
Rimegepant	Drug Info	Approved	Migraine	ICD11: 8A80	[566]
Rimegepant	Drug Info	Approved	Migraine	ICD11: 8A80	[567]
Rimexolone	Drug Info	Approved	Anterior uveitis	ICD11: 9A96	[568]
Ripretinib	Drug Info	Approved	Gastrointestinal stromal tumour	ICD11: 2B5B	[569]
Risdiplam	Drug Info	Approved	Muscular atrophy	ICD11: 8B61	[570]
Risperidone	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[18]
Roflumilast	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[571]
Rolapitant hydrochloride	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[572]
Romidepsin	Drug Info	Approved	Cutaneous T-cell lymphoma	ICD11: 2B01	[573]
Saxagliptin hydrochloride	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[574]
Selpercatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[575]
Selpercatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[318], [575], [576]
Sevoflurane	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[577]
Simeprevir sodium	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[578]
Sufentanil	Drug Info	Approved	Neuropathic pain	ICD11: 8E43	[579]
Tadalafil	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[580]
Tenapanor	Drug Info	Approved	Hyperphosphatemia	ICD11: 5C64	[581]
Tenofovir alafenamide	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[582]
Tenofovir disoproxil fumarate	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[582]
Testosterone cypionate	Drug Info	Approved	Testosterone deficiency	ICD11: 5A81	[583]
Tilidine	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[584]
Triamcinolone diacetate	Drug Info	Approved	Allergy	ICD11: 4A80	[585]
Trilostane	Drug Info	Approved	Cushing syndrome	ICD11: 5A70	[586]
Trimethadione	Drug Info	Approved	Epilepsy	ICD11: 8A60	[587]
Troleandomycin	Drug Info	Approved	Acute upper respiratory infection	ICD11: CA07	[588]
Vardenafil hydrochloride	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[589]
Velpatasvir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[590]
Velpatasvir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[591]
Venetoclax	Drug Info	Approved	Chronic lymphocytic leukaemia	ICD11: 2A82	[526]
Vinblastine sulfate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[592]
Vincristine sulfate	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[593]
Vitamin D	Drug Info	Approved	Hyperparathyroidism	ICD11: 5A51	[594]
Voxilaprevir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[595]
Voxilaprevir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[596]
Zalcitabine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[597]
Alclometasone	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[598]
Alfuzosin	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[599]
Alfuzosin	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[600]
Amcinonide	Drug Info	Approved	Allergic contact dermatitis	ICD11: EK00	[118]
Atovaquone	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[601]
Azithromycin	Drug Info	Approved	Congenital syphilis	ICD11: 1A60	[18]
Bepridil hydrochloride	Drug Info	Approved	Angina pectoris	ICD11: BA40	[507]
Cefalexin	Drug Info	Approved	Acute otitis media	ICD11: AB00	[602]
Clobetasol propionate	Drug Info	Approved	Psoriasis vulgaris	ICD11: EA90	[603]
Corticotropin	Drug Info	Approved	Cushing syndrome	ICD11: 5A70	[604]
Desonide	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[18]
Desoxycorticosterone acetate	Drug Info	Approved	Osteoporosis	ICD11: FB83	[605]
Desoxycorticosterone pivalate	Drug Info	Approved	Adrenocortical deficiency	ICD11: 5A74	[605]
Dexamethasone acetate	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[357]
Doxycycline	Drug Info	Approved	Periodontal disease	ICD11: DA0C	[606]
Ergoloid mesylate	Drug Info	Approved	Alzheimer disease	ICD11: 8A20	[607]
Eribulin	Drug Info	Approved	Breast cancer	ICD11: 2C60	[608]
Eribulin mesylate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[609]
Flumethasone	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[598]
Fluocinolone acetonide	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[291]
Fluocinonide	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[291]
Flurandrenolide	Drug Info	Approved	Psoriasis vulgaris	ICD11: EA90	[598]
Gemtuzumab ozogamicin	Drug Info	Approved	Acute myeloid leukaemia	ICD11: 2A60	[294]
Glecaprevir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[610]
IPI-145	Drug Info	Approved	Follicular lymphoma	ICD11: 2A80	[611]
Liotrix	Drug Info	Approved	Hypothyroidism	ICD11: 5A00	[612]
Macrolides	Drug Info	Approved	Bacterial infection	ICD11: 1A00-1C4Z	[613]
Meprednisone	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[118]
Methoxsalen	Drug Info	Approved	Psoriasis vulgaris	ICD11: EA90	[614]
Methoxyflurane	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[577]
Miconazole	Drug Info	Approved	Dermatophytosis	ICD11: 1F28	[615]
Nabilone	Drug Info	Approved	Insomnia	ICD11: 7A00-7A0Z	[616]
NERATINIB MALEATE	Drug Info	Approved	HER2/NEU overexpressing breast cancer	ICD11: 2C60-2C6Y	[617]
Podophyllotoxin	Drug Info	Approved	Anogenital warts	ICD11: 1A95	[618]
Ramelteon	Drug Info	Approved	Insomnia	ICD11: 7A00	[619]
Retapamulin	Drug Info	Approved	Impetigo	ICD11: 1B72	[620]
Ribociclib succinate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[621]
Testosterone	Drug Info	Approved	Osteoporosis	ICD11: FB83	[622]
Trifarotene	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[623]
Trilaciclib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[624]
Umbralisib	Drug Info	Approved	Follicular lymphoma	ICD11: 2A80	[625]
Upadacitinib	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[626]
Upadacitinib	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[627]
Voclosporin	Drug Info	Approved	Lupus erythematosus	ICD11: 4A40	[628]
Ziconotide	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[507]
Lestaurtinib	Drug Info	Approved (orphan drug)	Acute lymphoblastic leukemia	ICD11: 2B33	[629]
Berberine	Drug Info	Phase 4	Discovery agent	ICD: N.A.	[631]
Guanfacine	Drug Info	Phase 4	Hepatocellular carcinoma	ICD11: 2C12	[644]
LAROPIPRANT	Drug Info	Phase 4	Atherosclerosis	ICD11: BA80	[646]
Neupro	Drug Info	Phase 4	Restless legs syndrome	ICD11: 7A80	[648]
Ingrezza	Drug Info	Phase 4	Dyskinesia	ICD11: 8A02	[683]
Drugs in Phase 4 Clinical Trial			Click to Show/Hide the Full List of Drugs: 88 Drugs
Etoperidone	Drug Info	Phase 4	Depression	ICD11: 6A71	[630]
Ethinylestradiol propanesulfonate	Drug Info	Phase 4	Prostate cancer	ICD11: 2C82	[632]
Desogestrel	Drug Info	Phase 4	Female pelvic pain	ICD11: GA34	[112]
Mosapride	Drug Info	Phase 4	Postoperative ileus	ICD11: DA93	[633]
Parecoxib	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[634]
Reboxetine	Drug Info	Phase 4	Depression	ICD11: 6A71	[635]
Ebastine	Drug Info	Phase 4	Irritable bowel syndrome	ICD11: DD91	[636]
Ebastine	Drug Info	Phase 4	Irritable bowel syndrome	ICD11: DD91	[]
Sertindole	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[637]
Brotizolam	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[638]
Cyproterone acetate	Drug Info	Phase 4	Polycystic ovary syndrome	ICD11: 5A80	[639]
Mestranol	Drug Info	Phase 4	Menorrhagia	ICD11: GA20	[640]
Artemisinin	Drug Info	Phase 4	Malaria	ICD11: 1F40	[641]
Dapoxetine	Drug Info	Phase 4	Ejaculatory dysfunction	ICD11: HA03	[642]
Fendiline	Drug Info	Phase 4	Atherosclerosis	ICD11: BA80	[507]
Barnidipine	Drug Info	Phase 4	Essential hypertension	ICD11: BA00	[643]
Cinnarizine	Drug Info	Phase 4	Haemorrhagic stroke	ICD11: 8B20	[507]
Glibenclamide	Drug Info	Phase 4	Diabetes mellitus	ICD11: 5A10	[24]
Ketobemidone	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[645]
Mibefradil	Drug Info	Phase 4	Essential hypertension	ICD11: BA00	[647]
Nimesulide	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[507]
Piperaquine	Drug Info	Phase 4	Malaria	ICD11: 1F40	[649], [650], [651]
Bezafibrate	Drug Info	Phase 4	Myocardial infarction	ICD11: BA41	[294]
Cibenzoline	Drug Info	Phase 4	Atrial fibrillation	ICD11: BC81	[652]
Methaqualone	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[653]
Mianserin	Drug Info	Phase 4	Depression	ICD11: 6A71	[303]
Propiverine	Drug Info	Phase 4	Overactive bladder	ICD11: GC50	[654]
Roxithromycin	Drug Info	Phase 4	Acute lower respiratory infection	ICD11: CA4Z	[655]
Tropisetron	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[281]
Vonoprazan	Drug Info	Phase 4	Gastro-oesophageal reflux disease	ICD11: DA22	[656]
Vonoprazan	Drug Info	Phase 4	Gastro-oesophageal reflux disease	ICD11: DA22	[657]
Zotepine	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[658]
Astemizole	Drug Info	Phase 4	Allergic rhinitis	ICD11: CA08	[18]
Bromperidol	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[659]
Dihydrocodeine	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[660]
Etoricoxib	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[661]
Fluspirilene	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[507]
Imrecoxib	Drug Info	Phase 4	Osteoarthritis	ICD11: FA00	[662]
Ipecac	Drug Info	Phase 4	Pulmonary tuberculosis	ICD11: 1B10	[663]
Lacidipine	Drug Info	Phase 4	Essential hypertension	ICD11: BA00	[664]
Levamlodipine	Drug Info	Phase 4	Essential hypertension	ICD11: BA00	[33]
Medifoxamine	Drug Info	Phase 4	Depression	ICD11: 6A71	[18]
Phenacetin	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[665]
Terfenadine	Drug Info	Phase 4	Allergy	ICD11: 4A80	[666]
Tianeptine	Drug Info	Phase 4	Depression	ICD11: 6A71	[667]
Tranilast	Drug Info	Phase 4	Conjunctivitis	ICD11: 9A60	[507]
Aminophenazone	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[668]
Chlorphenamine	Drug Info	Phase 4	Allergy	ICD11: 4A80	[53]
Clotiazepam	Drug Info	Phase 4	Anxiety disorder	ICD11: 6B00	[669]
Dextropropoxyphene	Drug Info	Phase 4	Lung cancer	ICD11: 2C25	[670]
Dihydralazine	Drug Info	Phase 4	Essential hypertension	ICD11: BA00	[666]
Flunitrazepam	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[671]
Gestodene	Drug Info	Phase 4	Contraception	ICD11: JA65	[672]
Gestrinone	Drug Info	Phase 4	Endometriosis	ICD11: GA10	[673]
Lynestrenol	Drug Info	Phase 4	Transsexualism	ICD11: HA60	[93]
Perazine	Drug Info	Phase 4	Cerebrovascular dementia	ICD11: 6D81	[674]
Trimebutine	Drug Info	Phase 4	Irritable bowel syndrome	ICD11: DD91	[507]
Zopiclone	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[675]
Azelnidipine	Drug Info	Phase 4	Essential hypertension	ICD11: BA00	[676]
Benidipine	Drug Info	Phase 4	Diabetic nephropathy	ICD11: GB61	[677]
Enclomiphene	Drug Info	Phase 4	Female infertility	ICD11: GA31	[678]
Etizolam	Drug Info	Phase 4	Insomnia	ICD11: 7A00	[679]
Flucloxacillin	Drug Info	Phase 4	Staphylococcus infection	ICD11: 1B73	[680]
Grazoprevir	Drug Info	Phase 4	Viral hepatitis	ICD11: 1E51	[681]
Hydroquinone	Drug Info	Phase 4	Melasma	ICD11: ED60	[682]
Ketazolam	Drug Info	Phase 4	Anxiety disorder	ICD11: 6B00	[249]
Mexazolam	Drug Info	Phase 4	Anxiety disorder	ICD11: 6B00	[256]
Milnacipran	Drug Info	Phase 4	Asperger syndrome	ICD11: 6A02	[684]
Otilonium	Drug Info	Phase 4	Irritable bowel syndrome	ICD11: DD91	[507]
Pranlukast	Drug Info	Phase 4	Obstructive sleep apnea	ICD11: 7A41	[685]
Pregnenolone	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[686]
Proguanil	Drug Info	Phase 4	Malaria	ICD11: 1F40	[687]
Promegestone	Drug Info	Phase 4	Corpus luteum cyst	ICD11: GA18	[639]
Rupatadine	Drug Info	Phase 4	Allergy	ICD11: 4A80	[688]
Beclabuvir	Drug Info	Phase 4	Viral hepatitis	ICD11: 1E51	[689]
Dienogest	Drug Info	Phase 4	Endometriosis	ICD11: GA10	[639]
Ergometrine	Drug Info	Phase 4	Postpartum haemorrhage	ICD11: JA43	[690]
Ergonovine maleate	Drug Info	Phase 4	Abnormal vaginal bleeding	ICD11: GA2Y	[690]
Nomegestrol	Drug Info	Phase 4	Hypercoagulability	ICD11: 3B61	[639]
Pinaverium	Drug Info	Phase 4	Irritable bowel syndrome	ICD11: DD91	[507]
Prenylamine	Drug Info	Phase 4	Angina pectoris	ICD11: BA40	[507]
Tenofovir disoproxil	Drug Info	Phase 4	Human immunodeficiency virus infection	ICD11: 1C60	[582]
Thiamylal	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[691]
Ciprofibrate	Drug Info	Phase 4	Hypertriglyceridaemia	ICD11: 5C80	[294]
Demegestone	Drug Info	Phase 4	Corpus luteum cyst	ICD11: GA18	[692]
Lidoflazine	Drug Info	Phase 4	Cognitive impairment	ICD11: 6D71	[507]
Yohimbine	Drug Info	Phase 4	Erectile dysfunction	ICD11: HA01	[693]
Zomepirac	Drug Info	Phase 4	Anaesthesia	ICD11: 8E22	[694]
Drugs in Phase 3 Clinical Trial			Click to Show/Hide the Full List of Drugs: 119 Drugs
E-3A	Drug Info	Phase 3	Turner syndrome	ICD11: LD50	[695]
Fruquintinib	Drug Info	Phase 3	Solid tumour/cancer	ICD11: 2A00-2F9Z	[696]
Selumetinib	Drug Info	Phase 3	Neurofibromatosis	ICD11: LD2D	[697]
MK-0859	Drug Info	Phase 3	Atherosclerosis	ICD11: BA80	[698]
EPIANDROSTERONE	Drug Info	Phase 3	Discovery agent	ICD: N.A.	[699]
ABL001	Drug Info	Phase 3	Chronic myelogenous leukaemia	ICD11: 2A20	[700]
Gemigliptin	Drug Info	Phase 3	Diabetic complication	ICD11: 5A2Y	[701]
Lisuride	Drug Info	Phase 3	Parkinsonism	ICD11: 8A00	[702]
LY-2484595	Drug Info	Phase 3	Myocardial infarction	ICD11: BA41	[703]
PG-490	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[704]
AZD-2171	Drug Info	Phase 3	Lung cancer	ICD11: 2C25	[705]
BMS-298585	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[706]
BMS-650032	Drug Info	Phase 3	Viral hepatitis	ICD11: 1E51	[707]
GSK2140944	Drug Info	Phase 3	Urinary tract infection	ICD11: GC08	[708]
LCZ-696	Drug Info	Phase 3	Myocardial infarction	ICD11: BA41	[709]
BAF-312	Drug Info	Phase 3	Multiple sclerosis	ICD11: 8A40	[72]
Finerenone	Drug Info	Phase 3	Diabetic nephropathy	ICD11: GB61	[710], [711], [712]
Finerenone	Drug Info	Phase 3	Diabetic nephropathy	ICD11: GB61	[712]
Finerenone	Drug Info	Phase 3	Diabetic nephropathy	ICD11: GB61	[713]
LAS-17177	Drug Info	Phase 3	Functional nausea/vomiting	ICD11: DD90	[714]
Omecamtiv mecarbil	Drug Info	Phase 3	Heart failure	ICD11: BD10-BD1Z	[715]
Tivantinib	Drug Info	Phase 3	Solid tumour/cancer	ICD11: 2A00-2F9Z	[716]
ABT-333	Drug Info	Phase 3	Viral hepatitis	ICD11: 1E51	[717]
BPI-2009	Drug Info	Phase 3	Lung cancer	ICD11: 2C25	[718]
Chlorpromazine	Drug Info	Phase 3	Coronavirus Disease 2019 (COVID-19)	ICD11: 1D6Y	[719]
JTT-705	Drug Info	Phase 3	Acute coronary syndrome	ICD11: BA4Z	[720]
KW-5338	Drug Info	Phase 3	Gastroparesis	ICD11: DA41	[721]
LAU-7b	Drug Info	Phase 3	Macular degeneration	ICD11: 9B78	[722]
Mavacamten	Drug Info	Phase 3	Hypertrophic cardiomyopathy	ICD11: BC43	[723]
NE-10064	Drug Info	Phase 3	Cardiac arrhythmia	ICD11: BC65	[724]
Nestorone	Drug Info	Phase 3	Endometriosis	ICD11: GA10	[725]
NSC-122758	Drug Info	Phase 3	Vitamin deficiency	ICD11: 5B55	[726]
SCH-417690	Drug Info	Phase 3	Human immunodeficiency virus infection	ICD11: 1C60	[24]
TV-5600	Drug Info	Phase 3	Lupus erythematosus	ICD11: 4A40	[727]
Alilusem	Drug Info	Phase 3	Essential hypertension	ICD11: BA00	[728]
Bexagliflozin	Drug Info	Phase 3	Type-2 diabetes	ICD11: 5A11	[729]
CKD-501	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[730]
ED-71	Drug Info	Phase 3	Osteoporosis	ICD11: FB83	[731]
GW-1000	Drug Info	Phase 3	Cerebral vasospasm	ICD11: BA85	[732]
Maribavir	Drug Info	Phase 3	Cytomegalovirus infection	ICD11: 1D82	[733]
MLN4924	Drug Info	Phase 3	Myelodysplastic syndrome	ICD11: 2A37	[734]
SB-939	Drug Info	Phase 3	Acute myeloid leukaemia	ICD11: 2A60	[735]
Y-100032	Drug Info	Phase 3	Multiple myeloma	ICD11: 2A83	[736]
AD-5423	Drug Info	Phase 3	Schizophrenia	ICD11: 6A20	[737]
AK-602	Drug Info	Phase 3	Human immunodeficiency virus infection	ICD11: 1C60	[512]
Brivanib	Drug Info	Phase 3	Breast cancer	ICD11: 2C60-2C6Y	[738]
HSDB-3466	Drug Info	Phase 3	Psoriasis vulgaris	ICD11: EA90	[739]
Losartan	Drug Info	Phase 3	Hypertension	ICD11: BA00-BA04	[740]
LU-AE58054	Drug Info	Phase 3	Alzheimer disease	ICD11: 8A20	[741]
Masitinib	Drug Info	Phase 3	Amyotrophic lateral sclerosis	ICD11: 8B60	[742]
Pacritinib	Drug Info	Phase 3	Chronic myelogenous leukaemia	ICD11: 2A20	[743]
Pacritinib	Drug Info	Phase 3	Chronic myelogenous leukaemia	ICD11: 2A20	[744]
SUVN-G3031	Drug Info	Phase 3	Cognitive impairment	ICD11: 6D71	[745]
TAK-875	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[746]
VX-661	Drug Info	Phase 3	Cystic fibrosis	ICD11: CA25	[747]
BRN-0077922	Drug Info	Phase 3	Influenza virus infection	ICD11: 1E30	[748]
FCU-2711	Drug Info	Phase 3	Diffuse large B-cell lymphoma	ICD11: 2A81	[749]
Hydroxychloroquine	Drug Info	Phase 3	Malaria	ICD11: 1F40-1F45	[506]
KRM-1648	Drug Info	Phase 3	Chlamydial lymphogranuloma	ICD11: 1A80	[750]
LEE011	Drug Info	Phase 3	Solid tumour/cancer	ICD11: 2A00-2F9Z	[751]
LY-450139	Drug Info	Phase 3	Alzheimer disease	ICD11: 8A20	[752]
Nitrazepam	Drug Info	Phase 3	Insomnia	ICD11: 7A00	[753]
R-1124	Drug Info	Phase 3	Functional nausea/vomiting	ICD11: DD90	[754]
WSM-3978G	Drug Info	Phase 3	Hypertrophic cardiomyopathy	ICD11: BC43	[755]
ABC294640	Drug Info	Phase 3	Advanced solid tumour	ICD11: 2A00-2F9Z	[756]
CR-2017	Drug Info	Phase 3	Irritable bowel syndrome	ICD11: DD91	[757]
DW-1030	Drug Info	Phase 3	Cerebral vasospasm	ICD11: BA85	[758]
DX-8951	Drug Info	Phase 3	Pancreatic cancer	ICD11: 2C10	[759]
Fenfluramine	Drug Info	Phase 3	Dravet syndrome	ICD11: 8A61-8A6Z	[760]
FRC-8653	Drug Info	Phase 3	Essential hypertension	ICD11: BA00	[761]
Imatinib	Drug Info	Phase 3	Mantle cell lymphoma	ICD11: 2A85	[762]
Imatinib	Drug Info	Phase 3	Mantle cell lymphoma	ICD11: 2A85	[763]
INCB-024360	Drug Info	Phase 3	Renal cell carcinoma	ICD11: 2C90	[764]
KW-3902	Drug Info	Phase 3	Congestive heart failure	ICD11: BD10	[765]
L-651582	Drug Info	Phase 3	Lung cancer	ICD11: 2C25	[507]
NSC-9705	Drug Info	Phase 3	Osteoarthritis	ICD11: FA00	[766]
OPC-12759	Drug Info	Phase 3	Peptic ulcer	ICD11: DA61	[767]
TD-758	Drug Info	Phase 3	Cerebral vasospasm	ICD11: BA85	[507]
BAY-8697661	Drug Info	Phase 3	Hepatocellular carcinoma	ICD11: 2C12	[768]
BNP-1350	Drug Info	Phase 3	Ovarian cancer	ICD11: 2C73	[769]
CQA 206-291	Drug Info	Phase 3	Parkinsonism	ICD11: 8A00	[770]
CV-4093	Drug Info	Phase 3	Essential hypertension	ICD11: BA00	[771]
DUP-996	Drug Info	Phase 3	Cognitive impairment	ICD11: 6D71	[772]
Ganaxolone	Drug Info	Phase 3	Complex partial seizure	ICD11: 8A61-8A6Z	[773]
JNJ-54135419	Drug Info	Phase 3	Depression	ICD11: 6A71	[116]
LAS-X-113	Drug Info	Phase 3	Allergy	ICD11: 4A80	[636]
LS-248	Drug Info	Phase 3	Prostate cancer	ICD11: 2C82	[774]
LY-317615	Drug Info	Phase 3	Mantle cell lymphoma	ICD11: 2A85	[775]
Mirvetuximab soravtansine	Drug Info	Phase 3	Ovarian cancer	ICD11: 2C73	[776]
MRTX849	Drug Info	Phase 3	Lung cancer	ICD11: 2C25	[777]
PR-934423	Drug Info	Phase 3	Anaesthesia	ICD11: 8E22	[778]
PT2977	Drug Info	Phase 3	Renal cell carcinoma	ICD11: 2C90	[779]
RO-7-0207	Drug Info	Phase 3	Colon cancer	ICD11: 2B90	[780]
SHP-620	Drug Info	Phase 3	Cytomegalovirus infection	ICD11: 1D82	[781]
Sildenafil	Drug Info	Phase 3	Erectile dysfunction	ICD11: HA00-HA01	[782]
WY-1485	Drug Info	Phase 3	Haemorrhagic stroke	ICD11: 8B20	[18]
ABT-627	Drug Info	Phase 3	Diabetic nephropathy	ICD11: GB61	[783]
ABT-761	Drug Info	Phase 3	Asthma	ICD11: CA23	[784]
Ag-221	Drug Info	Phase 3	Acute myelogenous leukaemia	ICD11: 2A41	[785]
Al3-818	Drug Info	Phase 3	Leiomyosarcoma	ICD11: 2B58	[786]
AMD-070	Drug Info	Phase 3	Whim syndrome	ICD11: 4A00	[787]
ANA-756	Drug Info	Phase 3	Essential hypertension	ICD11: BA00	[18]
ARC-029	Drug Info	Phase 3	Alzheimer disease	ICD11: 8A20	[788]
ASP-2151	Drug Info	Phase 3	Herpes simplex virus infection	ICD11: 1F00	[789]
Atorvastatin	Drug Info	Phase 3	Hypertriglyceridaemia	ICD11: 5C80	[790]
CC-25430	Drug Info	Phase 3	Tinnitus	ICD11: AB37	[507]
CS-011	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[42]
CYT-387	Drug Info	Phase 3	Myelofibrosis	ICD11: 2A22	[791]
DEB-025	Drug Info	Phase 3	Muscular dystrophy	ICD11: 8C70	[792]
DRF-2593	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[42]
FT-0755769	Drug Info	Phase 3	Stomach cancer	ICD11: 2B72	[793]
GTPL-9088	Drug Info	Phase 3	Atopic dermatitis	ICD11: EA80	[794]
HE-3286	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[795]
Montelukast	Drug Info	Phase 3	Asthma	ICD11: CA23	[24]
Palovarotene	Drug Info	Phase 3	Fibrodysplasia ossificans progressiva	ICD11: FB31	[796]
RG7388	Drug Info	Phase 3	Acute myeloid leukaemia	ICD11: 2A60	[797]
Ridaforolimus	Drug Info	Phase 3	Sarcoma	ICD11: 2A60-2C35	[798]
SCY-078	Drug Info	Phase 3	Candidiasis	ICD11: 1F23	[799]
Solithromycin	Drug Info	Phase 3	Bacillus anthracis infection	ICD11: 1G40-1G41	[800]
Drugs in Phase 2 Clinical Trial			Click to Show/Hide the Full List of Drugs: 113 Drugs
Emixustat	Drug Info	Phase 2/3	Age-related macular degeneration	ICD11: 9B75	[801]
Verapamil	Drug Info	Phase 2/3	Hypertension	ICD11: BA00-BA04	[802], [803]
EMD-128130	Drug Info	Phase 2/3	Rett syndrome	ICD11: LD90	[804]
Pexacerfont	Drug Info	Phase 2/3	Anxiety disorder	ICD11: 6B00-6B0Z	[805]
Amiodarone	Drug Info	Phase 2/3	Ventricular tachyarrhythmia	ICD11: BC71	[806], [807]
AY-27,255	Drug Info	Phase 2/3	Haemorrhagic stroke	ICD11: 8B20	[507]
DA-8159	Drug Info	Phase 2/3	Pulmonary hypertension	ICD11: BB01	[808]
Fexinidazole	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1D51-1F53	[809], [810]
Fexinidazole	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1D51-1F53	[810]
HOE-239	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1F51	[810]
Lilly-112531	Drug Info	Phase 2/3	Diffuse large B-cell lymphoma	ICD11: 2A81	[811]
Ramatroban	Drug Info	Phase 2/3	Allergic rhinitis	ICD11: CA08	[812]
LDE225	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[813]
PF-00734200	Drug Info	Phase 2	Type-2 diabetes	ICD11: 5A11	[814]
UK-453,061	Drug Info	Phase 2	Human immunodeficiency virus infection	ICD11: 1C60	[815]
Leniolisib	Drug Info	Phase 2	Sjogren syndrome	ICD11: 4A43	[816]
ABT-450	Drug Info	Phase 2	Hepatitis C virus infection	ICD11: 1E50-1E51	[817], [818]
BRN-0456976	Drug Info	Phase 2	Anaesthesia	ICD11: 8E22	[819]
CYC-202	Drug Info	Phase 2	Lung cancer	ICD11: 2C25	[820]
NITD609	Drug Info	Phase 2	Malaria	ICD11: 1F40-1F45	[821]
Paritaprevir	Drug Info	Phase 2	Hepatitis C virus infection	ICD11: 1E50-1E51	[818]
PF-06463922	Drug Info	Phase 2	Lung cancer	ICD11: 2C25	[822]
BLZ-945	Drug Info	Phase 2	Amyotrophic lateral sclerosis	ICD11: 8B60	[823]
BMS-690514	Drug Info	Phase 2	Chronic pain	ICD11: MG30	[824]
GS-9620	Drug Info	Phase 2	Viral hepatitis	ICD11: 1E51	[825]
LIK-066	Drug Info	Phase 2	Heart failure	ICD11: BD10-BD1Z	[826]
TD-8954	Drug Info	Phase 2	Gastrointestinal disease	ICD11: DE2Z	[827]
AZD-2014	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[828]
BAY-1002670	Drug Info	Phase 2	Uterine leiomyoma	ICD11: 2E86	[829]
Ethanol	Drug Info	Phase 2	Diabetic nephropathy	ICD11: GB61	[18]
LJN452	Drug Info	Phase 2	Primary biliary cholangitis	ICD11: DB96	[830]
S-297995	Drug Info	Phase 2	Opiate dependence	ICD11: 6C43	[831]
(S)-oxybutynin	Drug Info	Phase 2	Urinary incontinence	ICD11: MF50	[832]
MT-1303	Drug Info	Phase 2	Crohn disease	ICD11: DD70	[833]
PT2385	Drug Info	Phase 2	Von hippel-lindau disease	ICD11: 5A75	[834]
VATALANIB	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[835]
VATALANIB	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[836]
AP26113	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[837]
AP26113	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[838]
BMS-275183	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[839]
CBL-0102	Drug Info	Phase 2	Creutzfeldt-Jakob disease	ICD11: 8E02	[840]
GSK2269557	Drug Info	Phase 2	Asthma	ICD11: CA23	[841]
JNJ-53718678	Drug Info	Phase 2	Respiratory syncytial virus infection	ICD11: 1C80	[842]
KNI-272	Drug Info	Phase 2	Human immunodeficiency virus infection	ICD11: 1C60	[843]
Remogliflozin etabonate	Drug Info	Phase 2	Type-1/2 diabetes	ICD11: 5A10-5A11	[844]
SSR-97193	Drug Info	Phase 2	Malaria	ICD11: 1F40	[845]
BIIB-014	Drug Info	Phase 2	Parkinsonism	ICD11: 8A00	[846]
Gepirone	Drug Info	Phase 2	Depression	ICD11: 6A70-6A7Z	[847]
HE-3235	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[848]
HP-184	Drug Info	Phase 2	Multiple sclerosis	ICD11: 8A40	[849]
Org-33062	Drug Info	Phase 2	Cocaine addiction	ICD11: 6C45	[850]
PF-04991532	Drug Info	Phase 2	Diabetic complication	ICD11: 5A2Y	[851]
Saracatinib	Drug Info	Phase 2	Osteosarcoma	ICD11: 2B51	[852]
BMS-911543	Drug Info	Phase 2	Chronic myelogenous leukaemia	ICD11: 2A20	[853]
CP-122721	Drug Info	Phase 2	Depression	ICD11: 6A71	[854]
EXR-202	Drug Info	Phase 2	Parkinsonism	ICD11: 8A00	[18]
Ibrolipim	Drug Info	Phase 2	Hypertriglyceridaemia	ICD11: 5C80	[855]
PD-115934	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[476]
Vincamine	Drug Info	Phase 2	Cerebrovascular dementia	ICD11: 6D81	[414]
Ym-758	Drug Info	Phase 2	Angina pectoris	ICD11: BA40	[856]
Z-4828	Drug Info	Phase 2	Histiocytic sarcoma	ICD11: 2B31	[857]
ABT-384	Drug Info	Phase 2	Viral hepatitis	ICD11: 1E51	[858]
AR-67	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[859]
AS-703026	Drug Info	Phase 2	Mantle cell lymphoma	ICD11: 2A85	[860]
AZD2624	Drug Info	Phase 2	Multiple sclerosis	ICD11: 8A40	[861]
CT-1501R	Drug Info	Phase 2	Diabetes mellitus	ICD11: 5A10	[862]
D-600	Drug Info	Phase 2	Asthma	ICD11: CA23	[863]
EBP-994	Drug Info	Phase 2	Progeria	ICD11: LD2B	[541]
HPPH	Drug Info	Phase 2	Lung cancer	ICD11: 2C25	[864]
ICN-2001-3	Drug Info	Phase 2	Viral hepatitis	ICD11: 1E51	[865]
JI-101	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[866]
LY-2603618	Drug Info	Phase 2	Pancreatic cancer	ICD11: 2C10	[867]
LY-333531	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[868]
MB-07811	Drug Info	Phase 2	Hypertriglyceridaemia	ICD11: 5C80	[869]
MK-3118	Drug Info	Phase 2	Candidiasis	ICD11: 1F23	[870]
MK-3118	Drug Info	Phase 2	Candidiasis	ICD11: 1F23	[871]
NCI-C50000	Drug Info	Phase 2	Pruritus	ICD11: EC90	[507]
PNU-100480	Drug Info	Phase 2	Pulmonary tuberculosis	ICD11: 1B10	[872]
SAM-531	Drug Info	Phase 2	Alzheimer disease	ICD11: 8A20	[873]
Verubulin	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[874]
VX-680	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[875]
ZK-31224	Drug Info	Phase 2	Pulmonary hypertension	ICD11: BB01	[876]
ABT-263	Drug Info	Phase 2	Ovarian cancer	ICD11: 2C73	[877]
AZD-2327	Drug Info	Phase 2	Anxiety disorder	ICD11: 6B00-6B0Z	[878]
BC-3781	Drug Info	Phase 2	Pneumocystis pneumonia	ICD11: CA40	[879]
EZN-2208	Drug Info	Phase 2	Colorectal cancer	ICD11: 2B91	[880]
GS-5806	Drug Info	Phase 2	Respiratory syncytial virus infection	ICD11: 1C80	[881]
MKC-442	Drug Info	Phase 2	Human immunodeficiency virus infection	ICD11: 1C60	[882]
NSC-603071	Drug Info	Phase 2	Ovarian cancer	ICD11: 2C73	[883]
Nuplazid	Drug Info	Phase 2	Alzheimer disease	ICD11: 8A20	[884]
Oxfendazole	Drug Info	Phase 2	Trichuris trichiura infection	ICD11: 1F6G	[885]
PF-04937319	Drug Info	Phase 2	Type-2 diabetes	ICD11: 5A11	[886]
PTC299	Drug Info	Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[887]
RG-7916	Drug Info	Phase 2	Muscular atrophy	ICD11: 8B61	[888]
RO-5190591	Drug Info	Phase 2	Viral hepatitis	ICD11: 1E51	[889]
TAK-063	Drug Info	Phase 2	Schizophrenia	ICD11: 6A20	[890]
TAK-272	Drug Info	Phase 2	Type-2 diabetes	ICD11: 5A11	[891]
TAK-906	Drug Info	Phase 2	Gastroparesis	ICD11: DA41	[892]
Tesofensine	Drug Info	Phase 2	Pain	ICD11: MG30-MG3Z	[893]
Tocopherol	Drug Info	Phase 2	Phenylketonuria	ICD11: 5C50	[894]
CC-220	Drug Info	Phase 2	Sarcoidosis	ICD11: 4B20	[895]
Encequidar	Drug Info	Phase 2	Metastatic breast cancer	ICD11: 2C60-2C6Y	[896]
Estetrol	Drug Info	Phase 2	Diabetes mellitus	ICD11: 5A10	[897]
GS-9857	Drug Info	Phase 2	Hepatitis C virus infection	ICD11: 1E50-1E51	[898]
GSK2330672	Drug Info	Phase 2	Pruritus	ICD11: EC90	[899]
HY-126236	Drug Info	Phase 2	Congestive heart failure	ICD11: BD10	[900]
JNJ-37822681	Drug Info	Phase 2	Schizophrenia	ICD11: 6A20	[901]
KD025	Drug Info	Phase 2	Psoriasis vulgaris	ICD11: EA90	[902]
KW-4354	Drug Info	Phase 2	Muscular dystrophy	ICD11: 8C70	[903]
N-DESMETHYLCLOZAPINE	Drug Info	Phase 2	Schizophrenia	ICD11: 6A20	[904]
RWJ-241947	Drug Info	Phase 2	Fatty liver disease	ICD11: DB92	[42]
SHR-1020	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[905]
TAK-652	Drug Info	Phase 2	Human immunodeficiency virus infection	ICD11: 1C60	[906]
Drugs in Phase 1 Clinical Trial			Click to Show/Hide the Full List of Drugs: 47 Drugs
GEA-6414	Drug Info	Phase 1/2	Parkinsonism	ICD11: 8A00	[507]
CB-3304	Drug Info	Phase 1/2	Chronic lymphocytic leukaemia	ICD11: 2A82	[907]
CC-223	Drug Info	Phase 1/2	Lung cancer	ICD11: 2C25	[908]
LS-172108	Drug Info	Phase 1/2	Cerebral stroke	ICD11: 8B11	[909]
CCRIS-1920	Drug Info	Phase 1/2	Osteoporosis	ICD11: FB83	[910]
KB-2796	Drug Info	Phase 1/2	Migraine	ICD11: 8A80	[507]
NOVA-63035	Drug Info	Phase 1/2	Choroidal neovascularization	ICD11: 9B76	[911]
BRN-5220127	Drug Info	Phase 1/2	Chlamydial lymphogranuloma	ICD11: 1A80	[912]
TRV-130	Drug Info	Phase 1/2	Hypothyroidism	ICD11: 5A00	[913]
BRN-3122594	Drug Info	Phase 1/2	Haemorrhoid	ICD11: DB60	[118]
GTPL7557	Drug Info	Phase 1/2	Schizophrenia	ICD11: 6A20	[914]
LY-2940680	Drug Info	Phase 1/2	Breast cancer	ICD11: 2C60	[915]
SB-1317	Drug Info	Phase 1/2	Brain cancer	ICD11: 2A00	[916]
ZK-299	Drug Info	Phase 1/2	Contraception	ICD11: JA65	[917]
KBP-5074	Drug Info	Phase 1/2	Hypertension	ICD11: BA00-BA04	[918]
TJN-324	Drug Info	Phase 1/2	Essential hypertension	ICD11: BA00	[919]
AG-1549	Drug Info	Phase 1	Human immunodeficiency virus infection	ICD11: 1C60	[920]
STX 64	Drug Info	Phase 1	Prostate cancer	ICD11: 2C82	[921]
MK-0822	Drug Info	Phase 1	Osteoporosis	ICD11: FB83	[922]
AST-1306	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[923]
BE-14348A	Drug Info	Phase 1	Viral hepatitis	ICD11: 1E51	[924]
H3B-6545	Drug Info	Phase 1	Breast cancer	ICD11: 2C60	[925]
M-813	Drug Info	Phase 1	Schizophrenia	ICD11: 6A20	[926]
M-813	Drug Info	Phase 1	Schizophrenia	ICD11: 6A20	[927], [926]
PPI-2458	Drug Info	Phase 1	Diabetes mellitus	ICD11: 5A10	[928]
Alvespimycin hydrochloride	Drug Info	Phase 1	Ovarian cancer	ICD11: 2C73	[929]
SC-20713	Drug Info	Phase 1	Contraception	ICD11: JA65	[445]
Benzoylphenylurea	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[930], [931]
DA-1229	Drug Info	Phase 1	Type-2 diabetes	ICD11: 5A11	[932]
GS-9883	Drug Info	Phase 1	Human immunodeficiency virus infection	ICD11: 1C60	[933]
MP-513	Drug Info	Phase 1	Diabetes mellitus	ICD11: 5A10	[934]
SPC-100270	Drug Info	Phase 1	Psoriasis vulgaris	ICD11: EA90	[935]
Talinolol	Drug Info	Phase 1	Intestine motility disorder	ICD11: DA39	[936]
BRN-3224996	Drug Info	Phase 1	Allergy	ICD11: 4A80	[937]
CBT-1	Drug Info	Phase 1	Histiocytic sarcoma	ICD11: 2B31	[507]
H3B-6527	Drug Info	Phase 1	Hepatocellular carcinoma	ICD11: 2C12	[938]
MLN-8054	Drug Info	Phase 1	Colon cancer	ICD11: 2B90	[939]
BRN-0498823	Drug Info	Phase 1	Essential hypertension	ICD11: BA00	[18]
H3B-8800	Drug Info	Phase 1	Myelodysplastic syndrome	ICD11: 2A37	[940]
BI-11634	Drug Info	Phase 1	Thrombosis	ICD11: DB61-GB90	[941]
BS-572	Drug Info	Phase 1	Raynaud disease	ICD11: BD42	[507]
NSC-675451	Drug Info	Phase 1	Pulmonary tuberculosis	ICD11: 1B10	[942]
OSI-930	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[943]
AZD-3839	Drug Info	Phase 1	Alzheimer disease	ICD11: 8A20	[944]
G-23350	Drug Info	Phase 1	Venous thromboembolism	ICD11: BD72	[945]
ITX-5061	Drug Info	Phase 1	Human immunodeficiency virus infection	ICD11: 1C60	[946]
MK-6186	Drug Info	Phase 1	Human immunodeficiency virus infection	ICD11: 1C60-1C62	[947]
Discontinued/withdrawn Drugs			Click to Show/Hide the Full List of Drugs: 49 Drugs
Ecabapide	Drug Info	Discontinued in Preregistration	Peptic ulcer	ICD11: DA61	[948]
Cilomilast	Drug Info	Discontinued in Phase 3	Emphysema	ICD11: CA21	[949]
Motesanib	Drug Info	Discontinued in Phase 3	Lung cancer	ICD11: 2C25	[950]
Darapladib	Drug Info	Discontinued in Phase 3	Arteriosclerosis obliterans	ICD11: BD40	[951]
Taranabant	Drug Info	Discontinued in Phase 3	Obesity	ICD11: 5B80-5B81	[952]
Avitriptan	Drug Info	Discontinued in Phase 3	Migraine	ICD11: 8A80	[953]
BMS-204352	Drug Info	Discontinued in Phase 3	Nerve injury	ICD11: ND56	[954]
KRP-297	Drug Info	Discontinued in Phase 2	Hypertriglyceridaemia	ICD11: 5C80	[955]
Napitane mesilate	Drug Info	Discontinued in Phase 2	Major depressive disorder	ICD11: 6A70-6A7Z	[956]
Lexacalcitol	Drug Info	Discontinued in Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[957], [958]
CP-195543	Drug Info	Discontinued in Phase 2	Rheumatoid arthritis	ICD11: FA20	[959]
AZD0328	Drug Info	Discontinued in Phase 2	Alzheimer disease	ICD11: 8A20	[960]
Perillyl alcohol	Drug Info	Discontinued in Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[961]
TAK-802	Drug Info	Discontinued in Phase 2	Urinary dysfunction	ICD11: GC2Z	[962]
Tetramethylpyrazine	Drug Info	Discontinued in Phase 2	Neurological disorder	ICD11: 6B60	[963]
YM-992	Drug Info	Discontinued in Phase 2	Depression	ICD11: 6A70-6A7Z	[964]
BMS-181168	Drug Info	Discontinued in Phase 2	Cognitive impairment	ICD11: 6D71	[965]
SINOMENINE	Drug Info	Discontinued in Phase 2	Rheumatoid arthritis	ICD11: FA20	[966]
AZD0837	Drug Info	Discontinued in Phase 2	Atrial fibrillation	ICD11: BC81	[967]
UK-369003	Drug Info	Discontinued in Phase 1/2	Erectile dysfunction	ICD11: HA00-HA01	[968]
ABT-107	Drug Info	Discontinued in Phase 1	Attention deficit hyperactivity disorder	ICD11: 6A05	[969]
E2101	Drug Info	Discontinued in Phase 1	Dyskinesia	ICD11: 8A02	[970]
YM-17E	Drug Info	Discontinued in Phase 1	Hypertriglyceridaemia	ICD11: 5C80	[971]
JTK-853	Drug Info	Discontinued in Phase 1	Hepatitis C virus infection	ICD11: 1E50-1E51	[972]
DPC-681	Drug Info	Discontinued in Phase 1	Human immunodeficiency virus infection	ICD11: 1C60-1C62	[973]
CJ-11974	Drug Info	Discontinued	Irritable bowel syndrome	ICD11: DD91	[974]
CP-529414	Drug Info	Discontinued	Hypertriglyceridaemia	ICD11: 5C80	[975]
FCF-89	Drug Info	Discontinued	Rheumatoid arthritis	ICD11: FA20	[976]
CAM-2028	Drug Info	Discontinued	Acute nasopharyngitis	ICD11: CA00	[977]
Nomifensine	Drug Info	Discontinued	Depression	ICD11: 6A71	[978]
ADD-3878	Drug Info	Discontinued	Endometriosis	ICD11: GA10	[42]
ML-3000	Drug Info	Discontinued	Osteoarthritis	ICD11: FA00	[24]
ABT-001	Drug Info	Discontinued	Asthma	ICD11: CA23	[979]
BMY-42569	Drug Info	Discontinued	Depression	ICD11: 6A71	[980]
EPO-906	Drug Info	Discontinued	Breast cancer	ICD11: 2C60	[300]
GTPL-463	Drug Info	Discontinued	Lung cancer	ICD11: 2C25	[507]
Norcisapride	Drug Info	Discontinued	Gastro-oesophageal reflux disease	ICD11: DA22	[981]
RO-408757	Drug Info	Discontinued	Breast cancer	ICD11: 2C60	[982]
AN-16649	Drug Info	Discontinued	Acute lymphoblastic leukemia	ICD11: 2B33	[983]
BMS-488043	Drug Info	Discontinued	Human immunodeficiency virus infection	ICD11: 1C60	[984]
CB-44212	Drug Info	Discontinued	Epilepsy	ICD11: 8A60	[507]
GBR-12909	Drug Info	Discontinued	Cocaine addiction	ICD11: 6C45	[985]
GW-873140	Drug Info	Discontinued	Human immunodeficiency virus infection	ICD11: 1C60	[986]
ATL-2502	Drug Info	Discontinued	Inflammatory bowel disease	ICD11: DD72	[987]
GW-766994	Drug Info	Discontinued	Asthma	ICD11: CA23	[988]
NSC-303812	Drug Info	Discontinued	Hyperphosphatemia	ICD11: 5C64	[989]
Octopamine	Drug Info	Discontinued	Thrombosis	ICD11: DB61	[990]
RS-8359	Drug Info	Discontinued	Depression	ICD11: 6A71	[991]
YMB-1002	Drug Info	Discontinued	Breast cancer	ICD11: 2C60	[992]
Preclinical/investigative Agents			Click to Show/Hide the Full List of Drugs: 46 Drugs
EPX-100	Drug Info	Preclinical	Dravet syndrome	ICD11: 8A61	[993]
VA-10872	Drug Info	Preclinical	Anaesthesia	ICD11: 8E22	[176]
Q-100155	Drug Info	Preclinical	Rheumatoid arthritis	ICD11: FA20	[663]
VUFB-11502	Drug Info	Preclinical	Amebiasis	ICD11: 1A36	[994]
BRN-3148038	Drug Info	Preclinical	Schizophrenia	ICD11: 6A20	[995]
WIN 55212-2	Drug Info	Investigative	Anaesthesia	ICD11: 8E22	[507]
Agmatine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[507]
Coumarin	Drug Info	Investigative	Discovery agent	ICD: N.A.	[996]
Ethylmorphine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[997]
Benzotetronic acid	Drug Info	Investigative	Discovery agent	ICD: N.A.	[998]
Androstenedione	Drug Info	Investigative	Discovery agent	ICD: N.A.	[242]
Butyrfentanyl	Drug Info	Investigative	Anaesthesia	ICD11: 8E22	[999]
Adinazolam	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[1000]
Bencyclane	Drug Info	Investigative	Cerebral vasospasm	ICD11: BA85	[507]
Medazepam	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1001]
Antipyrine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[24]
Clorazepic acid	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[1002]
Desmethylastemizole	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1003]
Estrone sulfate	Drug Info	Investigative	Discovery agent	ICD: N.A.	[444]
Imipramine oxide	Drug Info	Investigative	Depression	ICD11: 6A71	[1004]
Lauric acid	Drug Info	Investigative	Alzheimer disease	ICD11: 8A20	[1005]
Cyamemazine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1006]
Dihydrostreptomycin	Drug Info	Investigative	Pulmonary tuberculosis	ICD11: 1B10	[604]
Equilenin	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1007]
Manidipine 2HCl	Drug Info	Investigative	Discovery agent	ICD: N.A.	[771]
Niguldipine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[507]
Paraoxon	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1008]
Chenyltaurine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1009]
CTK1G9578	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1010]
Darodipine	Drug Info	Investigative	Cerebral ischaemia	ICD11: 8B1Z	[507]
Dexverapamil	Drug Info	Investigative	Discovery agent	ICD: N.A.	[507]
Dotarizine	Drug Info	Investigative	Migraine	ICD11: 8A80	[507]
Ethyl biscoumacetate	Drug Info	Investigative	Thrombosis	ICD11: DB61	[1011]
Flosequinan	Drug Info	Investigative	Congestive heart failure	ICD11: BD10	[1012]
Lorpiprazole	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[1013]
Medrogestone	Drug Info	Investigative	Corpus luteum cyst	ICD11: GA18	[1014]
Miocamycin	Drug Info	Investigative	Pulmonary tuberculosis	ICD11: 1B10	[1015]
Nordazepam	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[488]
O-Benzylguanine	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1016]
Benzodiazepine	Drug Info	Investigative	Anxiety disorder	ICD11: 6B00	[18]
Benzyloxyresorufin	Drug Info	Investigative	Discovery agent	ICD: N.A.	[1017]
Chlormadinone	Drug Info	Investigative	Discovery agent	ICD: N.A.	[692]
Clorindione	Drug Info	Investigative	Hypertriglyceridaemia	ICD11: 5C80	[1018]
Emopamil	Drug Info	Investigative	Cerebral ischaemia	ICD11: 8B1Z	[507]
Erythromycin salnacedin	Drug Info	Investigative	Discovery agent	ICD: N.A.	[518]
Niludipine	Drug Info	Investigative	Cerebral vasospasm	ICD11: BA85	[507]

Full List of Metabolic Reactions (MR) Catalyzed by This DME

MR ID	Reactant	Product	MR Type	Source Drug	REF
MR010130	(+)-JQ1	(+)-JQ1 Metabolite M1	Unclear - Unclear	(+)-JQ1	[1019]
MR010136	(+)-JQ1	(+)-JQ1 Metabolite M7	Unclear - Unclear	(+)-JQ1	[1019]
MR010132	(+)-JQ1	(+)-JQ1 Metabolite M3	Unclear - Unclear	(+)-JQ1	[1019]
MR010133	(+)-JQ1	(+)-JQ1 Metabolite M4	Unclear - Unclear	(+)-JQ1	[1019]
MR010134	(+)-JQ1	(+)-JQ1 Metabolite M5	Unclear - Unclear	(+)-JQ1	[1019]
MR010135	(+)-JQ1	(+)-JQ1 Metabolite M6	Unclear - Unclear	(+)-JQ1	[1019]
MR010137	(+)-JQ1	(+)-JQ1 Metabolite M8	Unclear - Unclear	(+)-JQ1	[1019]
MR010138	(+)-JQ1	(+)-JQ1 Metabolite M9	Unclear - Unclear	(+)-JQ1	[1019]
MR012388	(S)-oxybutynin	Oxy-NO	Unclear - Unclear	(S)-oxybutynin	[1020]
MR000009	Abemaciclib	N-desethylabemaciclib	Oxidation - N-Dealkylation	Abemaciclib	[418]
MR000010	Abemaciclib	Hydroxyabemaciclib	Oxidation - Hydroxylation	Abemaciclib	[418]
MR000008	Hydroxyabemaciclib	Hydroxy-N-desethylabemaciclib	Oxidation - N-Dealkylation	Abemaciclib	[418]
MR000007	N-desethylabemaciclib	Hydroxy-N-desethylabemaciclib	Oxidation - Hydroxylation	Abemaciclib	[418]
MR000012	Abiraterone sulfate	N-oxide abiraterone sulfate	Oxidation - Oxidation	Abiraterone acetate	[1021]
MR005416	ABL001	Asciminib metabolite M37	Oxidation - Oxidationn ring opening	ABL001	[1022]
MR004533	ABT-001	ABT-001 Metabolite M-	Other reaction - Methylhydroxylation	ABT-001	[979], [1023]
MR011470	ABT-107	ABT-107 Metabolite M2	Unclear - Unclear	ABT-107	[969]
MR006065	ABT-263	ABT-263 metabolite	Unclear - Unclear	ABT-263	[877]
MR006066	ABT-384	A-1331480	Unclear - Unclear	ABT-384	[858]
MR006067	ABT-384	A-847082	Unclear - Unclear	ABT-384	[858]
MR010400	ABT-450	ABT-450 Metabolite M6	Oxidation - Oxidation	ABT-450	[1024]
MR010406	ABT-450	ABT-450 Metabolite M2	Oxidation - Oxidation	ABT-450	[1024]
MR010407	ABT-450	ABT-450 Metabolite M24	Multi-steps Reaction - Oxidation& conjugation	ABT-450	[1024]
MR010401	ABT-450 Metabolite M6	ABT-450 Metabolite M3	Oxidation - Oxidation	ABT-450	[1024]
MR000023	Acalabrutinib	ACP-5862	Oxidation - Oxidation	Acalabrutinib	[1025], [1026], [1027]
MR000050	Acetaminophen	NAPQI	Oxidation - Oxidation	Acetaminophen	[1028], [1029]
MR011014	Adefovir	Cyclic prodrug of Adefovir 3	Unclear - Unclear	adefovir	[1030]
MR002798	Adinazolam	Desmethyladinazolam	Oxidation - N-Demethylation	Adinazolam	[1000]
MR000107	(-) albendazole sulfoxide	Albendazole sulfone	Oxidation - Oxidation	Albendazole	[1031], [1032], [1033]
MR000110	Albendazole	(-) albendazole sulfoxide	Oxidation - Oxidation	Albendazole	[1034], [1031], [1032], [1033]
MR000112	Albendazole	.	Oxidation - Oxidation	Albendazole	[1035]
MR003455	Alectinib hydrochloride	Alectinib metabolite M5	Oxidation - Hydroxylation	Alectinib hydrochloride	[265]
MR003457	Alectinib metabolite M4	Alectinib metabolite M6	Oxidation - N-dealkylation	Alectinib hydrochloride	[265]
MR003456	Alectinib metabolite M5	Alectinib metabolite M4	Oxidation - Oxidation	Alectinib hydrochloride	[265]
MR000122	Alfentanil	Noralfentanil	Oxidation - N-Dealkylation	Alfentanil	[1036]
MR000125	Alfentanil	2-(4-ethyl-5-oxo-1,2,3,4-tetrazol-1-yl)acetaldehyde	Oxidation - N-Dealkylation	Alfentanil	[1037]
MR000127	Alfuzosin hydrochloride	.	Oxidation - O-Demethylations	Alfuzosin hydrochloride	[1038]
MR000127	Alfuzosin hydrochloride	.	Oxidation - N-Dealkylation	Alfuzosin hydrochloride	[1038]
MR000127	Alfuzosin hydrochloride	.	Oxidation - Oxidation	Alfuzosin hydrochloride	[1038]
MR012080	Alilusem	MU2'	Unclear - Unclear	Alilusem	[728]
MR000133	Aliskiren	Aliskiren metabolite M4	Oxidation - O-Dealkylation	Aliskiren	[1039]
MR000134	Aliskiren	Aliskiren metabolite M1	Oxidation - O-Demethylation	Aliskiren	[1039]
MR000130	Aliskiren metabolite M2	Aliskiren metabolite M4	Oxidation - O-Dealkylation	Aliskiren	[1039]
MR000129	Aliskiren metabolite M3	Aliskiren metabolite M4	Oxidation - O-Dealkylation	Aliskiren	[1039]
MR002988	Alitretinoin	4-oxo-9-cis-retinoic acid	Unclear - Unclear	Alitretinoin	[142]
MR002991	Alitretinoin	4-hydroxy-9-cis-retinoic acid	Unclear - Unclear	Alitretinoin	[142]
MR008995	Almogran	N-desmethylalmotriptan	Oxidation - N-demethylation	Almogran	[1040]
MR008988	Almogran	2-OH-almotriptan	Oxidation - Aliphatic hydroxylation	Almogran	[44]
MR008998	Almogran	1-[({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methane)sulfonyl]pyrrolidin-2-ol	Oxidation - Oxidation	Almogran	[1040]
MR000155	Almotriptan malate	LAS 31612	Oxidation - N-Demethylation	Almotriptan malate	[46], [45]
MR000153	Almotriptan malate	Almotriptan malate metabolite M3	Oxidation - Pyrrolidine Oxidation	Almotriptan malate	[45]
MR000158	Alogliptin	Alogliptin M2	Oxidation - Deamination	Alogliptin	[420]
MR009835	Alpelisib	Alpelisib Metabolite M3	Oxidation - Oxidation	Alpelisib	[1041]
MR009846	Alprazolam	4-hydroxyalprazolam	Unclear - Unclear	Alprazolam	[1042], [1043]
MR009781	17-DMAG M2	17-DMAG M6	Oxidation - Hydroxylation	Alvespimycin hydrochloride	[929]
MR009779	Alvespimycin hydrochloride	17-DMAG M2	Oxidation - Hydroxylation	Alvespimycin hydrochloride	[929]
MR009782	Alvespimycin hydrochloride	17-DMAG M1	Oxidation - Hydroxylation	Alvespimycin hydrochloride	[929]
MR009783	Alvespimycin hydrochloride	17-DMAG M3	Oxidation - Demethylation	Alvespimycin hydrochloride	[929]
MR009784	Alvespimycin hydrochloride	17-DMAG M4	Oxidation - Demethylation	Alvespimycin hydrochloride	[929]
MR009849	Ambrisentan	4-hydroxymethyl?ambrisentan	Oxidation - Oxidation	Ambrisentan	[1044], [1045]
MR010544	Amiodarone	Desethylamiodarone	Unclear - Unclear	Amiodarone	[807]
MR013093	Amiodarone hydrochloride	Mono-N-desethylamiodarone	Oxidation - N-dealkylation	Amiodarone hydrochloride	[1046], [1047], [36]
MR000181	Amlodipine besylate	Amlodipine besylate metabolite M9	Oxidation - Dehydrogenation	Amlodipine besylate	[33]
MR000194	Amlodipine besylate	Amlodipine besylate metabolite M9	Oxidation - Dehydrogenation	Amlodipine maleate	[33]
MR000228	Amprenavir	Amprenavir metabolite M2	Unclear - Unclear	Amprenavir	[1048]
MR000227	Amprenavir	Amprenavir metabolite M1	Unclear - Unclear	Amprenavir	[1048]
MR000229	Amprenavir	Amprenavir metabolite M3	Unclear - Unclear	Amprenavir	[1048]
MR000231	Amprenavir	Amprenavir metabolite M5	Unclear - Unclear	Amprenavir	[1048]
MR000230	Amprenavir	Amprenavir metabolite M4	Unclear - Unclear	Amprenavir	[1048]
MR004542	AN-16649	AQ4	Unclear - Unclear	AN-16649	[1049], [1050], [1051]
MR000237	Anastrozole	Hydroxyanastrozole	Oxidation - Hydroxylation	Anastrozole	[266]
MR012849	Androstenedione	6beta-hydroxy-androstenedione	Oxidation - Aliphatic hydroxylation	Androstenedione	[242]
MR007487	Antipyrine	4-OH-antipyrine	Oxidation - Hydrolyzationn	Antipyrine	[24]
MR008510	AP26113	AP26123	Multi-steps Reaction - N-demethylation; cysteine conjugation	AP26113	[837]
MR003361	Apalutamide	N-desmethyl apalutamide	Oxidation - N-Demethylation	Apalutamide	[1052]
MR000248	Apixaban	Apixaban M2 metabolite	Oxidation - O-Demethylation	Apixaban	[1053], [1054]
MR000249	Apixaban	Apixaban M4/7 metabolite	Oxidation - Hydroxylation	Apixaban	[1053], [1054]
MR000256	Apomorphine	Norapomorphine	Oxidation - N-Demethylation	Apomorphine	[103]
MR000276	Apremilast	O-desmethyl Apremilast	Oxidation - O-Demethylation	Apremilast	[1055]
MR002970	Aprepitant	5-({[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}methyl)-2,3-dihydro-1H-1,2,4-triazol-3-one	Oxidation - O-Dealkylation	Aprepitant	[1056], [76]
MR002971	Aprepitant	(2R)-2-(4-fluorophenyl)-2-{[(5-oxo-2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]amino}acetic acid	Oxidation - O-Dealkylation	Aprepitant	[1056], [76]
MR002969	Aprepitant	(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine	Oxidation - N-Dealkylation	Aprepitant	[1056], [76]
MR002972	Aprepitant	5-oxo-1,4-dihydro-1,2,4-triazole-3-carbaldehyde	Oxidation - N-Dealkylation	Aprepitant	[1056], [76]
MR002973	Aprepitant	1-[3,5-bis(trifluoromethyl)phenyl]ethanone	Oxidation - N-Demethylation	Aprepitant	[1056], [76]
MR002974	Aprepitant	5-{[(2S,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-2,4-dihydro-1,2,4-triazol-3-one	Oxidation - N-Demethylation	Aprepitant	[1056], [76]
MR002969	Aprepitant	(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine	Oxidation - N-Dealkylation	Aprepitant	[1056], [76]
MR011561	AR-67	AR-67 hypothesize	Unclear - Unclear	AR-67	[859]
MR008734	Arbidol	Arbidol M5 metabolite	Multi-steps Reaction - N-demethylation; sulfoxidation	Arbidol	[8]
MR008740	Arbidol	Arbidol M7 metabolite	Multi-steps Reaction - N-demethylation; sulfoxidation	Arbidol	[8]
MR008731	Arbidol	Arbidol M3-2 metabolite	Oxidation - N-demethylation	Arbidol	[8]
MR008743	Arbidol	Arbidol M8 metabolite	Oxidation - Sulfoxidation	Arbidol	[8]
MR012560	Arecaidine	N-methylnipecotic acid	Unclear - Unclear	Arecoline	[1057]
MR000290	Aripiprazole	Dehydro-aripiprazole	Oxidation - Dehydrogenation	Aripiprazole lauroxil	[1058], [1059]
MR000294	Armodafinil	Modafinil sulfone	Unclear - Unclear	Armodafinil	[1060]
MR008681	Arteether	Dihydroqinghaosu (DQHS)	Oxidation - Deethylation	Arteether	[143], [1061]
MR000298	Artemether	Dihydroartemisinin	Oxidation - Oxidation	Artemether	[1062]
MR007272	AS-703026	AS-703026 M445	Unclear - Unclear	AS-703026	[860]
MR009785	AST-1306	Allitinib M1	Oxidation - O-dealkylation	AST-1306	[923]
MR003055	Atazanavir	Atazanavir metabolite m1	Unclear - Unclear	Atazanavir	[1063]
MR003062	Atazanavir	Atazanavir metabolite M15	Unclear - Unclear	Atazanavir	[1063]
MR009873	Atorvastatin calcium	2-hydroxyatorvastatin acid	Unclear - Unclear	Atorvastatin calcium	[1064], [1065]
MR009875	Atorvastatin calcium	4-hydroxyatorvastatin acid	Unclear - Unclear	Atorvastatin calcium	[1064]
MR009879	Atorvastatin lactone	4-hydroxyatorvastatin lactone	Unclear - Unclear	Atorvastatin calcium	[1066]
MR009880	Avanafil	Avanafil Metabolite M1	Unclear - Unclear	Avanafil	[1067], [1068]
MR009881	Avanafil	Avanafil Metabolite M2	Unclear - Unclear	Avanafil	[1067], [1068]
MR009882	Avanafil	Avanafil Metabolite M4-1	Unclear - Unclear	Avanafil	[1067], [1068]
MR009883	Avanafil	Avanafil Metabolite M4-2	Unclear - Unclear	Avanafil	[1067], [1068]
MR009884	Avanafil	Avanafil Metabolite M16	Unclear - Unclear	Avanafil	[1067], [1068]
MR005429	Avapritinib	M690	Conjugation - Hydroxy glucuronidation	Avapritinib	[346]
MR005428	Avapritinib	Unclear	Unclear - Unclear	Avapritinib	[346]
MR009432	Avitriptan	OD048	Oxidation - O-desmethylation	Avitriptan	[953]
MR009891	Axitinib	Axitinib Metabolite M14	Unclear - Unclear	axitinib	[1069]
MR009885	Axitinib	Axitinib Metabolite M12	Unclear - Unclear	axitinib	[1069]
MR009889	Axitinib	Axitinib Metabolite M8b	Unclear - Unclear	axitinib	[1069]
MR009886	Axitinib Metabolite M12	Axitinib Metabolite M9	Unclear - Unclear	axitinib	[1069]
MR009887	Axitinib Metabolite M12	Axitinib Metabolite M15	Unclear - Unclear	axitinib	[1069]
MR006510	AY-27,255	Apovincaminic acid	Oxidation - Hydrolyzationn; dealkylation	AY-27,255	[1070]
MR007285	AZD-2014	Unclear	Unclear - Unclear	AZD-2014	[1071]
MR012382	AZD-2327	N-deethylated AZD-2327	Oxidation - N-deethylation	AZD-2327	[878]
MR009369	AZD0328	AZD0328 Metabolite M6	Oxidation - N-oxidation	AZD0328	[960]
MR011862	AZD0837	AR-H069927	Oxidation - Oxidation	AZD0837	[967]
MR011562	AZD2624	AZD2624 Metabolite M1	Unclear - Unclear	AZD2624	[861]
MR011563	AZD2624	AZD2624 Metabolite M2	Unclear - Unclear	AZD2624	[861]
MR012427	AZD8931	AZD8931 M12	Oxidation - O-desmethylation	AZD8931	[1072]
MR012428	AZD8931 M12	AZD8931 M17	Conjugation - Glucuronidation	AZD8931	[1072]
MR009614	BAF-312	Siponimod M7	Oxidation - Hydroxylation	BAF-312	[72]
MR009616	BAF-312	Siponimod M6	Oxidation - Hydroxylation	BAF-312	[72]
MR009618	BAF-312	Siponimod M5	Oxidation - Hydroxylation	BAF-312	[72]
MR014170	Baloxavir marboxil	Baloxavir acid	Unclear - Unclear	Baloxavir marboxil	[502]
MR003199	Barnidipine	Barnidipine metabolite M-1	Oxidation - N-Debenzylization	Barnidipine	[643]
MR003200	Barnidipine	Barnidipine metabolite M-8	Oxidation - Oxidation	Barnidipine	[643]
MR003190	Barnidipine metabolite M-1	Barnidipine metabolite M-3	Hydrolysis - Hydrolysis	Barnidipine	[643]
MR003193	Barnidipine metabolite M-3	Barnidipine metabolite M-4	Oxidation - Oxidation	Barnidipine	[643]
MR003198	Barnidipine metabolite M-8	Barnidipine metabolite M-2	Oxidation - N-Debenzylization	Barnidipine	[643]
MR007289	BAY-1002670	BAY-1002670 M7	Multi-steps Reaction - Reduction; oxidation	BAY-1002670	[829]
MR007290	BAY-1002670	BAY-1002670 M12	Multi-steps Reaction - Reduction; oxidation	BAY-1002670	[829]
MR007291	BAY-1002670	BAY-1002670 M19	Oxidation - Oxidationn	BAY-1002670	[829]
MR007292	BAY-1002670	BAY-1002670 M1	Conjugation - Glucuronidation	BAY-1002670	[829]
MR007287	BAY-1002670 M4	Vilaprisan	Oxidation - Oxidationn	BAY-1002670	[829]
MR007288	BAY-1002670 M4	BAY-1002670 M7	Oxidation - Oxidationn	BAY-1002670	[829]
MR007294	BC-3781	Unclear	Unclear - Unclear	BC-3781	[1073]
MR003839	BE-14348A	Eriodictyol	Oxidation - Hydrolyzationn	BE-14348A	[924]
MR003841	BE-14348A	Apigenin	Oxidation - Dehydrogenation	BE-14348A	[924]
MR000351	Beclabuvir	BCV M1	Oxidation - N-Demethylation	Beclabuvir	[1074]
MR009246	Beclomethasone dipropionate	Beclomethasone-17-monopropionate (17-BMP)	Hydrolysis - Hydrolysis	Beclomethasone dipropionate	[1075]
MR009251	Beclomethasone dipropionate	Beclomethasone-21-monopropionate (21-BMP)	Hydrolysis - Hydrolysis	Beclomethasone dipropionate	[105]
MR009253	Beclomethasone dipropionate	6beta-OH-BDP	Unclear - Unclear	Beclomethasone dipropionate	[104]
MR009254	Beclomethasone dipropionate	Delta6-BDP	Unclear - Unclear	Beclomethasone dipropionate	[104]
MR006029	Bedaquiline fumarate	N-desmethyl BDQ (M1)	Oxidation - N-demethylation	Bedaquiline fumarate	[269], [1076]
MR006027	Bedaquiline fumarate	Bedaquiline fumarate Metabolite M2	Oxidation - N-demethylation	Bedaquiline fumarate	[269], [1076]
MR006031	Belinostat	Belinostat Amide	Unclear - Unclear	Belinostat	[1077]
MR006033	Belinostat	Belinostat Acid	Unclear - Unclear	Belinostat	[1077]
MR003037	Benidipine	N-desbenzylbenidipine	Hydrolysis - Hydrolysis; Reduction	Benidipine	[677]
MR003038	Benidipine	Dehydrobenidipine	Unclear - Unclear	Benidipine	[677]
MR003476	Benzbromarone	Benzbromarone metabolite M7	Unclear - Unclear	Benzbromarone	[1078]
MR003477	Benzbromarone	Benzbromarone metabolite M6	Oxidation - Hydroxylation	Benzbromarone	[1078]
MR010376	Benzoylphenylurea	MmBPU	Oxidation - Desmethylation	Benzoylphenylurea	[930], [931]
MR013779	Berberine	Demethyleneberberine	Oxidation - Demethylenation	Berberine	[1079], [631]
MR008942	Betrixaban	O-desmethylbetrixaban	Oxidation - Demethylation	Betrixaban	[193]
MR011594	Bexagliflozin	EGT0001301	Oxidation - Oxidation	Bexagliflozin	[729]
MR011595	EGT0001301	EGT0001494	Oxidation - Oxidation	Bexagliflozin	[729]
MR010123	BI-11634	BI-11634 Metabolite M1	Oxidation - Mono-oxidation	BI-11634	[941]
MR000372	Binimetinib	1,4-Diiminoquinone intermediate	Oxidation - Two-Electron Oxidation	Binimetinib	[348]
MR000374	Bisoprolol	Bisoprolol metabolite M4	Oxidation - O-Dealkylation	Bisoprolol	[504]
MR012422	BLZ-945	BLZ-945 M5/M7	Unclear - Unclear	BLZ-945	[823]
MR012425	BLZ-945	BLZ-945 M3	Unclear - Unclear	BLZ-945	[823]
MR012426	BLZ-945	BLZ-945 M4	Unclear - Unclear	BLZ-945	[823]
MR011144	BMS-201038	Lomitapide Metabolite M1	Oxidation - N-dealkylation	BMS-201038	[1080]
MR011145	BMS-201038	Lomitapide Metabolite M3	Oxidation - Oxidation	BMS-201038	[1080]
MR009443	BMS-204352	BMS-204352 Metabolite M2	Unclear - Unclear	BMS-204352	[954]
MR012650	BMS-275183	Unclear	Unclear - Unclear	BMS-275183	[839]
MR012656	BMS-275183	BMS-275183 Metabolite M23	Unclear - Unclear	BMS-275183	[839]
MR000381	BMS-298585	BMS-298585 metabolite M10	Unclear - Unclear	BMS-298585	[706], [1081]
MR000378	BMS-298585	BMS-298585 metabolite M16	Unclear - Unclear	BMS-298585	[706], [1081]
MR000376	BMS-298585	BMS-298585 metabolite M1	Oxidation - O-Dealkylation	BMS-298585	[706], [1081]
MR000380	BMS-298585	BMS-298585 metabolite M14	Unclear - Unclear	BMS-298585	[706], [1081]
MR004543	BMS-488043	BMS-488043 Metabolite M1	Unclear - Unclear	BMS-488043	[1082]
MR012092	Brivanib	Brivanib Metabolites M7	Unclear - Unclear	BMS-582664	[738]
MR000384	Asunaprevir metabolite M6	Asunaprevir metabolite M9	Oxidation - Oxidation	BMS-650032	[1074], [1083]
MR000389	BMS-650032	Asunaprevir metabolite M6	Oxidation - O-Demethylation	BMS-650032	[1074], [1083]
MR000394	BMS-650032	Asunaprevir metabolite M3,5,7	Oxidation - Monohydroxylation	BMS-650032	[1074], [1083]
MR012504	BMS-690514	BMS-690514 M2	Unclear - Unclear	BMS-690514	[1084]
MR012393	BMS-911543	BMS-911543 M1	Unclear - Unclear	BMS-911543	[853]
MR000396	BNP-1350	.	Unclear - Unclear	BNP-1350	[1085]
MR006805	Boceprevir	Boceprevir metabolite M28	Multi-steps Reaction - Oxidationn; keto-reduction	Boceprevir	[1086]
MR006806	Boceprevir	Boceprevir metabolite M31	Multi-steps Reaction - Oxidationn; keto-reduction	Boceprevir	[1086]
MR000411	Bortezomib	Bortezomib metabolite M23	Unclear - Unclear	Bortezomib	[24]
MR000412	Bortezomib	Bortezomib metabolite M24	Unclear - Unclear	Bortezomib	[24]
MR000409	Bortezomib	Bortezomib metabolite M2	Oxidation - Oxidation; Deboronation	Bortezomib	[24]
MR000408	Bortezomib	Bortezomib metabolite M1	Oxidation - Oxidative Deboronation	Bortezomib	[24]
MR000403	Bortezomib metabolite M2	Bortezomib metabolite M8	Oxidation - Hydoxylation	Bortezomib	[24]
MR000416	Bosentan	Bosentan metabolite Ro 47-8634	Oxidation - O-Demethylation	Bosentan	[24]
MR000417	Bosentan	Bosentan metabolite Ro 48-5033	Oxidation - Methyl-Hydroxylation	Bosentan	[24]
MR006807	Bosutinib	N-desmethyl bosutinib	Oxidation - N-desmethylation	Bosutinib	[1087]
MR000420	BPI-2009	BPI-2009 metabolite M4	Oxidation - Oxidation	BPI-2009	[718]
MR000433	Brentuximab vedotin	Monomethyl Auristatin E (MMAE)	Oxidation - Oxidation	Brentuximab vedotin	[1088]
MR000436	Brexpiprazole	Brexpiprazole S-oxide	Unclear - Unclear	Brexpiprazole	[146], [1089]
MR000442	Brigatinib	AP26123	Oxidation - N-Demethylation; Cysteine Conjugation	Brigatinib	[837]
MR012083	Brivanib	Brivanib Metabolites M7	Unclear - Unclear	Brivanib	[738]
MR002552	Brivaracetam	Brivaracetam metabolite M1b	Oxidation - Hydroxylation	Brivaracetam	[1090]
MR006076	BRN-3122594	Alpha-keto acid 4a	Unclear - Unclear	BRN-3122594	[118], [1091]
MR006955	BRN-3148038	6beta?OH BRN-3148038	Oxidation - 6-hydroxylation	BRN-3148038	[995]
MR006077	BRN-5220127	10"-OH-rokitamycin	Oxidation - Hydrolyzationn	BRN-5220127	[912]
MR006080	BRN-5220127	Leucomycin a7	Unclear - Unclear	BRN-5220127	[912]
MR000458	Bromfenac indolinone	Bromfenac metabolite M3	Unclear - Unclear	Bromfenac	[1092], [1093]
MR000457	Bromfenac indolinone	Bromfenac metabolite M2	Unclear - Unclear	Bromfenac	[1092], [1093]
MR005708	Bromocriptine mesylate	Bromolysergic acid	Hydrolysis - Hydrolysis	Bromocriptine mesylate	[1094], [1095], [1096]
MR005709	Bromocriptine mesylate	Bromoisolysergic acid	Hydrolysis - Hydrolysis	Bromocriptine mesylate	[1094], [1095], [1096]
MR000470	16alpha-butyrloxyprednisolone	16alpha-hydroxyprednisolone	Unclear - Unclear	Budesonide	[291]
MR000469	22-hydroxy Intermediate metabolite of Budesonide	16alpha-butyrloxyprednisolone	Unclear - Unclear	Budesonide	[291]
MR000471	Budesonide	22-hydroxy Intermediate metabolite of Budesonide	Oxidation - Hydroxylation	Budesonide	[291]
MR000472	Budesonide	6-beta-hydroxybudesonide	Oxidation - Hydroxylation	Budesonide	[291]
MR000481	Bupivacaine hydrochloride	N-desbutylbupivacaine	Unclear - Unclear	Bupivacaine hydrochloride	[1097]
MR000491	Bupivacaine hydrochloride	Hydroxybuprenorphine	Oxidation - Hydroxylation	Buprenorphine hydrochloride	[1098]
MR000490	Buprenorphine hydrochloride	Norbuprenorphine	Oxidation - N-Dealkylation	Buprenorphine hydrochloride	[1098]
MR000513	Bupropion	S-hydroxybupropion	Oxidation - Hydroxylation	Bupropion	[3]
MR000513	Bupropion	R-hydroxybupropion	Oxidation - Hydroxylation	Bupropion	[3]
MR000524	Buspirone	Buspirone N-oxide	Oxidation - N-Oxidation	Buspirone	[1099]
MR000522	Buspirone	5-hydroxybuspirone	Oxidation - Hydroxylation	Buspirone	[1100]
MR000523	Buspirone	1-Pyrimidinylpiperazine	Oxidation - N-Dealkylation	Buspirone	[1101], [1099], [1102]
MR000525	Buspirone	3'-hydroxybuspirone	Oxidation - Hydroxylation	Buspirone	[1099]
MR000526	Buspirone	6'-hydroxybuspirone	Oxidation - Hydroxylation	Buspirone	[1099], [1102]
MR007588	Butyrfentanyl	Beta-hydroxy-butyrylfentanyl	Oxidation - Hydrolyzationn	Butyrfentanyl	[999]
MR007589	Butyrfentanyl	(omega-1)-hydroxy-butyrylfentanyl	Oxidation - Hydrolyzationn	Butyrfentanyl	[999]
MR007590	Butyrfentanyl	Nor-butyrylfentanyl	Unclear - Unclear	Butyrfentanyl	[999]
MR002575	Cabazitaxel	RPR123142	Oxidation - 10-O-Demethylation	Cabazitaxel	[1103]
MR002576	Cabazitaxel	RPR112698	Oxidation - 7-O-Demethylation	Cabazitaxel	[1103]
MR002577	Cabazitaxel	Cabazitaxel metabolite M1	Oxidation - Hydroxylation	Cabazitaxel	[1103]
MR003120	Cabergoline	FCE-21904	Oxidation - Oxidation	Cabergoline	[1104]
MR000538	Cabozantinib	EXEL-5162	Oxidation - N-Oxidation	Cabozantinib	[1105]
MR000544	Caffeine	1,3,7-Trimethyluric acid	Oxidation - 8-Hydroxylation	Caffeine	[1106], [1107]
MR000546	Caffeine	Theophylline	Oxidation - 7-N-Demethylation	Caffeine	[1106], [1107]
MR002816	Calcitriol	1a,25R(OH)2-26,23S-lactone D3	Oxidation - Hydroxylation	Calcitriol	[349], [1108]
MR000550	Canagliflozin	Canagliflozin metabolite M9	Oxidation - Hydroxylation	Canagliflozin	[1109]
MR002513	Cannabidiol	6beta-Hydroxycannabidiol	Oxidation - Hydroxylation	Cannabidiol	[56]
MR002514	Cannabidiol	6alpha-Hydroxycannabidiol	Oxidation - Hydroxylation	Cannabidiol	[56]
MR002516	Cannabidiol	2''-Hydroxycannabidiol	Oxidation - Hydroxylation	Cannabidiol	[56]
MR002518	Cannabidiol	4''-Hydroxycannabidiol	Oxidation - Hydroxylation	Cannabidiol	[56]
MR002818	Capsaicin	Capsaicin metabolite M1	Oxidation - Dehydrogenation	Capsaicin	[57]
MR002819	Capsaicin	Capsaicin metabolite M2	Oxidation - Omega-Hydroxylation	Capsaicin	[57]
MR002820	Capsaicin	Capsaicin metabolite M3	Oxidation - Omega-1-Hydroxylation	Capsaicin	[57]
MR002821	Capsaicin	Capsaicin metabolite M4	Oxidation - Dehydrogenation	Capsaicin	[57]
MR002822	Capsaicin	Capsaicin metabolite M5M7	Oxidation - Hydroxylation	Capsaicin	[57]
MR002823	Capsaicin	Capsaicin metabolite M6	Oxidation - O-Dehydrogenation	Capsaicin	[57]
MR002824	Capsaicin	Capsaicin metabolite M8	Oxidation - N-Dehydrogenation; Oxygenation	Capsaicin	[57]
MR002825	Capsaicin	Capsaicin metabolite M9	Oxidation - N-Dehydrogenation	Capsaicin	[57]
MR002582	2-hydroxycarbamazepine	2-hydroxyiminostilbene	Unclear - Unclear	Carbamazepine	[1110]
MR002586	3-hydroxycarbamazepine	2,3-Dihydroxycarbamazepine	Unclear - Unclear	Carbamazepine	[1110]
MR002588	Carbamazepine	10,11-Epoxycarbamazepine	Oxidation - 10,11-Epoxidation	Carbamazepine	[1110]
MR002589	Carbamazepine	3-hydroxycarbamazepine	Oxidation - 3-Hydroxylation	Carbamazepine	[1110]
MR003126	Cariprazine hydrochloride	Desmethyl cariprazine	Oxidation - Demethylation	Cariprazine hydrochloride	[431]
MR003127	Cariprazine hydrochloride	Didesmethyl cariprazine	Oxidation - Demethylation	Cariprazine hydrochloride	[431]
MR003125	Desmethyl cariprazine	Didesmethyl cariprazine	Oxidation - Demethylation	Cariprazine hydrochloride	[431]
MR000570	Carvedilol	4'-hydroxyphenylcarvedilol	Oxidation - 4'-Hydroxylation	Carvedilol	[1111]
MR000571	Carvedilol	5'-hydroxyphenylcarvedilol	Oxidation - 5'-Hydroxylation	Carvedilol	[1111]
MR000569	Carvedilol	8-hydroxycarbazolylcarvedilol	Oxidation - 8-Hydroxylation	Carvedilol	[1111]
MR006092	CB-3304	CB-3304 Metabolite X	Oxidation - Bis-demethylation	CB-3304	[907]
MR007386	CBL-0102	CBL-0102 M2	Oxidation - N-desethylation	CBL-0102	[840]
MR007386	CBL-0102	CBL-0102 M2	Oxidation - O-demethylation	CBL-0102	[840]
MR013351	O-demethylated tetrandrine	Quinone methide	Unclear - Unclear	CBT-1	[1112]
MR006095	CC-223	O-desmethyl CC-223	Oxidation - N-demethylation	CC-223	[908]
MR006096	CC-223	Keto CC-223	Unclear - Unclear	CC-223	[908]
MR006097	CC-223	N-oxide CC-223	Oxidation - N-oxidation	CC-223	[908]
MR006098	CC-223	Imine CC-223	Unclear - Unclear	CC-223	[908]
MR006103	CCRIS-1920	CCRIS-1920 Metabolite M1	Oxidation - Oxidationn	CCRIS-1920	[876], [1113]
MR000587	Celecoxib	Hydroxycelecoxib	Oxidation - Hydroxylation	Celecoxib	[1114]
MR000602	Cerivastatin sodium	Desmethylcerivastatin	Oxidation - Demethylation	Cerivastatin sodium	[1115]
MR000609	Cevimeline hydrochloride	Cevimeline trans-sulfoxide	Oxidation - Sulfoxidation	Cevimeline hydrochloride	[1116]
MR000610	Cevimeline hydrochloride	Cevimeline cis-sulfoxide	Unclear - Unclear	Cevimeline hydrochloride	[1116]
MR002541	Chenodeoxycholic acid	7alpha-hydroxy-3-oxo-5beta-cholan-24-oic Acid	Oxidation - Oxidation	Chenodeoxycholic acid	[106]
MR006230	Chenyltaurine	6-hydroxy Taurochenodeoxycholic acid	Oxidation - Hydrolyzationn	Chenyltaurine	[1009]
MR000624	Chloramphenicol	Desmethylcerivastatin	Unclear - Unclear	Chloramphenicol	[1117]
MR000625	Chloramphenicol	D-threo-2-amino-1-(p-nitrophenyl)-1,3-propanediol	Unclear - Unclear	Chloramphenicol	[1117]
MR000628	Chloroquine	(R)-chloroquine, N-desethyl	Oxidation - N-Dealkylation	Chloroquine	[1118], [506], [505]
MR011384	Chlorpromazine	Opromazine	Oxidation - S-oxidation	Chlorpromazine	[1119]
MR000642	Chlorpromazine hydrochloride	Demonomethylchlorpromazine	Unclear - Unclear	Chlorpromazine hydrochloride	[1120], [1121]
MR000645	Chlorpromazine hydrochloride	Opromazine	Unclear - Unclear	Chlorpromazine hydrochloride	[1120], [1121]
MR000641	Demonomethylchlorpromazine	Dedimethylchlorpromazine	Unclear - Unclear	Chlorpromazine hydrochloride	[1120]
MR000650	Chlorpropamide	2-OH-chlorpropamide	Oxidation - Hydroxylation	Chlorpropamide	[24]
MR000653	Cholic acid	3-dehydrocholic acid	Unclear - Unclear	Cholic acid	[1122]
MR003607	Cibenzoline	4,5-dehydrocibenzoline	Oxidation - Hydrolyzationn	Cibenzoline	[652]
MR003608	Cibenzoline	Cibenzoline Metabolite M3	Oxidation - Hydrolyzationn	Cibenzoline	[652]
MR003609	Cibenzoline	Cibenzoline Metabolite M4	Oxidation - Hydrolyzationn	Cibenzoline	[652]
MR003206	Desisobutyrylciclesonide	Ciclesonide metabolite M2	Unclear - Unclear	Ciclesonide	[1123]
MR003205	Desisobutyrylciclesonide	Ciclesonide metabolite M3	Unclear - Unclear	Ciclesonide	[1123]
MR014160	Ciclosporin	AM1	Oxidation - Oxidation	Ciclosporin	[1124]
MR014166	Ciclosporin	AM4N	Oxidation - Oxidation	Ciclosporin	[1124]
MR000657	Cilostazol	OPC-13326	Unclear - Unclear	Cilostazol	[1125], [1126]
MR005295	Cis-4-hydroxytamoxifen	Endoxifen	Oxidation - N-demethylation	Cis-4-hydroxytamoxifen	[1127]
MR009936	Cisapride	Norcisapride	Unclear - N-deataelon	Cisapride	[1128]
MR005751	Cisplatin	Aquated cisplatin	Unclear - Unclear	Cisplatin	[353]
MR006517	Citalopram hydrobromide	Demethylcitalopram	Oxidation - N-demethylation	Citalopram hydrobromide	[275], [1129]
MR005924	CJ-11974	M16 CL12764	Unclear - Unclear	CJ-11974	[1130]
MR005935	CJ-11974	M17 CJ-12458	Unclear - Unclear	CJ-11974	[1130]
MR006528	Clarithromycin	14-hydroxyclarithromycin	Oxidation - Hydrolyzationn	Clarithromycin	[1131]
MR006529	Clarithromycin	N-desmethylclarithromycin	Oxidation - N-demethylation	Clarithromycin	[1131]
MR006539	Clindamycin	Clindamycin sulfoxide	Unclear - Unclear	Clindamycin	[434]
MR006540	Clindamycin	N-desmethylclindamycin	Unclear - Unclear	Clindamycin	[434]
MR006541	Clobazam	Clobazam Metabolite M9	Unclear - Unclear	Clobazam	[1132], [201]
MR006547	Clobazam Metabolite M7	Clobazam Metabolite M5	Unclear - Unclear	Clobazam	[1132]
MR006559	Clofazimine	Hydrolytic-deaminated clofazimine	Hydrolysis - Hydrolytic Deamination	Clofazimine	[1133]
MR008660	(E)-4-OH-CLOM	(E)-4-OH-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[107]
MR008657	(E)-DE-CLOM	(E)-DDE-CLOM	Unclear - Unclear	Clomiphene citrate	[107]
MR008656	Clomiphene citrate	(E)-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[107]
MR008664	Clomiphene citrate	(Z)-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[107]
MR008662	Clomiphene citrate	(E)-DDE-CLOM	Unclear - Unclear	Clomiphene citrate	[107]
MR009006	8-hydroxyclomipramine	8-hydroxydesmethyl clomipramine	Unclear - Unclear	Clomipramine	[384], [81]
MR009009	Clomipramine	Desmethylclomipramine	Oxidation - N-demethylation	Clomipramine	[384]
MR006567	Clomipramine hydrochloride	Desmethylclomipramine	Oxidation - N-demethylation	Clomipramine hydrochloride	[1134], [1135]
MR006581	Clonazepam	7-amino-clonazepam	Reduction - Reduction	Clonazepam	[1136]
MR006587	Clonidine	4-Hydroxyclonidine	Oxidation - 4-hydroxylation	Clonidine	[277]
MR006592	2-Oxoclopidogrel	Active Metabolite of Clopidogrel	spontaneous - spontaneous	Clopidogrel bisulfate	[24]
MR006591	Clopidogrel bisulfate	2-Oxoclopidogrel	Oxidation - Oxidationn	Clopidogrel bisulfate	[24]
MR005298	Clorazepic acid	Nordazepam	Oxidation - N-demethylation	Clorazepic acid	[1137]
MR006006	Clotiazepam	Unclear	Unclear - Unclear	Clotiazepam	[669]
MR005750	Clotrimazole	Unclear	Unclear - Unclear	Clotrimazole	[1138]
MR002835	Clozapine	N-desmethylclozapine	Oxidation - N-Demethylation	Clozapine	[24]
MR002836	Clozapine	Clozapine N-oxide	Oxidation - N-Oxidation	Clozapine	[24]
MR000685	Cobicistat	Cobicistat metabolite M3	Unclear - Unclear	Cobicistat	[1139]
MR000686	Cobicistat	Cobicistat metabolite M9	Unclear - Unclear	Cobicistat	[1139]
MR000687	Cobicistat	Cobicistat metabolite M2	Unclear - Unclear	Cobicistat	[1139]
MR000689	Cobicistat	Cobicistat metabolite M1	Unclear - Unclear	Cobicistat	[1139]
MR000694	Cobicistat	Cobicistat metabolite M18	Unclear - Unclear	Cobicistat	[1139]
MR000677	Cobicistat metabolite M2	Cobicistat metabolite M4	Unclear - Unclear	Cobicistat	[1139]
MR004090	Cocaine	Cocaine	Oxidation - N-demethylation	Cocaine	[1140]
MR004094	Codeine	Norcodeine	Oxidation - N-demethylation	Codeine	[1141]
MR012819	Colchicine	2-O-demethylcolchicine	Oxidation - Demethylation	Colchicine	[1142]
MR012820	Colchicine	3-O-desmethylchochicine	Oxidation - Demethylation	Colchicine	[1142]
MR013654	Conivaptan hydrochloride	Unclear	Unclear - Unclear	Conivaptan hydrochloride	[1143]
MR004101	Conjugated estrogens	Estrone	Reduction - Reduction	Conjugated estrogens	[1144]
MR005310	Coumarin	3-Hydroxycoumarin	Oxidation - Aromatic hydroxylation	Coumarin	[996]
MR003080	CR-2017	O-demethyl dexloxiglumide	Unclear - Unclear	CR-2017	[1145]
MR007425	CT-1501R	Lisofylline 4,5-diol	Unclear - Unclear	CT-1501R	[862]
MR005796	CTK1G9578	Unclear	Unclear - Unclear	CTK1G9578	[1010]
MR005317	Cyamemazine	N-desmethyl cyamemazine	Oxidation - N-demethylation	Cyamemazine	[1146], [1006]
MR007433	CYC-202	Met-4	Unclear - Unclear	CYC-202	[820]
MR007434	CYC-202	PMF30-128	Unclear - Unclear	CYC-202	[820]
MR012897	Cyclobenzaprine	4-Hydroxycyclophosphamide	Oxidation - 4-hydroxylation	Cyclobenzaprine	[1147], [24]
MR012907	Cyclobenzaprine	Dechloroethyl cyclophosphamide	Unclear - Unclear	Cyclobenzaprine	[1148]
MR009942	Cyclophosphamide	4-Hydroxycyclophosphamide	Unclear - Unclear	Cyclophosphamide	[1149]
MR009948	Cyclophosphamide	Dechloroethyl cyclophosphamide	Unclear - Unclear	Cyclophosphamide	[24]
MR007066	Cyproterone acetate	15beta-hydroxycyproterone acetate	Oxidation - Hydrolyzationn	Cyproterone acetate	[1150]
MR007438	D-600	D-600 M2	Unclear - Unclear	D-600	[863]
MR008451	DA-1229	4S-Hydroxyevogliptin	Oxidation - Hydroxylation	DA-1229	[932]
MR008454	DA-1229	4R-Hydroxyevogliptin	Oxidation - Hydroxylation	DA-1229	[932]
MR006516	DA-8159	N-desalkyludenafil	Oxidation - N-dealkylation	DA-8159	[808]
MR006601	Desmethyl-dabrafenib	M31-Dabrafenib	Oxidation - Oxidationn	Dabrafenib mesylate	[1151]
MR006602	M31-Dabrafenib	Dabrafenib mesylate Metabolite M26	Unclear - Unclear	Dabrafenib mesylate	[1151]
MR002839	Dapagliflozin	Dapagliflozin BMS-511926	Oxidation - O-Deethylation	Dapagliflozin	[1152]
MR002840	Dapagliflozin	Dapagliflozin BMS-639432	Oxidation - Hydroxylation	Dapagliflozin	[1152]
MR007076	Dapoxetine Metabolite M1	Desmethyldapoxetine	Oxidation - Demethylation	Dapoxetine	[1153], [1154], [1155]
MR000733	Dapsone	Dapsone hydroxylamine	Oxidation - N-Hydroxylation	Dapsone	[24]
MR000736	Darifenacin hydrobromide	UK-148,993	Oxidation - Hydroxylation	Darifenacin hydrobromide	[206]
MR000737	Darifenacin hydrobromide	Phenyl hydroxylate	Oxidation - Hydroxylation	Darifenacin hydrobromide	[206]
MR000740	Darifenacin hydrobromide	UK-222,247	Unclear - Unclear	Darifenacin hydrobromide	[206]
MR000738	Darifenacin hydrobromide	UK-88,862	Oxidation - N-Dealkylation	Darifenacin hydrobromide	[206]
MR000739	Darifenacin hydrobromide	UK-73,689	Oxidation - N-Dealkylation	Darifenacin hydrobromide	[206]
MR000741	Darunavir	Darunavir metabolite MB	Unclear - Unclear	Darunavir	[1156]
MR000744	Dasatinib	Dasatinib metabolite M4	Oxidation - N-Dealkylation	Dasatinib	[1157]
MR000747	Dasatinib	Dasatinib metabolite M20	Oxidation - Hydroxylation	Dasatinib	[1157]
MR000748	Dasatinib	Dasatinib metabolite M24	Oxidation - Hydroxylation	Dasatinib	[1157]
MR000759	21-Deflazacort	Deflazacort 6-beta-OH	Unclear - Unclear	Deflazacort	[1158]
MR003144	17-beta-estradiol	Estriol	Unclear - Unclear	Dehydroepiandrosterone	[1159]
MR003147	4-androstene-3,17-dione(AD)	Estrone	Unclear - Unclear	Dehydroepiandrosterone	[1159]
MR003250	(4RS,5S)-DM-6720	(S)-DM-6718	Unclear - Unclear	Delamanid	[279]
MR003252	Delamanid	(4RS,5S)-DM-6720	Unclear - Unclear	Delamanid	[279]
MR003137	Delavirdine mesylate	N-desalkyl delavirdine	Oxidation - N-Dealkylation	Delavirdine mesylate	[1160]
MR013673	Deoxycholic acid	1beta-OH-DCA	Unclear - Unclear	Deoxycholic acid	[110]
MR000770	Desloratadine	5-hydroxydesloratadine	Oxidation - Hydroxylation	Desloratadine	[356]
MR000771	Desloratadine	6-hydroxydesloratadine	Oxidation - Hydroxylation	Desloratadine	[356]
MR006261	Desmethylastemizole	Norastemizole	Oxidation - N-Dealkylation	Desmethylastemizole	[1003]
MR008963	Desvenlafaxine	N,O-Didesmethylvenlafaxine	Oxidation - N-demethylation	Desvenlafaxine	[1161]
MR000772	Desvenlafaxine succinate	N,O-Didesmethylvenlafaxine	Oxidation - N-Demethylation	Desvenlafaxine succinate	[1162]
MR000791	Dexamethasone sodium phosphate	6alpha-hydroxydexamethasone	Oxidation - Hydroxylation	Dexamethasone sodium phosphate	[1163]
MR000792	Dexamethasone sodium phosphate	6beta-hydroxydexamethasone	Oxidation - Hydroxylation	Dexamethasone sodium phosphate	[1163]
MR000794	Dexlansoprazole	Lansoprazole Sulfone	Oxidation - Oxidation	Dexlansoprazole	[358]
MR000818	Dextromethorphan hydrobromide	(+)-3-Methoxymorphinan	Oxidation - N-Demethylation	Dextromethorphan hydrobromide	[1164], [1165]
MR000811	Dextrorphan	3-hydroxymorphinan	Oxidation - N-Demethylation	Dextromethorphan hydrobromide	[24], [1165]
MR007109	Dextropropoxyphene	Nordextropropoxyphene	Oxidation - N-demethyiation	Dextropropoxyphene	[670], [1166]
MR000819	Diazepam	Nordazepam	Oxidation - N-Demethylation	Diazepam	[1167], [1168], [1169]
MR000825	Nordazepam	Oxazepam	Unclear - Unclear	Diazepam	[1167], [1168], [1169]
MR000823	Temazepam	Oxazepam	Oxidation - N-Demethylation	Diazepam	[1170], [1169]
MR002614	Diclofenac sodium	5-hydroxy diclofenac	Oxidation - 5-Hydroxylation	Diclofenac sodium	[1171], [1172]
MR002617	Diclofenac sodium	Diclofenac radical	Oxidation - Oxidation	Diclofenac sodium	[1173]
MR007113	Dienogest	Unclear	Unclear - Unclear	Dienogest	[1174]
MR000848	Digoxigenin-bisdigitoxoside	Digoxigenin-monodigitoxoside	Oxidation - Cleavage	Digoxin	[1175]
MR000855	Digoxin	Digoxigenin-bisdigitoxoside	Oxidation - Cleavage	Digoxin	[1175]
MR007114	Dihydralazine	Unclear	Unclear - Unclear	Dihydralazine	[666]
MR007121	Dihydrocodeine	Nordihydrocodeine	Unclear - Unclear	Dihydrocodeine	[660]
MR000868	Diltiazem hydrochloride	N-monodesmethyl diltilazem	Oxidation - N-Demethylation	Diltiazem hydrochloride	[1176]
MR003406	Diphenylpyraline	Levomepromazine sulfoxide	Oxidation - Sulfoxidation	Diphenylpyraline	[1177], [1178]
MR003407	Diphenylpyraline	N-monodesmethyl Levomepromazine	Oxidation - N-Demethylation	Diphenylpyraline	[1177], [1178]
MR000880	Disopyramide phosphate	Mono-isopropyl-disopyramide	Oxidation - N-Dealkylation	Disopyramide phosphate	[513], [1179]
MR000883	Diethyldithiocarbamic acid methyl ester	.	Oxidation - Thiono-Oxidation	Disulfiram	[1180]
MR000883	Diethyldithiocarbamic acid methyl ester	.	Oxidation - Sulfoxidation	Disulfiram	[1180]
MR000890	Docetaxel	Hydroxy-Docetaxel	Oxidation - Hydroxylation	Docetaxel	[1181], [1182]
MR000892	Dofetilide	N-desmethyl dofetllfde	Oxidation - N-Dealkylation	Dofetilide	[1183]
MR000893	Dofetilide	Dofetilide N-oxide	Oxidation - N-Oxidation	Dofetilide	[1183]
MR006614	Dolutegravir sodium	Hydroxilated form of dolutegravir (M3)	Oxidation - Hydrolyzationn	Dolutegravir sodium	[1184]
MR006637	Doravirine	Doravirine M9 Metabolite	Oxidation - Oxidationn	Doravirine	[1185]
MR005762	Doxapram hydrochloride	AHR 5955	Oxidation - Oxidationn	Doxapram hydrochloride	[1186], [1187], [282]
MR005766	Doxapram metabolite D	Doxapram metabolite C	Oxidation - Deethylation	Doxapram hydrochloride	[1186], [1187], [282]
MR006661	Doxepin hydrochloride	N-desmethyldoxepin	Oxidation - N-demethylation	Doxepin hydrochloride	[384]
MR006686	Dronabinol	11-Hydroxy-delta-9-THC	Oxidation - 11-hydroxylation	Dronabinol	[24], [1188], [1189], [1190]
MR006696	Dronabinol	11-OH-delata-Tetrahydrocannabinol	Oxidation - Aliphatic hydroxylation	Dronabinol	[24], [242]
MR006695	Dronabinol	9-alpha,10-alpha-epoxyhexahydrocannabinol	Oxidation - 9, 10-epoxidation	Dronabinol	[24], [1190]
MR006691	Dronabinol	8-Hydroxy-delta-9-THC	Oxidation - 8-hydroxylation	Dronabinol	[24]
MR006693	Dronabinol	7-beta-Hydroxy-delta-9-THC	Oxidation - 7-hydroxylation	Dronabinol	[24]
MR006693	Dronabinol	7-alpha-Hydroxy-delta-9-THC	Oxidation - 7-hydroxylation	Dronabinol	[24]
MR006694	Dronabinol	8-beta-Hydroxy-delta-9-THC	Oxidation - 8-hydroxylation	Dronabinol	[24]
MR006697	Dronabinol	7-OH-delta-9-Tetrahydrocannabinol	Oxidation - Aliphatic hydroxylation	Dronabinol	[24], [242]
MR006699	Dronabinol	8-OH-delta-9-Tetrahydrocannabinol	Unclear - Unclear	Dronabinol	[24], [242]
MR006700	Dronabinol	8alpha-OH-delta-9-Tetrahydrocannabinol	Unclear - Unclear	Dronabinol	[24], [242]
MR013922	Dronabinol	7-alpha-Hydroxy-delta-9-THC	Oxidation - 7-hydroxylation	Dronabinol	[24]
MR006701	Dronedarone hydrochloride	N-debutyl-dronedarone	Oxidation - N-debutylation	Dronedarone hydrochloride	[1191]
MR006707	N-debutyl-dronedarone	N,N'-didebutyl-dronedarone	Oxidation - Debutylation	Dronedarone hydrochloride	[1192]
MR005771	Dutasteride	4'-hydroxydutasteride	Oxidation - Hydrolyzationn	Dutasteride	[361]
MR005772	Dutasteride	6beta-hydroxydutasteride	Oxidation - Hydrolyzationn	Dutasteride	[361]
MR005773	Dutasteride	1,2-dihydrodutasteride	Oxidation - Hydrolyzationn	Dutasteride	[361]
MR006009	DW-1030	DW-1030 Metabolite M4	Unclear - Unclear	DW-1030	[758]
MR006011	DW-1030	DW-1030 Metabolite M3	Unclear - Unclear	DW-1030	[758]
MR002843	Dydrogesterone	20alpha-dihydroxydydrogesterone	Oxidation - Hydroxylation	Dydrogesterone	[1193]
MR013313	E-3A	2-hydroxyestrone	Oxidation - 2-hydroxylation	E-3A	[1194]
MR013313	E-3A	2-hydroxyestrone	Oxidation - Aromatic hydroxylation	E-3A	[1195]
MR012208	E2101	E2101 M2	Unclear - Unclear	E2101	[970]
MR012210	E2101	E2101 M4	Unclear - Unclear	E2101	[970]
MR012211	E2101	E2101 M1	Unclear - Unclear	E2101	[970]
MR012209	E2101 M2	E2101 M3	Unclear - Unclear	E2101	[970]
MR009221	Carebastine	Deslakylebastine	Oxidation - N-dealkylation	Ebastine	[636]
MR009218	Ebastine	Hydroxy-ebastine	Oxidation - Hydroxylation	Ebastine	[636]
MR009228	Ebastine	4-(4-tert-butylphenyl)-4-oxobutanal	Oxidation - N-dealkylation	Ebastine	[1196]
MR009229	Ebastine	Deslakylebastine	Oxidation - N-dealkylation	Ebastine	[1196]
MR013470	EBP-994	EBP-994 M1	Unclear - Unclear	EBP-994	[541]
MR013471	EBP-994	EBP-994 M2	Unclear - Unclear	EBP-994	[541]
MR009497	Ecabapide	Ecabapide Metabolite M1	Unclear - Unclear	Ecabapide	[948]
MR003616	ED-71	1a,2beta,25(OH)3D3	Unclear - Unclear	ED-71	[731]
MR003447	Edoxaban	Edoxaban metabolite M7	Unclear - Unclear	Edoxaban	[1197]
MR003449	Edoxaban	Edoxaban metabolite M6	Unclear - Unclear	Edoxaban	[1197]
MR003450	Edoxaban	Edoxaban metabolite M5	Unclear - Unclear	Edoxaban	[1197]
MR000903	Efavirenz	8-hydroxy-efavirenz	Oxidation - Hydroxylation	Efavirenz	[216], [1198], [1199], [1200]
MR002845	Elbasvir	.	Unclear - Unclear	Elbasvir	[514]
MR006849	Eletriptan hydrobromide	N-Desmethyl eletriptan	Oxidation - N-demethylation	Eletriptan hydrobromide	[1201]
MR006851	Eliglustat tartrate	Genz-256416	Oxidation - Oxidationn	Eliglustat tartrate	[1202]
MR006855	Eliglustat tartrate	Genz-311752	Oxidation - Oxidationn	Eliglustat tartrate	[1202]
MR006859	Eliglustat tartrate	Genz-258179	Oxidation - Oxidationn	Eliglustat tartrate	[1202]
MR006856	Genz-311752	Genz-527862	Oxidation - Oxidationn	Eliglustat tartrate	[1202]
MR009950	Elvitegravir	Elvitegravir Metabolite M1	Oxidation - HYDROXYLATION	Elvitegravir	[1203]
MR006042	EMD 329989	Sarizotan metabolite M362	Oxidation - Oxidationn	EMD-128130	[804]
MR006048	EMD-128130	Sarizotan metabolite M364D	Oxidation - Monohydroxylation	EMD-128130	[804]
MR006050	EMD-128130	Sarizotan metabolite M203	Conjugation - Glycosylation	EMD-128130	[747]
MR010500	ACU-5116	ACU-5124	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010501	ACU-5116	ACU-5149	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010502	ACU-5116	ACU-5144	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010503	ACU-5116	ACU-5145	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010506	Emixustat	ACU-4861	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010507	Emixustat	ACU-4949	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010508	Emixustat	ACU-4982	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR010509	Emixustat	Emixustat Metabolite M20	Oxidation - Hydroxylation	Emixustat	[801], [1204]
MR006866	Enalapril	Enalapril demethylation	Oxidation - N-Demethylation	Enalapril	[1205]
MR006868	AGI-16903	Unclear	Unclear - Unclear	Enasidenib	[515]
MR007131	Enclomiphene	Clomiphenet of N-demethylation	Oxidation - Demethylation	Enclomiphene	[678]
MR006869	Encorafenib	Encorafenib dealkylation	Oxidation - N-dealkylation	Encorafenib	[516]
MR006879	Entrectinib	ENB547	Oxidation - N-dealkylation	Entrectinib	[1206]
MR013681	Enzalutamide	Enzalutamide metabolite M6 enzalutamide	Oxidation - Hydroxylation	Enzalutamide	[1207], [1208]
MR013683	N-desmethyl enzalutamide	Carboxyl metabolite enzalutamide (M1)	Unclear - Unclear	Enzalutamide	[1209], [1207]
MR009031	7alpha-OH-EpiA	EPIANDROSTERONE Metabolite M1	Unclear - Unclear	EPIANDROSTERONE	[1210]
MR009039	EPIANDROSTERONE	EPIANDROSTERONE Metabolite M3	Unclear - Unclear	EPIANDROSTERONE	[1210]
MR000908	Epinastine	9,13b-dehydroepinastine	Unclear - Unclear	Epinastine	[1211]
MR000910	Eplerenone	21-hydroxyeplerenone	Oxidation - Hydroxylation	Eplerenone	[1212]
MR000909	Eplerenone	6beta-hydroxyeplerenone	Unclear - Unclear	Eplerenone	[1212]
MR006964	EPX-100	EPX-100 M1	Oxidation - Oxidationn	EPX-100	[993]
MR007138	Ergometrine	Unclear	Unclear - Unclear	Ergometrine	[690]
MR007139	Ergonovine maleate	Unclear	Unclear - Unclear	Ergonovine maleate	[690]
MR000922	Ergotamine tartrate	Ergotamine tartrate metabolite ME1	Unclear - Unclear	Ergotamine tartrate	[1213]
MR000923	Ergotamine tartrate	Ergotamine tartrate metabolite ME2	Unclear - Unclear	Ergotamine tartrate	[1213]
MR003018	Erlotinib hydrochloride	Erlotinib M14	Oxidation - O-demethylation	Erlotinib hydrochloride	[44], [207]
MR003007	Erlotinib M2	Erlotinib M14	Oxidation - O-demethylation	Erlotinib hydrochloride	[44], [207]
MR000932	Ertugliflozin	Ertugliflozin metabolite M2	Conjugation - Glucuronidation	Ertugliflozin	[1214], [1215]
MR000933	Ertugliflozin	Ertugliflozin metabolite M1a	Oxidation - Hydroxylation	Ertugliflozin	[1214], [1215]
MR000934	Ertugliflozin	Ertugliflozin metabolite M1b	Oxidation - Hydroxylation	Ertugliflozin	[1214], [1215]
MR000935	Ertugliflozin	Ertugliflozin metabolite M3	Conjugation - Glucuronidation	Ertugliflozin	[1214], [1215]
MR000939	Erythromycin	N-Desmethylerythromycin	Oxidation - Demethylation	Erythromycin stearate	[1216], [1217], [1218]
MR000942	Escitalopram	S-desmethylcitalopram	Oxidation - N-Demethylation	Escitalopram	[275], [1219]
MR000954	Esomeprazole	Omeprazole sulfone metabolite	Oxidation - S-Oxidation	Esomeprazole	[1119], [1220]
MR009958	Estazolam	4-hydroxy-estazolam	Unclear - Unclear	Estazolam	[364]
MR002625	Estradiol	2-hydroxyestrone	Oxidation - 2-Hydroxylation	Estradiol acetate	[1221], [242]
MR002625	Estradiol	2-hydroxyestrone	Oxidation - Hydroxylation	Estradiol acetate	[242]
MR002648	Estradiol	2-hydroxyestrone	Oxidation - Hydroxylation	Estradiol cypionate	[1221], [242]
MR002648	Estradiol	2-hydroxyestrone	Oxidation - 2-Hydroxylation	Estradiol cypionate	[242]
MR002671	Estradiol	2-hydroxyestrone	Oxidation - Hydroxylation	Estradiol valerate	[1221], [242]
MR002671	Estradiol	2-hydroxyestrone	Oxidation - 2-Hydroxylation	Estradiol valerate	[242]
MR002696	Estrone	2-hydroxyestrone	Oxidation - Hydroxylation	Estrone	[1222]
MR002701	Estrone	4-OH-estrone	Oxidation - Hydroxylation	Estrone	[44]
MR002702	Estrone	6alpha-OH-estrone	Oxidation - Hydroxylation	Estrone	[44]
MR002696	Estrone	2-hydroxyestrone	Oxidation - 2-Hydroxylation	Estrone	[1222]
MR002697	Estrone	4-hydroxyestrone	Oxidation - 4-Hydroxylation	Estrone	[1222]
MR002713	Eszopiclone	N-desmethylzopiclone	Oxidation - N-Demethylation	Eszopiclone	[1223]
MR002711	Eszopiclone	Zopiclone N-oxide	Oxidation - N-Oxidation	Eszopiclone	[1223]
MR002721	Ethinyl estradiol	2-hydroxyethinylestradiol	Oxidation - 2-Hydroxylation	Ethinyl estradiol	[1224]
MR002722	Ethinyl estradiol	4-hydroxyethinylestradiol	Oxidation - 4-Hydroxylation	Ethinyl estradiol	[1224]
MR002723	Ethinyl estradiol	6-hydroxyethinylestradiol	Oxidation - 6-Hydroxylation	Ethinyl estradiol	[1224]
MR002724	Ethinyl estradiol	7-hydroxyethinylestradiol	Oxidation - 7-Hydroxylation	Ethinyl estradiol	[1224]
MR002725	Ethinyl estradiol	16alpha-hydroxyethinylestradiol	Oxidation - 16-Hydroxylation	Ethinyl estradiol	[1224]
MR014077	Ethinylestradiol propanesulfonate	Unclear	Oxidation - 16alpha-hydroxylation	Ethinylestradiol propanesulfonate	[1225], [1226]
MR002730	Ethosuximide	2-(2-hydroxyethyl)-2-methylsuccinimide	Oxidation - Hydroxylation	Ethosuximide	[1227], [284], [1228]
MR002731	Ethosuximide	2-(1-hydroxyethyl)-2-methylsuccinimide	Oxidation - Hydroxylation	Ethosuximide	[1227], [284], [1229]
MR002732	Ethosuximide	2-ethyl-3-hydroxy-2-methylsuccinimide	Oxidation - Hydroxylation	Ethosuximide	[1227], [284], [1228]
MR002733	Ethosuximide	2-ethyl-2-hydroxymethyl succinimide	Oxidation - Hydroxylation	Ethosuximide	[1227]
MR012146	Irinotecan	APC,NPC	Oxidation - Oxidation	Etirinotecan pegol	[1230]
MR007159	Etizolam	alpha-hydroxyetizolam	Oxidation - 1'-hydroxylation	Etizolam	[1231], [679]
MR013442	Etoperidone	Etoperidone Metabolite M2	Oxidation - Oxidationn	Etoperidone	[1232], [630]
MR013451	Etoperidone	Etoperidone Metabolite M5	Oxidation - Hydrolyzationn	Etoperidone	[1232], [630]
MR013453	Etoperidone	1-(3-chlorophenyl) piperazine	Unclear - Unclear	Etoperidone	[1232], [630]
MR000982	Etoposide	Etoposide catechol	Unclear - Unclear	Etoposide	[1233]
MR000983	Etoposide	3'-demethyletoposide	Oxidation - 3'-Demethylation	Etoposide	[1234]
MR007168	6-Hydroxymethyletoricoxib	6-Hydroxymethyletoricoxib-1'-N'-oxide	Oxidation - 1-N-oxidation	Etoricoxib	[24]
MR007166	6-Hydroxymethyletoricoxib	6-Carboxy-etoricoxib	Oxidation - Oxidationn	Etoricoxib	[24]
MR007163	Etoricoxib	Etoricoxib 1'-N'-oxide	Oxidation - 1-N-oxidation	Etoricoxib	[24]
MR007165	Etoricoxib	6-Hydroxymethyletoricoxib	Other reaction - 6-methylhydroxylation	Etoricoxib	[24]
MR007164	Etoricoxib 1'-N'-oxide	6-Hydroxymethyletoricoxib-1'-N'-oxide	Other reaction - 6-methylhydroxylation	Etoricoxib	[1235]
MR000990	Etravirine	Etravirine metabolite M1	Oxidation - Hydroxylation	Etravirine	[1236], [1237]
MR000995	Everolimus	46-hydroxy Everolimus	Oxidation - Hydroxylation	Everolimus	[1238]
MR000996	Everolimus	25-hydroxy Everolimus	Oxidation - Hydroxylation	Everolimus	[1238]
MR000997	Everolimus	24-hydroxy Everolimus	Oxidation - Hydroxylation	Everolimus	[1238]
MR000998	Everolimus	39-O-desmethyl everolimus	Oxidation - Demethylation	Everolimus	[1238], [1239]
MR001002	Exemestane	.	Oxidation - Oxidation	Exemestane	[287], [1240]
MR004608	EXR-202	DBAA	Unclear - Unclear	EXR-202	[1241]
MR007454	EZN-2208	SN38	Unclear - Unclear	EZN-2208	[880]
MR005969	FCF-89	PNU-212684 4-hydroxy-N-(4-hydroxyphenyl)-N,1-dimethyl-2-oxoquinoline-3-carboxamide	Unclear - Unclear	FCF-89	[1242], [976]
MR005966	FCF-89	PNU-213708 4,6-dihydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide	Unclear - Unclear	FCF-89	[1242], [976]
MR005967	FCF-89	PNU-214608 4,7-dihydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide	Unclear - Unclear	FCF-89	[1242], [976]
MR005968	FCF-89	PNU-213831 4,8-dihydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide	Unclear - Unclear	FCF-89	[1242], [976]
MR005970	FCF-89	4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide	Unclear - Unclear	FCF-89	[1242], [976]
MR005971	FCF-89	PNU-212679 N-Phenyl-N-methyl-2-oxo-4-hydroxy-1,2-dihydroquinoline-3-carboxamide	Unclear - Unclear	FCF-89	[1242], [976]
MR001011	Fedratinib hydrochloride	.	Unclear - Unclear	Fedratinib hydrochloride	[65], [1243], [1244]
MR002850	Felodipine	Dehydrofelodipine	Oxidation - Oxidation	Felodipine	[1245]
MR012196	Fenfluramine	Norfenfluramine	Unclear - Unclear	Fenfluramine	[1246]
MR001023	Fentanyl citrate	Norfentanyl	Oxidation - N-Dealkylation	Fentanyl citrate	[1247], [1248], [1249], [1250]
MR001028	Fesoterodine	Fesoterodine carboxy-N-desisopropyl metabolite	Unclear - Unclear	Fesoterodine	[1251], [1252]
MR001029	Fesoterodine	Fesoterodine N-desisopropyl metabolite	Unclear - Unclear	Fesoterodine	[1251], [1252]
MR001026	Fesoterodine 5-hydroxymethyl tolterodine	Fesoterodine carboxy metabolite	Unclear - Unclear	Fesoterodine	[1251], [1252]
MR005476	Fexinidazole	Fexinidazole sulfoxide metabolite (M1)	Oxidation - Oxidationn	Fexinidazole	[809], [810]
MR005477	Fexinidazole sulfoxide metabolite (M1)	Fexinidazole sulfone metabolite (M2)	Oxidation - Oxidationn	Fexinidazole	[809], [810]
MR001034	6alpha-hydroxyfinasteride	Dihydroxyfinasteride	Oxidation - Oxidation	Finasteride	[1253]
MR001035	Finasteride	Omega-hydroxyfinasteride	Oxidation - Hydroxylation	Finasteride	[1253], [1254]
MR001036	Finasteride	6alpha-hydroxyfinasteride	Oxidation - Oxidation	Finasteride	[1253]
MR001037	Finasteride	Finasteride monocarboxylic acid metabolite	Oxidation - Oxidation	Finasteride	[1254]
MR001033	Finasteride-omega-oic acid	Finasteride carboxylic acid giucuronide	Oxidation - Oxidation	Finasteride	[1253]
MR001032	Omega-aldehyde finasteride	Finasteride-omega-oic acid	Oxidation - Oxidation	Finasteride	[1253]
MR001030	Omega-hydroxyfinasteride	Omega-aldehyde finasteride	Oxidation - Oxidation	Finasteride	[1253]
MR005478	Finerenone	Finerenone M1 Metabolite	Other reaction - Aromatization	Finerenone	[710], [711], [712]
MR005481	Finerenone	Finerenone M4 Metabolite	Oxidation - Epoxidation; hydroxylation	Finerenone	[710], [712]
MR005485	Finerenone	Finerenone M14 Metabolite	Unclear - Unclear	Finerenone	[710], [711], [712]
MR005484	Finerenone	Finerenone M13 Metabolite	Oxidation - O-deethylation	Finerenone	[710], [711]
MR005479	Finerenone M1 Metabolite	Finerenone M2 Metabolite	Oxidation - Hydrolyzationn	Finerenone	[1255]
MR005480	Finerenone M2 Metabolite	Finerenone M3 Metabolite	Oxidation - Oxidationn	Finerenone	[1255]
MR005482	Finerenone M4 Metabolite	Finerenone M5 Metabolite	Oxidation - Hydrolyzationn	Finerenone	[1255]
MR001043	Fingolimod	.	Unclear - Unclear	Fingolimod	[290]
MR001048	Fingolimod hydrochloride	.	Unclear - Unclear	Fingolimod hydrochloride	[290]
MR001054	Flibanserin	6-hydroxy-flibanserin-6-sulfate	Oxidation - Deamination	Flibanserin	[1256], [1257]
MR007190	Flucloxacillin	5-hydroxymethyl-flucloxacillin	Oxidation - Oxidationn	Flucloxacillin	[680]
MR001060	Fluconazole	Fluconazole N-oxide	Oxidation - Oxidation	Fluconazole	[447]
MR007193	Flunitrazepam	Desmethylflunitrazepam	Oxidation - Demethylation	Flunitrazepam	[1258], [1259], [1260]
MR007194	Flunitrazepam	3-hydroxyflunitrazepam	Oxidation - Hydrolyzationn	Flunitrazepam	[1258]
MR005014	4-Trifluoromethylphenol	Hippuric acid	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[1261]
MR005014	4-Trifluoromethylphenol	Hippuric acid	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[1261]
MR005012	Fluoxetine hydrochloride	Norfluoxetine	Oxidation - N-demethylation	Fluoxetine hydrochloride	[384], [24], [1262], [1263]
MR005018	Fluoxetine hydrochloride	4-Trifluoromethylphenol	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[220], [1263]
MR005013	Norfluoxetine	4-Trifluoromethylphenol	Oxidation - O-dealkylation	Fluoxetine hydrochloride	[1261]
MR013655	Fluprednisolone	Unclear	Unclear - Unclear	Fluprednisolone	[1264]
MR005050	Flutamide Metabolite M3	Flutamide Metabolite M5	Unclear - Unclear	Flutamide	[1265]
MR005057	Fluticasone propionate	Fluticasone 17beta-carboxylic acid	Unclear - Unclear	Fluticasone propionate	[1266]
MR001063	Fluvastatin sodium	5-hydroxyfluvastatin	Oxidation - 5-Hydroxylation	Fluvastatin sodium	[24], [1267]
MR001065	Fluvastatin sodium	5-OH-fluvastatin	Oxidation - Hydroxylation	Fluvastatin sodium	[24], [1268], [1269]
MR002852	Amprenavir	GW549444	Unclear - Unclear	Fosamprenavir	[448]
MR002853	Amprenavir	GW549445	Unclear - Unclear	Fosamprenavir	[448]
MR001087	R406	R529	Unclear - Unclear	Fostamatinib	[1270]
MR005500	Fostemsavir M20	Fostemsavir M14	Unclear - Unclear	Fostemsavir	[9]
MR005492	Fostemsavir M27	Fostemsavir M22	Unclear - Unclear	Fostemsavir	[9]
MR005495	Fostemsavir M28	Fostemsavir M13	Unclear - Unclear	Fostemsavir	[9]
MR005502	Fostemsavir M4	Fostemsavir M16	Unclear - Unclear	Fostemsavir	[9]
MR005494	Temsavir	Fostemsavir M28	Unclear - Unclear	Fostemsavir	[9]
MR005508	Temsavir	BMS-930644	Oxidation - N-dealkylation	Fostemsavir	[9]
MR012034	Fruquintinib	M409-1	Unclear - Unclear	fruquintinib	[1271], [696]
MR012015	Fruquintinib	M379-1	Unclear - Unclear	fruquintinib	[1272], [696]
MR012023	Fruquintinib	M409-2	Oxidation - Mono-oxidation	fruquintinib	[1273], [696]
MR012033	Fruquintinib	M409-4	Oxidation - Mono-oxidation	fruquintinib	[1274], [696]
MR001111	Galantamine hydrobromide	Galantamine N-oxide metabolite	Oxidation - N-Oxidation	Galantamine hydrobromide	[1275], [34]
MR011675	Ganaxolone	16-OH ganazolone	Oxidation - Hydroxylation	Ganaxolone	[773]
MR005973	GBR-12909	Unclear	Unclear - Unclear	GBR-12909	[1242]
MR008134	GDC-0199	GDC-0199 metabolite M27	Oxidation - Oxidation	GDC-0199	[526]
MR006114	GEA-6414	N-(2-methyl-3-chloro-4-hydroxyphenyl)-anthranilic acid	Multi-steps Reaction - Glucuronidation; hydroxylation	GEA-6414	[1276]
MR006117	GEA-6414	N-(2-methyl-3-chloro-5-hydroxyphenyl)-anthranilic acid form 2	Multi-steps Reaction - Glucuronidation; hydroxylation	GEA-6414	[1276]
MR006119	GEA-6414	N-(2-hydroxymethyl-3-chlorophenyl)-anthranilic acid	Multi-steps Reaction - Glucuronidation; hydroxylation	GEA-6414	[1276]
MR006125	GEA-6414	N-(2-methyl-3-chlorophenyl)-5-hydroxy-anthranilic acid	Multi-steps Reaction - Glucuronidation; hydroxylation	GEA-6414	[1276]
MR006128	GEA-6414	N-(2-methyl-3-chlorophenyl)-4-hydroxy-anthranilic acid	Multi-steps Reaction - Glucuronidation; hydroxylation	GEA-6414	[1276]
MR001115	Gefitinib	Metabolism of the N-propoxymorpholino-group	Unclear - Unclear	Gefitinib	[1277]
MR001117	Gefitinib	Oxidative defluorination of the halogenated phenyl group	Oxidation - Oxidative Defluorination	Gefitinib	[1277]
MR001116	Gefitinib	Desmethyl-gefitinib M523595	Oxidation - O-Demethylation	Gefitinib	[1278], [1279]
MR001124	Gemfibrozil	Gemfibrozil metabolite M1	Oxidation - 5-Hydroxylation	Gemfibrozil	[1280], [1281], [294]
MR001123	Gemfibrozil metabolite M1	Gemfibrozil metabolite M3	Unclear - Unclear	Gemfibrozil	[294], [1282], [1283]
MR011588	Gemigliptin	LC15-0636	Unclear - Unclear	Gemigliptin	[701]
MR012622	Gepirone	2-(1-Piperazinyl)pyrimidine	Unclear - Unclear	Gepirone	[847]
MR007218	Glibenclamide	2-trans-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[1284], [1285]
MR007219	Glibenclamide	4-cis-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[1284], [1285]
MR007220	Glibenclamide	3-trans-Hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[1284], [1285]
MR007221	Glibenclamide	Ethylhydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[1284], [1285]
MR007219	Glibenclamide	4-trans-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[1284], [1285], [1286]
MR007222	Glibenclamide	3-cis-Hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[1284], [1285], [1286]
MR007229	Gliquidone	Unclear	Unclear - Unclear	Gliquidone	[1287]
MR001152	Granisetron hydrochloride	9'-desmethylgranisetron	Oxidation - Demethylation	Granisetron hydrochloride	[1288]
MR010851	Ala-TFV	Tenofovir(TFV)	Unclear - Unclear	GS-7340	[1289], [527]
MR011611	GSK2140944	GSK2140944 Metabolite M4	Unclear - Unclear	GSK2140944	[1290]
MR006129	GTPL7557	Pipotiazine sulfoxyde	Oxidation - Sulfoxidation	GTPL7557	[914], [1291]
MR010578	Guanfacine	3-Hydroxyguanfacine	Oxidation - Oxidation	Guanfacine	[1292]
MR010581	Guanfacine	Guanfacine Metabolite M6	Oxidation - Oxidation	Guanfacine	[1292]
MR010578	Guanfacine	3-hydroxyGuanfacine	Oxidation - Oxidation	Guanfacine	[1292]
MR005062	Guanfacine hydrochloride	3-hydroxyguanfacine	Oxidation - Oxidationn	Guanfacine hydrochloride	[1293], [1294]
MR005980	GW-873140	Unclear	Unclear - Unclear	GW-873140	[1295]
MR003919	H3B-6527	H3B-68730	Oxidation - N-deethylation	H3B-6527	[938]
MR005784	Halcinonide	Unclear	Unclear - Unclear	Halcinonide	[1296]
MR005071	Halofantrine	N-debutylhalofantrine	Oxidation - N-debutylation	Halofantrine	[1297]
MR005072	Haloperidol decanoate	Reduced haloperidol	Unclear - Unclear	Haloperidol decanoate	[24]
MR005075	Haloperidol decanoate	Haloperidol 1,2,3,6-tetrahydropyridine	Other reaction - Dehydration	Haloperidol decanoate	[24]
MR005077	Haloperidol decanoate	4-(4-chlorophenyl)-4-hydroxypiperidine	Oxidation - N-dealkylation	Haloperidol decanoate	[24]
MR005080	Haloperidol decanoate	4-(4-Chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HPP+)	Unclear - Unclear	Haloperidol decanoate	[1298]
MR005074	Haloperidol reduced pyridinium ion derivative	Haloperidol pyridinium ion derivative	Unclear - Unclear	Haloperidol decanoate	[24]
MR005083	Halothane	2-chloro-1,1-difluoroethene	Reduction - Dehalogenation	Halothane	[18], [242]
MR005084	Halothane	1-chloro-2,2,2-trifluoroethanide	Reduction - Dehalogenation	Halothane	[18], [242]
MR005086	Halothane	Chlorotrifluoroethane	Reduction - Dehalogenation	Halothane	[242]
MR005083	Halothane	2-chloro-1,1-difluoroethene	Reduction - Dehalogenation	Halothane	[242]
MR006056	Fexinidazole Sulfone M1	Fexinidazole Sulfone M2	Oxidation - Oxidationn	HOE-239	[809]
MR006055	HOE-239	Fexinidazole Sulfone M1	Oxidation - Oxidationn	HOE-239	[809]
MR011205	Hydrocodone	Norhydrocodone	Oxidation - N-demethylation	Hydrocodone	[1299]
MR005123	Hydrocodone bitartrate	Norhydrocodone	Oxidation - N-demethylation	Hydrocodone bitartrate	[31]
MR005137	Hydromorphone	Norhydromorphone	Oxidation - N-demethylation	Hydromorphone	[1300]
MR012185	Hydroxychloroquine	Monodesethylchloroquine	Unclear - Unclear	Hydroxychloroquine	[1301], [506]
MR005140	Hydroxychloroquine sulfate	Desethylchloroquine	Oxidation - N-dealkylation	Hydroxychloroquine sulfate	[1302], [531], [506]
MR005141	Hydroxychloroquine sulfate	Desethylhydroxychloroquine	Oxidation - N-dealkylation	Hydroxychloroquine sulfate	[1302], [531], [506]
MR005142	Hydroxychloroquine sulfate	Bidesethylchloroquine	Oxidation - N-dealkylation	Hydroxychloroquine sulfate	[1302], [531], [506]
MR005144	Hydroxyzine	Cetirizine	Oxidation - Oxidationn	Hydroxyzine	[1303], [1304]
MR008501	Ibrolipim	Ibrolipim metabolite M-2	Unclear - Unclear	Ibrolipim	[1305], [855]
MR012963	Ibrutinib	PCI-45227 (M37)	Multi-steps Reaction - Epoxidation; hydrolyzation	Ibrutinib	[35]
MR004644	Ibuprofen	2-Hydroxyibuprofen	Oxidation - 2-hydroxylation	Ibuprofen	[24]
MR005774	Iclaprim	Unclear	Unclear - Unclear	Iclaprim	[452]
MR002620	Cyclic prodrug of Adefovir 3	Adefovir Diphosphate(ADV-DP)4	Unclear - Unclear	ICN-2001-3	[1030]
MR002622	ICN-2001-3	Adefovir	Unclear - Unclear	ICN-2001-3	[1030]
MR012974	GS-563117	Idelalisib Metabolite M20	Unclear - Unclear	Idelalisib	[1306]
MR012964	Idelalisib	Idelalisib Metabolite M2	Unclear - Unclear	Idelalisib	[1306]
MR012969	Idelalisib	GS-563117	Unclear - Unclear	Idelalisib	[1307], [1306]
MR004650	Ifosfamide	4-Hydroxyifosfamide	Oxidation - 4-hydroxylation	Ifosfamide	[1147]
MR004662	Ifosfamide	3-Dechloroethylifosfamide	Unclear - Unclear	Ifosfamide	[384], [1147]
MR004663	Ifosfamide	Dechloroethylifosfamide	Unclear - Unclear	Ifosfamide	[1147]
MR004660	Ifosfamide	Chloroacetaldehyde	Unclear - Unclear	Ifosfamide	[1147], [1308]
MR004666	Iloperidone	Iloperidone P89	Oxidation - O-demethylation	Iloperidone	[1309]
MR012007	Imatinib	N-desmethyl-imatinib	Unclear - Unclear	Imatinib	[1310]
MR004669	Imatinib mesylate	N-Desmethylimatinib	Oxidation - N-demethylation	Imatinib mesylate	[24], [1311], [1312]
MR004670	Imatinib mesylate	AFN911	Oxidation - Benzyl hydroxylation	Imatinib mesylate	[1312]
MR004673	Imatinib mesylate	M7 N-oxidation imatinib	Oxidation - N-oxidation	Imatinib mesylate	[1312]
MR004671	Imatinib mesylate	Piperidine N-oxide imatinib	Oxidation - N-4 oxidation	Imatinib mesylate	[1312]
MR004672	Imatinib mesylate	Pyridine N-oxide imatinib	Oxidation - N-oxidation	Imatinib mesylate	[1312]
MR012989	Imipramine hydrochloride	2-hydroxyimipramine	Oxidation - 2-hydroxylation	Imipramine hydrochloride	[384]
MR012986	Imipramine hydrochloride	Desipramine	Oxidation - N-demethylation	Imipramine hydrochloride	[1313]
MR004625	Imipramine	Desipramine	Unclear - Unclear	Imipramine oxide	[1314], [1315]
MR005775	Imiquimod	Unclear	Unclear - Unclear	Imiquimod	[18]
MR001175	Imrecoxib	Imrecoxib metabolite M1	Unclear - Unclear	Imrecoxib	[662], [1316]
MR001173	Imrecoxib metabolite M1	Imrecoxib metabolite M2	Unclear - Unclear	Imrecoxib	[662], [1316]
MR003660	INCB-024360 Metabolite M11	INCB-024360 Metabolite M12	Oxidation - N-dealkylation	INCB-024360	[1317]
MR001182	Indapamide	Indapamide metabolite M1	Oxidation - Oxidation	Indapamide	[296], [1318]
MR001183	Indapamide	Indapamide metabolite M5	Oxidation - Oxidation	Indapamide	[296]
MR001184	Indapamide	Indapamide epoxide intermediate	Oxidation - Oxidation	Indapamide	[296]
MR001176	Indapamide metabolite M1	Indapamide metabolite M3	Oxidation - Oxidation	Indapamide	[296]
MR001177	Indapamide metabolite M3	Indapamide metabolite M2	Oxidation - Oxidation	Indapamide	[296]
MR001179	Indapamide metabolite M4	Indapamide metabolite M2	Oxidation - Oxidation	Indapamide	[296]
MR001178	Indapamide metabolite M5	Indapamide metabolite M4	Oxidation - Oxidation	Indapamide	[296]
MR001191	Indinavir sulfate	Indinavir sulfate metabolite M4a	Oxidation - Oxidation	Indinavir sulfate	[1319]
MR001192	Indinavir sulfate	Indinavir sulfate metabolite M6	Oxidation - N-Depyridomethylation	Indinavir sulfate	[1319], [1320]
MR001193	Indinavir sulfate	Indinavir sulfate metabolite M3	Oxidation - Hydroxylation	Indinavir sulfate	[1319]
MR001195	Indinavir sulfate	Indinavir sulfate metabolite M4b	Oxidation - Hydroxylation	Indinavir sulfate	[1319]
MR001188	Indinavir sulfate metabolite M2	Indinavir sulfate metabolite M5	Oxidation - N-Depyridomethylation	Indinavir sulfate	[1319]
MR001189	Indinavir sulfate metabolite M3	Indinavir sulfate metabolite M5	Oxidation - N-Depyridomethylation	Indinavir sulfate	[1319]
MR001189	Indinavir sulfate metabolite M3	Indinavir sulfate metabolite M5	Oxidation - N-Depyridomethylation	Indinavir sulfate	[1319]
MR001190	Indinavir sulfate metabolite M3	Indinavir sulfate metabolite M3	Oxidation - Oxidation	Indinavir sulfate	[1319]
MR001185	Indinavir sulfate metabolite M4a	Indinavir sulfate metabolite M6	Oxidation - N-Depyridomethylation	Indinavir sulfate	[1319]
MR001186	Indinavir sulfate metabolite M4a	Indinavir sulfate metabolite M2	Oxidation - Hydroxylation	Indinavir sulfate	[1319]
MR001187	Indinavir sulfate metabolite M6	Indinavir sulfate metabolite M5	Oxidation - Hydroxylation	Indinavir sulfate	[1319]
MR001187	Indinavir sulfate metabolite M6	Indinavir sulfate metabolite M5	Oxidation - Hydroxylation	Indinavir sulfate	[1319]
MR011238	Indiplon	N-desmethylIndiplon	Oxidation - N-demethylation	indiplon	[1321]
MR011241	N-desacetylIndiplon	N-desmethyl-desacetyl-Indiplon	Oxidation - N-demethylation	indiplon	[1321]
MR005514	Infigratinib	Unclear	Oxidation - Hydrolyzationn	Infigratinib	[226], [227]
MR009235	Ingrezza	NBI-136110	Oxidation - Oxidation	Ingrezza	[683], [1322]
MR010632	Intedanib	BIBF1053	Unclear - Unclear	Intedanib	[297]
MR003497	Ipecac	Cephaeline	Oxidation - Demethylation	Ipecac	[663], [1323]
MR003499	Ipecac	9-O-demethylemetine	Oxidation - Demethylation	Ipecac	[663], [1323]
MR003499	Ipecac	9-O-demethylemetine	Oxidation - Demethylation	Ipecac	[663], [1323]
MR003501	Ipecac	10-O-demethylemetine	Oxidation - Demethylation	Ipecac	[663], [1323]
MR001224	Irinotecan hydrochloride	7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin	Unclear - Unclear	Irinotecan hydrochloride	[1324], [1325]
MR001225	Irinotecan hydrochloride	NPC	Unclear - Unclear	Irinotecan hydrochloride	[1324], [1326], [1327]
MR002854	Isavuconazole	.	Unclear - Unclear	Isavuconazole	[453], [1328]
MR002794	Isavuconazole	.	Unclear - Unclear	Isavuconazonium	[1328]
MR001247	Isosorbide dinitrate	Isosorbide dinitrate Nitric Oxide	Unclear - Unclear	Isosorbide dinitrate	[1329]
MR001250	Isosorbide mononitrate	Isosorbide mononitrate Nitric Oxide	Unclear - Unclear	Isosorbide mononitrate	[1329], [298]
MR001261	Isotretinoin	All-trans-retinoic acid	Unclear - Unclear	Isotretinoin	[1330], [1331], [1332], [228]
MR001262	Isotretinoin	4-hydroxy-13-cis-retinoic acid	Oxidation - 4-Hydroxylation	Isotretinoin	[1332]
MR001276	Istradefylline	1-beta-hydroxylated Istradefylline	Oxidation - Hydroxylation	Istradefylline	[231]
MR001273	Istradefylline	4'-O-monodesmethyl istradefylline	Oxidation - O-Demethylation	Istradefylline	[231], [1333]
MR011408	ITI-007	IC200161	Oxidation - Dealkylation	ITI-007	[1334]
MR011409	ITI-007	IC200565	Oxidation - Dealkylation	ITI-007	[1334]
MR001277	Itraconazole	Hydroxyitraconazole	Oxidation - O-Demethylation	Itraconazole	[1335], [1336], [1337], [1338], [1339]
MR001280	Ivabradine hydrochloride	N-desmethylivabradine	Oxidation - N-Demethylation	Ivabradine hydrochloride	[1340]
MR002855	Ivacaftor	M1 (hydroxymethyl-ivacaftor)	Oxidation - Hydroxylation	Ivacaftor	[1341], [454]
MR002856	Ivacaftor	M6 (ivacaftor-carboxylate)	Oxidation - Oxidation	Ivacaftor	[1341], [454]
MR001287	Ivermectin	3''-O-Desmethyl-ivermectin B1a	Oxidation - O-Demethylation	Ivermectin	[1342]
MR001288	Ivermectin	3''\O\demethyl, 4\hydroxymethyl ivermectin	Unclear - Unclear	Ivermectin	[1342]
MR001289	Ivermectin	3''-O-Desmethyl-ivermectin B1b	Oxidation - O-Demethylation	Ivermectin	[1342]
MR001290	Ivermectin	Ivermectin metabolite M3	Oxidation - Hydroxylation	Ivermectin	[1342]
MR012487	JI-101	JI-101 M1	Oxidation - Dihydroxylation	JI-101	[866]
MR012532	JNJ-53718678	JNJ-53718678 M5	Unclear - Unclear	JNJ-53718678	[842]
MR012533	JNJ-53718678	JNJ-53718678 M12	Unclear - Unclear	JNJ-53718678	[842]
MR012534	JNJ-53718678	JNJ-53718678 M19	Unclear - Unclear	JNJ-53718678	[842]
MR012535	JNJ-53718678	JNJ-53718678 M37	Unclear - Unclear	JNJ-53718678	[842]
MR013337	JNJ-54135419	Noresketamine	Oxidation - N-demethylation	JNJ-54135419	[1343]
MR011455	JTK-853	JTK-853 Metabolite M2	Unclear - Unclear	JTK-853	[972]
MR006131	KB-2796	1-[Bis(4-fluorophenyl)methyl]piperazine	Oxidation - N-dealkylation	KB-2796	[1344]
MR006132	KB-2796	Lomerizine M5	Oxidation - O-demethylation	KB-2796	[1344]
MR006133	KB-2796	Lomerizine M3	Oxidation - Hydrolyzationn	KB-2796	[1344]
MR001321	Ketamine	Norketamine	Oxidation - N-Demethylation	Ketamine	[116], [1345], [1346], [1347]
MR001329	Diazepam	Temazepam	Unclear - Unclear	Ketazolam	[1348]
MR001336	Ketobemidone	Norketobemidone	Oxidation - N-Demethylation	Ketobemidone	[24], [645]
MR001352	Ketoconazole	M13 (Ketoconazole)	Oxidation - N-Oxidation	Ketoconazole	[1349]
MR001354	Ketoconazole	M7 (Ketoconazole)	Oxidation - Oxidation	Ketoconazole	[1349]
MR001355	Ketoconazole	M8 (Ketoconazole)	Oxidation - Hydroxylation	Ketoconazole	[1349]
MR001351	Ketoconazole ketone hydroxyl intermediate	M2 (Ketoconazole)	Oxidation - N-Dealkylation	Ketoconazole	[1349]
MR001339	M8 (Ketoconazole)	M6 (Ketoconazole)	Oxidation - Hydroxylation	Ketoconazole	[1349]
MR012461	KLH-2109	KP046	Unclear - Unclear	KLH-2109	[1350]
MR013342	KRM-1648	32-hydroxy-benzoxazinorifamycin.	Oxidation - 32-hydroxylation	KRM-1648	[1351]
MR011883	KRP-297	KRP-297 Metabolite M2	Unclear - Unclear	KRP-297	[955]
MR011889	KRP-297	KRP-297 Metabolite M11	Unclear - Unclear	KRP-297	[955]
MR011888	KRP-297 Metabolite M1	KRP-297 Metabolite M20	Unclear - Unclear	KRP-297	[955]
MR011885	KRP-297 Metabolite M25	KRP-297 Metabolite M1	Unclear - Unclear	KRP-297	[955]
MR003684	KW-3902	M1-Trans	Oxidation - Oxidationn	KW-3902	[765]
MR003685	KW-3902	M1-Cis	Oxidation - Oxidationn	KW-3902	[765]
MR003687	KW-5338	KW-5338 Metabolite M1	Oxidation - Hydrolyzationn	KW-5338	[1352]
MR003688	KW-5338	KW-5338 Metabolite M3	Oxidation - Hydrolyzationn	KW-5338	[1352]
MR003689	KW-5338	KW-5338 Metabolite M4	Oxidation - Hydrolyzationn	KW-5338	[1352]
MR003691	KW-5338	KW-5338 Metabolite M2	Oxidation - Hydrolyzationn	KW-5338	[1352]
MR003686	KW-5338	5-hydroxydomperidone	Unclear - Unclear	KW-5338	[721]
MR001399	Lacosamide	O-Desmethyl-lacosamide	Oxidation - Demethylation	Lacosamide	[1353]
MR001413	Lansoprazole	5-hydroxylansoprazole	Oxidation - Hydroxylation	Lansoprazole	[1354], [1355]
MR001427	Lapatinib ditosylate	O-dealkylated lapatinib	Oxidation - O-Dealkylation	Lapatinib ditosylate	[1356]
MR001428	Lapatinib ditosylate	N-dealkylated lapatinib	Oxidation - N-Dealkylation	Lapatinib ditosylate	[1356]
MR001429	Lapatinib ditosylate	N-hydroxy lapatinib	Oxidation - N-Hydroxylation	Lapatinib ditosylate	[1356]
MR009267	LAROPIPRANT	LAROPIPRANT Metabolite M1	Oxidation - Monohydroxylation	LAROPIPRANT	[646]
MR009269	LAROPIPRANT	LAROPIPRANT Metabolite M4	Oxidation - Monohydroxylation	LAROPIPRANT	[646]
MR003703	LAS-X-113	Desalkylebastine	Oxidation - N-Dealkylation	LAS-X-113	[636]
MR008875	Lasofoxifene	5-hydroxy-lasofoxifene (5-OHLAS)	Oxidation - 5-hydroxylation	Lasofoxifene	[164]
MR003708	LAU-7b	4'-hydroxy 4-HPR	Unclear - Unclear	LAU-7b	[722]
MR003704	LAU-7b	4'-oxo 4-HPR	Unclear - Unclear	LAU-7b	[722]
MR003710	LAU-7b	Dehydrogenated 4-HPR	Unclear - Unclear	LAU-7b	[1357]
MR005371	Lauric acid	11-hydroxylauric acid	Oxidation - Hydrolyzationn	Lauric acid	[1005]
MR011378	LEE011 Metabolite M15	LEE011 Metabolite M4	Unclear - Unclear	LEE011	[751]
MR001433	Lefamulin	.	Unclear - Unclear	Lefamulin	[537], [1358], [1359]
MR003105	Leflunomide	.	Unclear - Unclear	Leflunomide	[235]
MR005523	Lenacapavir	Unclear	Unclear - Unclear	Lenacapavir	[538]
MR010933	Lenvatinib	O-demethyl Lenvatinib	Unclear - Unclear	Lenvatinib	[1360]
MR010934	Lenvatinib	N-descyclopropyl lenvatinib	Unclear - Unclear	Lenvatinib	[1360]
MR010932	Lenvatinib	Lenvatinib N-oxide	Unclear - Unclear	Lenvatinib	[1360]
MR001442	Lenvatinib mesylate	.	Unclear - Unclear	Lenvatinib mesylate	[68]
MR003108	Lesinurad	Lesinurad metabolite M3	Oxidation - Hydroxylation	Lesinurad	[237]
MR003109	Lesinurad	Lesinurad metabolite M6	Unclear - Unclear	Lesinurad	[237]
MR001444	Letermovir	.	Unclear - Unclear	Letermovir	[238]
MR001445	Letrozole ketone analog metabolite	4,4'-methanol-bisbenzonitrile	Unclear - Unclear	Letrozole	[540]
MR010686	Levallorphan	Levallorphan Metabolite M8	Unclear - Unclear	Levallorphan	[302]
MR010688	Levallorphan	Levallorphan Metabolite M4	Unclear - Unclear	Levallorphan	[302]
MR010684	Levallorphan	Levallorphan Metabolite M7	Unclear - Unclear	Levallorphan	[302]
MR010689	Levallorphan Metabolite M4	Levallorphan Metabolite M11	Unclear - Unclear	Levallorphan	[302]
MR010685	Levallorphan Metabolite M7	Levallorphan Metabolite M10	Unclear - Unclear	Levallorphan	[302]
MR010687	Levallorphan Metabolite M8	Levallorphan Metabolite M9	Unclear - Unclear	Levallorphan	[302]
MR001452	Levamlodipine	Levamlodipine metabolite M9	Oxidation - Dehydrogenation	Levamlodipine	[33], [1361]
MR001469	Levobupivacaine	Desbutyl levobupivacaine	Oxidation - Deamination	Levobupivacaine	[301]
MR009962	Levomepromazine	Levomepromazine5-sulfoxide	Unclear - Unclear	Levomepromazine	[239]
MR009963	Levomepromazine	N-desmethyl.levomepromazine	Unclear - Unclear	Levomepromazine	[239]
MR008028	Levomethadyl Acetate	Nor-levomethadyl acetate (nor-LAAM)	Oxidation - N-demethylation	Levomethadyl Acetate	[1147], [457]
MR008030	Levomethadyl Acetate	Noracymethadol	Oxidation - N-demethylation	Levomethadyl Acetate	[456]
MR003113	Levomethadyl acetate hydrochloride	NorLAAM	Oxidation - Demethylation	Levomethadyl acetate hydrochloride	[375], [1362]
MR003112	NorLAAM	Dinor-levomethadyl acetate	Oxidation - Demethylation	Levomethadyl acetate hydrochloride	[1362]
MR001505	Levomilnacipran	N-desethyl LVM	Oxidation - Desmethylation	Levomilnacipran	[1363]
MR001514	Levonorgestrel	.	Unclear - Unclear	Levonorgestrel	[1364]
MR001552	Lidocaine	3-hydroxylidocaine	Oxidation - Hydroxylation	Lidocaine	[1365]
MR001550	Lidocaine	Monoethylglycinexylidide	Oxidation - N-De-Ethylation	Lidocaine	[1366], [1365]
MR001546	Monoethylglycinexylidide	Glycinexylidide	Oxidation - Deamination	Lidocaine	[1365]
MR012306	LIK-066	LIK-066 M13,14	Oxidation - Oxidation	LIK-066	[826]
MR006058	Lilly-112531	Vindesine N-oxide	Oxidation - N-oxidation	Lilly-112531	[811]
MR001565	Linagliptin	Linagliptin CD10604	Oxidation - Oxidation	Linagliptin	[50], [51]
MR008300	LJN452	LJN452 metabolite M11.6	Multi-steps Reaction - Oxidative; O-dealkylation	LJN452	[830]
MR006893	Lomitapide mesylate	Lomitapide metabolite M1	Other reaction - Cleavage	Lomitapide mesylate	[458]
MR006894	Lomitapide mesylate	Lomitapide metabolite M3	Unclear - Unclear	Lomitapide mesylate	[458]
MR005524	Lonafarnib	Lonafarnib metabolite M1	Oxidation - Oxidationn	Lonafarnib	[541], [542]
MR005525	Lonafarnib metabolite M1	Lonafarnib metabolite M2	Other reaction - Dehydration	Lonafarnib	[541], [542]
MR006895	Loperamide hydrochloride	N-demethyl loperamide	Oxidation - N-demethylation	Loperamide hydrochloride	[1367]
MR006898	Lopinavir	Lopinavir Metabolite M-3/M-4	Oxidation - Oxidationn	Lopinavir	[459]
MR006901	Loratadine	Desloratadine	Oxidation - Oxidationn	Loratadine	[1368]
MR006906	Lorcaserin	N-hydroxylorcaserin	Oxidation - Hydrolyzationn	Lorcaserin	[168]
MR006908	Lorcaserin	5-Hydroxylorcaserin	Oxidation - Hydrolyzationn	Lorcaserin	[168]
MR006909	Lorcaserin	7-Hydroxylorcaserin	Oxidation - Hydrolyzationn	Lorcaserin	[168]
MR006907	Lorcaserin	1-Hydroxylorcaserin	Oxidation - Hydrolyzationn	Lorcaserin	[168]
MR006912	Lorlatinib	Lorlatinib benzoic acid metabolite (M8)	Oxidation - Oxidationn cleavage	Lorlatinib	[1369]
MR005870	Lorpiprazole	Unclear	Unclear - Unclear	Lorpiprazole	[1013]
MR013896	Losartan	E 3179	Unclear - Unclear	Losartan	[740]
MR006914	Losartan Carboxaldehyde	Losartan carboxylic acid	Unclear - Unclear	Losartan potassium	[24]
MR006916	Losartan potassium	Losartan carboxylic acid	Oxidation - N-oxidation	Losartan potassium	[740]
MR006913	Losartan potassium	Losartan Carboxaldehyde	Oxidation - Oxidationn	Losartan potassium	[740]
MR006922	beta-hydroxy acid of lovastatin	6'-beta-Hydroxylovastatin	Oxidation - Hydrolyzationn	Lovastatin	[1370]
MR006925	Loxapine succinate	Loxapine N-oxide	Oxidation - Oxidationn	Loxapine succinate	[304]
MR006926	Loxapine succinate	7-Hydroxyloxapine	Oxidation - Oxidationn	Loxapine succinate	[304]
MR006927	Loxapine succinate	Amoxapine	Oxidation - Oxidationn	Loxapine succinate	[304]
MR007964	Loxoprofen gel	Loxoprofen gel metabolite M3	Unclear - Unclear	Loxoprofen gel	[1371], [37]
MR006136	LS-172108	(6S,8S,10R,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-6-hydroxy-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one	Oxidation - Hydrolyzationn	LS-172108	[909]
MR006137	LS-172108	17-[2-[4-(2,6-Dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-6-hydroxy-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one	Oxidation - Hydrolyzationn	LS-172108	[909]
MR006138	LS-172108	17-[2-[4-[2-(3-Hydroxypyrrolidin-1-yl)-6-pyrrolidin-1-ylpyrimidin-4-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one	Oxidation - Hydrolyzationn	LS-172108	[909]
MR006139	LS-172108	17-[2-[4-[6-(3-Hydroxypyrrolidin-1-yl)-2-pyrrolidin-1-ylpyrimidin-4-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one	Oxidation - Hydrolyzationn	LS-172108	[909]
MR013343	LS-248	13'-hydroxy-alpha-tocopherol	Oxidation - Hydrolyzationn	LS-248	[1372]
MR004573	LU-AE58054	LU-AE58054 Metabolite M1	Unclear - Unclear	LU-AE58054	[741]
MR010268	Lumateperone tosylate	IC200565	Oxidation - N-desmethylation	lumateperone tosylate	[1334]
MR010268	Lumateperone tosylate	IC200565	Oxidation - Dealkylation	lumateperone tosylate	[1373]
MR014071	Lumateperone tosylate	IC200161	Oxidation - Dealkylation	lumateperone tosylate	[1373]
MR006929	Lumefantrine	Desbutyl-lumefantrine	Oxidation - Dealkylation	Lumefantrine	[544]
MR006930	Lurasidone	ID-14326	Unclear - Unclear	Lurasidone	[240]
MR012667	LY-2603618	LY-2603618 Metabolite H2	Oxidation - Hydroxylation	LY-2603618	[867]
MR012669	LY-2603618	LY-2603618 Metabolite H3	Oxidation - Hydroxylation	LY-2603618	[867]
MR006140	LY-2940680	Unclear	Unclear - Unclear	LY-2940680	[1374], [915]
MR003761	LY-450139	LY-2484595 Metabolite M4	Unclear - Unclear	LY-450139	[752]
MR001609	Lynestrenol	Norethindrone	Unclear - Unclear	Lynestrenol	[93]
MR001607	Lynestrenol metabolite M1/Lynestrenol metaboliteM2	Lynestrenol metabolite M3	Oxidation - Dihydroxylation	Lynestrenol	[93]
MR001608	Lynestrenol metabolite M1/Lynestrenol metaboliteM2	Lynestrenol metabolite M4	Unclear - Unclear	Lynestrenol	[93]
MR001605	Norethindrone	Lynestrenol metabolite M1/Lynestrenol metaboliteM2	Oxidation - Hydroxylation	Lynestrenol	[93]
MR001606	Norethindrone	Lynestrenol metabolite M4	Oxidation - Dehydrogenation	Lynestrenol	[93]
MR013356	Hydroxyperospirone	M-813 Metabolite MX11	Unclear - Unclear	M-813	[926], [1375]
MR013361	Hydroxyperospirone	M-813 Metabolite MX6	Unclear - Unclear	M-813	[1375]
MR013367	ID-15010	M-813 Metabolite MX6	Unclear - Unclear	M-813	[926]
MR013359	ID15002	ID15001	Unclear - Unclear	M-813	[1375]
MR013359	ID15002	ID15001	Unclear - Unclear	M-813	[1375]
MR013359	ID15002	ID15001	Unclear - Unclear	M-813	[1375]
MR013355	M-813	Hydroxyperospirone	Oxidation - Hydrolyzationn	M-813	[927], [926]
MR013365	M-813	ID-11614	Unclear - Unclear	M-813	[926]
MR013366	M-813	ID-15010	Unclear - Unclear	M-813	[926]
MR013368	M-813	ID-11926	Unclear - Unclear	M-813	[926]
MR013360	M-813 Metabolite MX11	M-813 Metabolite MX9	Unclear - Unclear	M-813	[926], [1375]
MR013362	M-813 Metabolite MX6	M-813 Metabolite MX9	Unclear - Unclear	M-813	[1375]
MR013362	M-813 Metabolite MX6	M-813 Metabolite MX9	Unclear - Unclear	M-813	[926]
MR006937	Macitentan	Aprocitentan	Oxidation - Depropylation	Macitentan	[1376]
MR012282	MAK683	MAK683 M56	Unclear - Unclear	MAK683	[1377]
MR005855	Manidipine 2HCl	Unclear	Unclear - Unclear	Manidipine 2HCl	[771]
MR005532	Maribavir	VP 44469	Oxidation - N-Dealkylation	Maribavir	[733]
MR011998	Masitinib	N-desmethyl masitinib(M485)	Unclear - Unclear	Masitinib	[742]
MR012001	MCN524	MCN526	Unclear - Unclear	Masitinib	[1378]
MR012001	MCN524	MCN526	Unclear - Unclear	Masitinib	[1379]
MR012000	Minium ion intermediate	MCN524	Unclear - Unclear	Masitinib	[1380]
MR012000	Minium ion intermediate	MCN524	Unclear - Unclear	Masitinib	[1381]
MR012006	Minium ion intermediate	MCN538	Unclear - Unclear	Masitinib	[1382]
MR010182	Mavacamten	MYK-1078	Unclear - Unclear	Mavacamten	[1383]
MR010178	Mavacamten	MYK-2241	Unclear - Unclear	Mavacamten	[1383]
MR012676	MB-07811	MB07344	Unclear - Unclear	MB-07811	[869]
MR006951	Mebendazole	2-amino-5-benzoylbenzimidazole	Oxidation - Decarboxylation	Mebendazole	[461]
MR001619	2beta-hydroxymedroxyprogesterone acetate	2beta-,6beta-dihydroxymedroxyprogesterone acetate	Oxidation - Hydroxylation	Medroxyprogesterone acetate	[380]
MR001618	6beta-hydroxymedroxyprogesterone Acetate	2beta-,6beta-dihydroxymedroxyprogesterone acetate	Oxidation - Hydroxylation	Medroxyprogesterone acetate	[380]
MR001620	Medroxyprogesterone acetate	6beta-hydroxymedroxyprogesterone Acetate	Oxidation - Hydroxylation	Medroxyprogesterone acetate	[380]
MR001621	Medroxyprogesterone acetate	2beta-hydroxymedroxyprogesterone acetate	Oxidation - Hydroxylation	Medroxyprogesterone acetate	[380]
MR001622	Medroxyprogesterone acetate	1beta-hydroxymedroxyprogesterone acetate	Oxidation - Hydroxylation	Medroxyprogesterone acetate	[380]
MR001632	Mefloquine hydrochloride	2,8-Bis(trifluoromethyl)quinoline-4-carboxylic acid	Oxidation - N-Demethylation	Mefloquine hydrochloride	[44]
MR001636	Megestrol acetate	Megestrol acetate metabolite M1	Oxidation - Oxidation	Megestrol acetate	[463]
MR001637	Megestrol acetate	Megestrol acetate metabolite M2	Oxidation - Oxidation	Megestrol acetate	[463]
MR002858	5-hydroxymethyl meloxicam	5-Carboxy meloxicam	Oxidation - Oxidation	Meloxicam	[1384], [1385]
MR002857	Meloxicam	5-hydroxymethyl meloxicam	Oxidation - Hydroxylation	Meloxicam	[1384], [1385]
MR013111	Meperidine	Normeperidine	Oxidation - N-demethylation	Meperidine	[1386], [1387], [1388]
MR001645	17alpha-Ethinylestradiol	2-hydroxyethinylestradiol	Oxidation - 2-Hydroxylation	Mestranol	[1225], [1226]
MR001646	17alpha-Ethinylestradiol	4-hydroxyethinylestradiol	Oxidation - 4-Hydroxylation	Mestranol	[1225], [1226]
MR001647	17alpha-Ethinylestradiol	6-hydroxyethinylestradiol	Oxidation - 6-Hydroxylation	Mestranol	[1225], [1226]
MR001648	17alpha-Ethinylestradiol	7-hydroxyethinylestradiol	Oxidation - 7-Hydroxylation	Mestranol	[1225], [1226]
MR001649	17alpha-Ethinylestradiol	16alpha-hydroxyethinylestradiol	Oxidation - 16-Hydroxylation	Mestranol	[1225], [1226]
MR001657	4-formyl-amino-antipyrine (FAA)	4-amino-antipyrine (AA)	Oxidation - N-Demethylation	Metamizole sodium	[1389], [1390]
MR001655	N-Desmethylaminopyrine	4-amino-antipyrine (AA)	Oxidation - N-Demethylation	Metamizole sodium	[1389], [1390]
MR009998	Methadone	EDDP	Oxidation - N-demethylation	Methadone	[381], [1391]
MR005749	Methylergometrine	Unclear	Unclear - Unclear	Methylergometrine	[442]
MR013395	Metoclopramide hydrochloride	Metoclopramide hydrochloride Metabolite M4	Oxidation - Oxidationn	Metoclopramide hydrochloride	[1392]
MR013401	Metoclopramide hydrochloride	Metoclopramide hydrochloride Metabolite M3	Oxidation - N-dealkylation	Metoclopramide hydrochloride	[1392]
MR013406	Metoclopramide hydrochloride	Metoclopramide hydrochloride Metabolite M10	Oxidation - Nitration	Metoclopramide hydrochloride	[1392]
MR004713	Metoprolol succinate	O-Demethylmetoprolol	Oxidation - O-dealkylation	Metoprolol succinate	[242]
MR004722	Metoprolol tartrate	O-Demethylmetoprolol	Oxidation - O-dealkylation	Metoprolol tartrate	[242]
MR004727	Metronidazole	2-hydroxymetronidazole	Oxidation - Hydrolyzationn	Metronidazole	[1393], [1394], [1395], [1396]
MR001667	8-hydroxyminaserin	8-hydroxy-N-desmethylmianserin	Oxidation - N-Dealkylation	Mianserin	[44]
MR001673	Mianserin	(R)-mianserin,N-Desmethyl	Oxidation - N-Dealkylation	Mianserin	[44]
MR001669	Mianserin	8-hydroxyminaserin	Oxidation - Hydroxylation	Mianserin	[44]
MR001672	Mianserin	(R)-mianserin,8-hydroxy	Oxidation - Hydroxylation	Mianserin	[44]
MR001670	Mianserin	N-desmethylmianserin	Oxidation - N-Oxidation	Mianserin	[44]
MR001671	Mianserin	(R)-mianserin,N-oxide	Oxidation - N-Oxidation	Mianserin	[44]
MR001668	N-desmethylmianserin	8-hydroxy-N-desmethylmianserin	Oxidation - 8-Hydroxylation	Mianserin	[44]
MR004742	Midazolam hydrochloride	4-hydroxymidazolam	Oxidation - 4-hydroxylation	Midazolam hydrochloride	[1397]
MR004744	Midazolam hydrochloride	Alpha-hydroxymidazolam	Oxidation - 1'-hydroxylation	Midazolam hydrochloride	[1397], [1398]
MR004755	Midostaurin	CGP 52421	Oxidation - 7-hydroxylation	Midostaurin	[1399], [1400]
MR004756	Midostaurin	CGP 62221	Oxidation - O-demethylation	Midostaurin	[1399]
MR004757	Mifepristone	Monodemethylated mifepristone	Oxidation - N-dealkylation	Mifepristone	[242], [1401]
MR004762	Mifepristone	17alpha-hydroxymifepristone	Oxidation - Aliphatic hydroxylation	Mifepristone	[242], [1402]
MR001685	Milnacipran	N-Desethyl milnacipran	Oxidation - Desethylation	Milnacipran	[684]
MR006019	Miocamycin	Unclear	Oxidation - Hydrolyzationn	Miocamycin	[1403]
MR010192	DM4	S-methyl-DM4	Unclear - Unclear	Mirvetuximab soravtansine	[1404]
MR010191	Mirvetuximab soravtansine	DM4	Unclear - Unclear	Mirvetuximab soravtansine	[1404]
MR005538	Mitapivat	Unclear	Unclear - Unclear	Mitapivat	[547]
MR003953	MK-0822	MK-0822 Metabolite M8 (Odanacatib)	Oxidation - Hydrolyzationn	MK-0822	[922]
MR003763	MK-0859	MK-0859 Metabolite M1	Oxidation - O-demethylation	MK-0859	[698]
MR012690	MK-3118	Unclear	Oxidation - Hydroxylation	MK-3118	[871]
MR012692	MKC-442	BIU	Unclear - Unclear	MKC-442	[882]
MR007630	ML-3000	Licofelone M4	Oxidation - Hydrolyzationn	ML-3000	[24]
MR005785	MLN-8054	Unclear	Unclear - Unclear	MLN-8054	[939]
MR011622	MLN4924	MLN4924 Metabolite M1	Oxidation - Hydroxylation	MLN4924	[734]
MR011624	MLN4924	MLN4924 Metabolite M3	Oxidation - Hydroxylation	MLN4924	[734]
MR013407	Modafinil	Modafinil acid	Oxidation - Oxidationn	Modafinil	[1405]
MR004802	Montelukast sodium	25-OH Montelukast	Unclear - Unclear	Montelukast sodium	[1406]
MR004799	Montelukast sodium	Montelukast sulfoxide	Oxidation - S-oxidation	Montelukast sodium	[24], [1406]
MR004800	Montelukast sodium	Montelukast metabolite M5a	Oxidation - Hydrolyzationn	Montelukast sodium	[24], [1406]
MR004801	Montelukast sodium	Montelukast metabolite M5b	Oxidation - Hydrolyzationn	Montelukast sodium	[24], [1406]
MR004799	Montelukast sodium	Montelukast metabolite M2a/b	Unclear - Unclear	Montelukast sodium	[24]
MR004801	Montelukast sodium	21-Hydroxymontelukast	Oxidation - Aliphatic hydroxylation	Montelukast sodium	[24]
MR004800	Montelukast sodium	21(S)-Hydroxy Montelukast	Oxidation - Aliphatic hydroxylation	Montelukast sodium	[24]
MR009723	Motesanib	Motesanib M5	Oxidation - Hydroxylation	Motesanib	[950]
MR009726	Motesanib	Motesanib M4	Unclear - Unclear	Motesanib	[950], [1407]
MR009732	Motesanib	Motesanib M3	Unclear - Unclear	Motesanib	[950]
MR012777	MP-513	MP-513 Metabolite M1	Oxidation - Thiazolidine-1-oxidation	MP-513	[1408], [1409]
MR012781	MP-513	MP-513 Metabolite M3	Hydrolysis - Hydrolysis	MP-513	[1408]
MR005404	MRTX849	Unclear	Unclear - Unclear	MRTX849	[1410]
MR012335	MT-1303	HU10	Unclear - Unclear	MT-1303	[833]
MR004812	Mycophenolic acid	6-O-desmethyl-MPA (DM-MPA)	Unclear - Unclear	Mycophenolate mofetil	[1411]
MR004823	Mycophenolic acid	6-O-desmethyl-mycophenolic acid	Oxidation - Demethylation	Mycophenolic acid	[384], [385]
MR003384	R-Naftopidil	R-Naftopidil metabolite M3	Unclear - Unclear	Naftopidil	[1412], [1413]
MR010771	Nalmefene	Nornalmefene	Oxidation - Dealkylation	Nalmefene	[1414]
MR005776	Naloxegol oxalate	HO-PEG5-Naloxol	Oxidation - Hydrolyzationn	Naloxegol oxalate	[1415], [309]
MR005778	Naloxegol oxalate	HO-PEG4-Naloxol	Oxidation - Hydrolyzationn	Naloxegol oxalate	[1415], [309]
MR005780	Naloxegol oxalate	Carboxymethyl-PEG6-Naloxol	Oxidation - Oxidationn	Naloxegol oxalate	[1415], [309]
MR004876	Nateglinide	Nateglinide metabolite M2/M3	Oxidation - Hydrolyzationn	Nateglinide	[24], [1416]
MR004878	Nateglinide	Nateglinide metabolite M1	Oxidation - Hydrolyzationn	Nateglinide	[24]
MR004883	Nateglinide	2-{[4-(1-hydroxypropan-2-yl)cyclohexyl]formamido}-3-phenylpropanoic acid	Oxidation - Aliphatic hydroxylation	Nateglinide	[24]
MR004884	Nateglinide	2-{[4-(2-hydroxypropan-2-yl)cyclohexyl]formamido}-3-phenylpropanoic acid	Oxidation - Aliphatic hydroxylation	Nateglinide	[24]
MR003787	NE-10064	NE-10064 Metabolite M5	Unclear - Unclear	NE-10064	[724]
MR003783	NE-10064	NE-10064 Metabolite M4	Oxidation - N-oxidation	NE-10064	[724]
MR013408	Nebivolol hydrochloride	4-hydroxy Nebivolol	Oxidation - 4-hydroxylation	Nebivolol hydrochloride	[548]
MR004885	Nefazodone	Hydroxynefazodone	Oxidation - Hydrolyzationn	Nefazodone	[1417]
MR004892	Nefazodone	3-[3-ethyl-5-oxo-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]propanal	Oxidation - N-dealkylation	Nefazodone	[1417]
MR004891	Nefazodone	M-Chlorophenylpiperazine	Oxidation - N-dealkylation	Nefazodone	[1418]
MR001720	Nelfinavir mesylate	3,4-Dihydroxynelfinavir	Oxidation - Hydroxylation	Nelfinavir mesylate	[1419]
MR001721	Nelfinavir mesylate	2-methoxy-3-hydroxynelfinavir	Unclear - Unclear	Nelfinavir mesylate	[1419]
MR011669	Nestorone	5alpha-dihydrosegesterone acetate	Reduction - Reduction	Nestorone	[1420]
MR011670	Nestorone	20alpha?-dihydrosegesterone acetate	Reduction - Reduction	Nestorone	[1420]
MR011671	Nestorone	3alpha, 5alpha-tetrahydrosegesterone acetate	Reduction - Reduction	Nestorone	[1420]
MR009257	N-despropyl-rotigotine	Neupro Metabolite M2	Unclear - Unclear	Neupro	[1421], [648]
MR009255	Neupro	N-despropyl-rotigotine	Unclear - Unclear	Neupro	[1421], [648]
MR003269	Nevirapine	12-hydroxynevirapine	Oxidation - Hydroxylation	Nevirapine	[1422], [1423], [1424]
MR003271	Nevirapine	8-hydroxynevirapine	Oxidation - 8-Hydroxylation	Nevirapine	[1425]
MR003270	Nevirapine	2-hydroxynevirapine	Oxidation - 2-Hydroxylation	Nevirapine	[1422], [1423]
MR001730	Nicardipine hydrochloride	Dehydronicardipine	Oxidation - Heteroring Dehydrogenation	Nicardipine hydrochloride	[242], [18], [467]
MR001729	Nicardipine hydrochloride	De-benzylated nicardipine	Oxidation - N-Dealkylation	Nicardipine hydrochloride	[242], [18]
MR002960	Nicotine	(S)-Nicotine delta-1',5'-iminium ion	Oxidation - Heteroring Dehydrogenation	Nicotine	[384]
MR001736	2,6-dimethyl-4-(2-nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid	2-hydroxymethyl-pyridine carboxylic acid	Unclear - Unclear	Nifedipine	[1426]
MR001737	Nifedipine	2,6-dimethyl-4-(2-nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid	Unclear - Unclear	Nifedipine	[1427]
MR001738	Nifedipine	Dehydronifedipine	Oxidation - Dehydrogenation	Nifedipine	[1428], [1427]
MR001748	Nimodipine	Dehydro nimodipine	Unclear - Unclear	Nimodipine	[1429], [1430]
MR003547	Nintedanib esylate	Nintedanib metabolite M13	Unclear - Unclear	Nintedanib esylate	[1431]
MR003531	Nintedanib esylate	Nintedanib metabolite M6	Oxidation - Demethylation	Nintedanib esylate	[1431]
MR003546	Nintedanib esylate	Nintedanib metabolite M8	Oxidation - Hydroxylation	Nintedanib esylate	[1431]
MR003544	Nintedanib esylate	Nintedanib metabolite M12	Unclear - Unclear	Nintedanib esylate	[1431]
MR001760	Nisoldipine	Nisoldipine metabolite M13	Oxidation - Dehydrogenation	Nisoldipine	[1432]
MR001758	Nisoldipine metabolite M1	Nisoldipine metabolite M2	Oxidation - Dehydrogenation	Nisoldipine	[1432]
MR001752	Nisoldipine metabolite M9	Nisoldipine metabolite M10	Oxidation - Dehydrogenation	Nisoldipine	[1433]
MR013610	NITD609	NITD609 Metabolite M37	Unclear - Unclear	NITD609	[821]
MR013617	NITD609	NITD609 Metabolite M40	Unclear - Unclear	NITD609	[821]
MR013611	NITD609 Metabolite M37	NITD609 Metabolite M18	Unclear - Unclear	NITD609	[821]
MR013618	NITD609 Metabolite M40	NITD609 Metabolite M48	Unclear - Unclear	NITD609	[821]
MR007640	Nomifensine	Nomifensine H1	Unclear - Unclear	Nomifensine	[978]
MR001783	Norethindrone acetate	Norethindrone acetate metabolite M1,M2	Oxidation - Hydroxylation	Norethindrone acetate	[93]
MR001784	Norethindrone acetate	Norethindrone acetate metabolite M4	Oxidation - Dehydrogenation	Norethindrone acetate	[93]
MR001780	Norethindrone acetate metabolite M1,M2	Norethindrone acetate metabolite M3	Oxidation - Dihydroxylation	Norethindrone acetate	[93]
MR001793	Norgestimate	17-desacetylnorgestimate	Oxidation - Deacetylation	Norgestimate	[1434], [549]
MR001794	Desmethylnortriptyline	E-10-hydroxydesmethylnortriptyline	Oxidation - N-Demethylation	Nortriptyline hydrochloride	[24], [1435]
MR006145	NOVA-63035	6alpha-Hydroxydexamethasone	Oxidation - Aliphatic hydroxylation	NOVA-63035	[1436]
MR006146	NOVA-63035	6beta-Hydroxydexamethasone	Oxidation - Aliphatic hydroxylation	NOVA-63035	[1436]
MR006380	NSC-122758	4-Hydroxyretinoic acid	Oxidation - 4-hydroxylation	NSC-122758	[75]
MR001797	9-Aminocamptothecin metabolite M2	9-Aminocamptothecin metabolite M1	Unclear - Unclear	NSC-603071	[883]
MR001798	NSC-603071	9-Aminocamptothecin metabolite M2	Unclear - Unclear	NSC-603071	[883]
MR006386	NSC-9705	Unclear	Unclear - Unclear	NSC-9705	[766]
MR013882	Nuplazid	AC-279	Unclear - Unclear	Nuplazid	[884]
MR004429	6-O-benzyl-8-oxoguanine	8-oxoguanine	Oxidation - Debenzylation	O-Benzylguanine	[1437]
MR004428	O-Benzylguanine	6-O-benzyl-8-oxoguanine	Oxidation - Oxidationn	O-Benzylguanine	[1437]
MR001812	Olaparib metabolite M10	Olaparib metabolite M12	Oxidation - Alcohol Oxidation	Olaparib	[1438]
MR001821	Olopatadine	N-desmethyl olopatadine	Oxidation - N-Demethylation	Olopatadine	[387]
MR001830	Omeprazole	5-hydroxyomeprazole	Oxidation - 5-Hydroxylation	Omeprazole	[24]
MR001829	Omeprazole	Omeprazole sulfone metabolite	Oxidation - Sulfoxidation	Omeprazole	[24]
MR001832	Omeprazole	3-hydroxyomeprazole	Oxidation - 3-Hydroxylation	Omeprazole	[24]
MR001836	Ondansetron	7-OH-ondansetron	Oxidation - Hydroxylation	Ondansetron	[44], [1439]
MR001839	Ondansetron	8-OH-ondansetron	Oxidation - Hydroxylation	Ondansetron	[44]
MR001840	Ondansetron	6-OH-ondansetron	Oxidation - Hydroxylation	Ondansetron	[1439]
MR006393	OPC-12759	6-Hydroxyrebamipide	Unclear - Unclear	OPC-12759	[1440]
MR006394	OPC-12759	8-Hydroxyrebamipide	Unclear - Unclear	OPC-12759	[767]
MR010454	Oprozomib	Oprozomib Metabolite M6	Unclear - Unclear	Oprozomib	[1441]
MR010455	Oprozomib	Oprozomib Metabolite M7	Unclear - Unclear	Oprozomib	[1441]
MR010456	Oprozomib	Oprozomib Metabolite M8	Unclear - Unclear	Oprozomib	[1441]
MR010457	Oprozomib	Oprozomib Metabolite M9	Unclear - Unclear	Oprozomib	[1441]
MR001843	Org-33062	3'-OH-gepirone	Unclear - Unclear	Org-33062	[1442]
MR001844	Org-33062	5-OH-gepirone	Unclear - Unclear	Org-33062	[1442]
MR001842	Org-33062	1-Pyrimidinylpiperazine	Unclear - Unclear	Org-33062	[1442]
MR001845	Org-33062	2-OH-gepirone	Unclear - Unclear	Org-33062	[1442]
MR010382	OSI-930	Sulfoxide	Oxidation - Oxidation	OSI-930	[943]
MR001851	Osimertinib	AZ5104	Unclear - Unclear	Osimertinib	[1443], [1444], [1445]
MR001852	Osimertinib	AZ7550	Unclear - Unclear	Osimertinib	[1443], [1444], [1445]
MR001857	Ospemifene	4-hydroxylation Ospemifene	Unclear - Unclear	Ospemifene	[310]
MR002863	Oxazepam	.	Oxidation - Deamination	Oxazepam	[1446]
MR001876	N-desethyloxybutynin	2-Cyclohexyl-2-hydroxy-2-phenylacetic acid	Unclear - Unclear	Oxybutynin chloride	[1447]
MR001877	Oxybutynin chloride	N-desethyloxybutynin	Oxidation - N-Deethylation	Oxybutynin chloride	[1447], [1448]
MR013818	Oxycodone	Noroxycodone	Unclear - Unclear	Oxycodone	[1449]
MR013821	Oxymorphone	Noroxymorphone	Unclear - Unclear	Oxycodone	[1449]
MR001878	Noroxycodone	Noroxymorphone	Oxidation - N-Demethylation	Oxycodone hydrochloride	[311], [1450]
MR001881	Oxycodone hydrochloride	Noroxycodone	Oxidation - N-Demethylation	Oxycodone hydrochloride	[311], [1450], [1451]
MR001886	Oxymorphone	Noroxymorphone	Oxidation - N-Demethylation	Oxycodone hydrochloride	[1452]
MR001898	Oxymorphone	Noroxymorphone	Oxidation - N-Demethylation	Oxymorphone	[95]
MR001899	Oxymorphone	Noroxycodone	Oxidation - N-Demethylation	Oxymorphone	[95]
MR001900	Oxymorphone	Nor-6alpha-Oxycodol	Oxidation - N-Demethylation	Oxymorphone	[95]
MR001901	Oxymorphone	Beta-noroxycodol	Oxidation - N-Demethylation	Oxymorphone	[95]
MR005573	Ozanimod	RP101075	Oxidation - N-Dealkylation	Ozanimod	[25]
MR005572	RP101075	RP112289	Unclear - Unclear	Ozanimod	[25]
MR005572	RP101075	RP112289	Unclear - Unclear	Ozanimod	[25]
MR014024	RP101075	RP112289	Unclear	Ozanimod	[25]
MR001907	Paclitaxel	6alpha, 3'-p-dihydroxypaclitaxel	Oxidation - Hydroxylation	Paclitaxel	[1453]
MR001908	Paclitaxel	3'-p-hydroxypaclitaxel	Oxidation - Hydroxylation	Paclitaxel	[1454]
MR005577	Pacritinib	Pacritinib M1 metabolite	Oxidation - Oxidationn	Pacritinib	[743]
MR005578	Pacritinib	Pacritinib M2 metabolite	Oxidation - O-dealkylation	Pacritinib	[743]
MR005579	Pacritinib	Pacritinib M3 metabolite	Other reaction - Oxidation	Pacritinib	[743]
MR005580	Pacritinib	Pacritinib M4 metabolite	Reduction - Reduction	Pacritinib	[743]
MR001911	Palbociclib	Palbociclib metabolite M6	Oxidation - Hydroxylation	Palbociclib	[1455]
MR001912	Palbociclib	Palbociclib metabolite M7	Oxidation - N-Oxidation	Palbociclib	[1455]
MR001913	Palbociclib	Palbociclib metabolite M1	Oxidation - Hydroxylation	Palbociclib	[1455]
MR001914	Palbociclib	Palbociclib metabolite M2	Oxidation - Hydroxylation	Palbociclib	[1455]
MR001915	Palbociclib	Palbociclib metabolite M3	Oxidation - Hydroxylation	Palbociclib	[1455]
MR001916	Palbociclib	Palbociclib metabolite M11	Oxidation - Hydroxylation	Palbociclib	[1455]
MR001917	Palbociclib	Palbociclib metabolite M4	Oxidation - N-Dealkylation	Palbociclib	[1455]
MR001918	Palbociclib	Palbociclib metabolite M14	Oxidation - N-Dealkylation	Palbociclib	[1455]
MR001920	Palbociclib	Palbociclib metabolite M9	Oxidation - N-Dealkylation	Palbociclib	[1455]
MR001921	Palbociclib	Palbociclib metabolite M10	Oxidation - N-Dealkylation	Palbociclib	[1455]
MR001922	Palbociclib	Palbociclib metabolite M12	Unclear - Unclear	Palbociclib	[1455]
MR001923	Palbociclib	Palbociclib metabolite M13	Conjugation - Acetylation	Palbociclib	[1455]
MR001924	Paliperidone	9-hydroxyrisperidone	Unclear - Unclear	Paliperidone	[1456]
MR001925	Paliperidone	Risperidone	Oxidation - Dehydrogenation	Paliperidone	[1457]
MR002864	Palonosetron hydrochloride	Palonosetron metabolite M4	Oxidation - Hydroxylation	Palonosetron hydrochloride	[390]
MR002865	Palonosetron hydrochloride	Palonosetron metabolite M9	Oxidation - N-Oxidation	Palonosetron hydrochloride	[390]
MR001937	Panobinostat lactate	Panobinostat lactate metabolite M5	Unclear - Unclear	Panobinostat lactate	[124]
MR001940	Pantoprazole Sodium	Pantoprazole Sulfone	Reduction - Reduction	Pantoprazole Sodium	[391]
MR001947	Paramethasone	Paramethasone metabolite M1	Oxidation - Hydroxylation	Paramethasone	[1458]
MR003485	Valdecoxib	Valdecoxib metabolite M1	Oxidation - Methyl-Hydroxylation	Parecoxib	[1459], [24]
MR003491	Valdecoxib	Valdecoxib metabolite M9	Oxidation - Hydroxylation	Parecoxib	[1459], [24]
MR010436	Paritaprevir	Paritaprevir Metabolite M6	Oxidation - Oxidation	Paritaprevir	[1024]
MR010442	Paritaprevir	Paritaprevir Metabolite M2	Oxidation - Oxidation	Paritaprevir	[1024]
MR010443	Paritaprevir	Paritaprevir Metabolite M24	Multi-steps Reaction - Oxidation& conjugation	Paritaprevir	[1024]
MR010437	Paritaprevir Metabolite M6	Paritaprevir Metabolite M3	Oxidation - Oxidation	Paritaprevir	[1024]
MR003337	Paroxetine hydrochloride	Paroxetine catechol	Unclear - Unclear	Paroxetine hydrochloride	[24], [1460]
MR001948	Pazopanib	Pazopanib hydrochloride	Oxidation - Hydroxylation; N-Demethylation	Pazopanib	[1461], [313], [1462]
MR001953	PD-115934	N-demethyl-PZA	Unclear - Unclear	PD-115934	[476]
MR013072	Pemigatinib	O-des-methyl-pemigatinib	Unclear - Unclear	Pemigatinib	[1463]
MR001985	N-desmethylperazine	N-{3-(phenothiazinyl-10)-propyl}ethylenediamine	Oxidation - N-Dealkylation	Perazine	[674]
MR001986	Perazine	N-desmethylperazine	Oxidation - N-Demethylation	Perazine	[674]
MR001987	Perazine	Perazine 5-sulfoxide metabolite	Oxidation - Sulphoxidation	Perazine	[674]
MR001990	Pergolide mesylate	N-Despropyl Pergolide	Oxidation - Demethylation	Pergolide mesylate	[1464]
MR002004	Permethrin	Phenoxybenzyl alcohol	Hydrolysis - Hydrolysis	Permethrin	[558], [1465]
MR002005	Perphenazine	N-Dealkylated perphenazine	Oxidation - N-Dealkylation	Perphenazine	[1464]
MR013146	Pexacerfont	DPH-124921	Unclear - Unclear	Pexacerfont	[805]
MR013148	Pexacerfont	DPH-123554	Unclear - Unclear	Pexacerfont	[805]
MR013150	Pexacerfont	Pexacerfont Metabolite M8	Unclear - Unclear	Pexacerfont	[805]
MR013153	Pexacerfont	BMS-749241	Unclear - Unclear	Pexacerfont	[805]
MR013716	PF-00734200	PF-00734200 metabolite M5	Unclear - Unclear	PF-00734200	[814]
MR010398	PF-04937319	PF-04937319 Metabolite M1	Oxidation - N-demethylation	PF-04937319	[886]
MR005388	PF-04965842	Abrocitinib M4 metabolite	Oxidation - Oxidationn	PF-04965842	[1466]
MR005393	PF-04965842	Abrocitinib M1 metabolite	Oxidation - Oxidationn	PF-04965842	[1466]
MR005400	PF-04965842	Abrocitinib M3 metabolite	Oxidation - Oxidationn	PF-04965842	[1466]
MR005397	PF-04965842	Abrocitinib M2 metabolite	Oxidation - Oxidationn	PF-04965842	[1466]
MR008326	PF-04991532	PF-04991532 metabolite M4	Oxidation - Hydroxylation	PF-04991532	[851]
MR008327	PF-04991532	PF-04991532 metabolite M5	Oxidation - Hydroxylation	PF-04991532	[851]
MR011750	PF-06463922	PF-06895751 (M8)	Unclear - Unclear	PF-06463922	[822]
MR006396	Hydroxytriptolide	Trihydroxytriptolide	Unclear - Unclear	PG-490	[704]
MR006395	PG-490	Hydroxytriptolide	Oxidation - Hydrolyzationn	PG-490	[704]
MR006401	PG-490	Dihydroxytriptolide	Oxidation - Hydrolyzationn	PG-490	[704]
MR006406	PG-490	Hydrolyzed hydroxytriptolide	Oxidation - Hydrolyzationn	PG-490	[704]
MR006408	PG-490	Hydrolyzed triptolide	Oxidation - Hydrolyzationn	PG-490	[704]
MR002014	Acetaminophen	NAPQI	Oxidation - Oxidation	Phenacetin	[1467]
MR002018	Phenelzine	Phenethylamine	Hydrolysis - Hydrolysis	Phenelzine	[1468]
MR002023	Phenobarbital	4-hydroxyphenobarbital	Oxidation - 4-Hydroxylation	Phenobarbital	[24]
MR002024	Phenobarbital	Mephobarbital	Conjugation - Methylation	Phenobarbital	[1469]
MR002026	Phenprocoumon	6-hydroxy-R-phenprocoumon	Oxidation - 6-Hydroxylation	Phenprocoumon	[24]
MR002027	Phenprocoumon	8-hydroxy-R-phenprocoumon	Oxidation - 8-Hydroxylation	Phenprocoumon	[24]
MR002028	Phenprocoumon	7-hydroxy-R-phenprocoumon	Oxidation - 7-Hydroxylation	Phenprocoumon	[24]
MR003159	N-hydroxyphentermine	Nitrophentermine	Oxidation - Oxidation	Phentermine	[1470]
MR003160	Phentermine	N-hydroxyphentermine	Oxidation - N-Hydroxylation	Phentermine	[1470]
MR003161	Phentermine	p-hydroxyphentermine	Oxidation - Hydroxylation	Phentermine	[1470]
MR002030	Hydroxyphenytoin	Phenytoin catechol	Oxidation - Oxidation	Phenytoin	[384]
MR002036	Phenytoin	Phenytoin dihydrodiol	Oxidation - Dihydroxylation; Oxidation	Phenytoin	[24]
MR002037	Pimecrolimus	metabolites of pimecrolimus	Oxidation - O-Demethylation; Oxygenation	Pimecrolimus	[559]
MR002038	Pimozide	DHBPI	Oxidation - N-Dealkylation	Pimozide	[1471]
MR002039	Pimozide	4,4-bis(4-fluorophenyl) butyric acid	Unclear - Unclear	Pimozide	[1472]
MR002042	Pinacidil	M-2	Oxidation - N-Oxidation	Pinacidil	[394]
MR002043	Pinacidil	Pinacidil amide	Unclear - Unclear	Pinacidil	[394]
MR002044	Pinacidil	M3 and M4	Unclear - Unclear	Pinacidil	[394]
MR002051	Pioglitazone hydrochloride	Pioglitazone metabolite M-II	Oxidation - Oxidation	Pioglitazone hydrochloride	[96], [1473]
MR002052	Pioglitazone hydrochloride	Pioglitazone metabolite M-VI	Oxidation - Oxidation	Pioglitazone hydrochloride	[96]
MR002053	Pioglitazone hydrochloride	Pioglitazone metabolite M-V	Oxidation - Oxidation	Pioglitazone hydrochloride	[96], [1473]
MR002054	Pioglitazone hydrochloride	Pioglitazone metabolite M-IV	Oxidation - Oxidation	Pioglitazone hydrochloride	[96], [1473]
MR002045	Pioglitazone metabolite M-II	Pioglitazone metabolite M-XI	Oxidation - Oxidation	Pioglitazone hydrochloride	[96], [1473]
MR002048	Pioglitazone metabolite M-IV	Pioglitazone metabolite M-XI	Oxidation - Oxidation	Pioglitazone hydrochloride	[96], [1473]
MR005160	Piperaquine	M2 (piperaquine)	Oxidation - N-oxidation	Piperaquine	[649], [650], [651]
MR008864	Pitavastatin	Pitavastatin metabolite M-3	Oxidation - Oxidation	Pitavastatin	[1474]
MR002067	Pitavastatin	M-3	Oxidation - Hydroxylation	Pitavastatin calcium	[1475]
MR011133	Pitolisant	BP2.941	Oxidation - Hydroxylation	Pitolisant	[1476]
MR011134	Pitolisant	BP2.951	Conjugation - Glycine conjugation	Pitolisant	[1477]
MR002076	Pomalidomide	5-hydroxypomalidomide	Oxidation - Hydroxylation	Pomalidomide	[1478], [174], [1479]
MR002077	Pomalidomide	7-hydroxypomalidomide	Oxidation - Hydroxylation	Pomalidomide	[1478], [174], [1479]
MR002079	Pomalidomide	Pomalidomide metabolite M19	Oxidation - Hydroxylation	Pomalidomide	[1478], [174]
MR002083	Ponatinib hydrochloride	AP24567	Oxidation - N-Demethylation	Ponatinib hydrochloride	[1480], [1481], [1482]
MR013198	Ponesimod	Ponesimod M12 Metabolite (ACT-204426)	Oxidation - Oxidationn	Ponesimod	[126]
MR013759	PPI-2458	PPI-2458 metabolite M1	Oxidation - Hydroxylation	PPI-2458	[928]
MR013760	PPI-2458	PPI-2458 metabolite M2	Unclear - Unclear	PPI-2458	[928]
MR013761	PPI-2458	PPI-2458 metabolite M3	Unclear - Unclear	PPI-2458	[928]
MR013762	PPI-2458	PPI-2458 metabolite M4	Oxidation - Hydroxylation	PPI-2458	[928]
MR013763	PPI-2458	PPI-2458 metabolite M5	Unclear - Unclear	PPI-2458	[928]
MR013764	PPI-2458	PPI-2458 metabolite M6	Unclear - Unclear	PPI-2458	[928]
MR006410	PR-934423	Desglycinyl-remacemide	Oxidation - Oxidationn	PR-934423	[778]
MR005182	Pranlukast	Pranlukast M-1	Oxidation - Hydrolyzationn	Pranlukast	[1483]
MR005184	Pranlukast	Pranlukast HM-1	Oxidation - Hydrolyzationn	Pranlukast	[1483]
MR002088	R-95913	R-138727	Unclear - Unclear	Prasugrel hydrochloride	[24], [1484], [1485], [1486]
MR002111	Nordazepam	Oxazepam	Oxidation - Hydroxylation	Prazepam	[249], [1487], [1488]
MR002107	Prazepam	Nordazepam	Oxidation - N-Dealkylation	Prazepam	[249], [1487], [1488]
MR002112	Praziquantel	10-hydroxypraziquantel	Oxidation - Hydroxylation	Praziquantel	[1489], [561], [40]
MR002127	Prednisolone	6beta-hydroxy-prednisolone(M-VI)	Oxidation - Hydroxylation	Prednisolone	[1490]
MR002130	Prednisone	6beta-hydroxy-prednisone (M-XII)	Oxidation - Hydroxylation	Prednisolone	[1490]
MR002779	Prednisolone	6beta-hydroxy-prednisolone(M-VI)	Unclear - Unclear	Prednisone	[32]
MR002770	Prednisone	6beta-hydroxy-prednisone (M-XII)	Oxidation - Hydroxylation	Prednisone	[1490], [32]
MR002774	Prednisone	Prednisolone	Unclear - Unclear	Prednisone	[1490]
MR002134	Pretomanid	.	Unclear - Unclear	Pretomanid	[1491]
MR002171	Progesterone	6beta-hydroxyprogesterone	Oxidation - Hydroxylation	Progesterone	[1492], [1493]
MR005189	Proguanil	Cycloguanil	Other reaction - Cyclisation	Proguanil	[687], [1494], [1495]
MR002781	Promazine	Promazine 5-sulfoxide	Oxidation - 5-Sulphoxidation	Promazine	[250]
MR002880	Propafenone hydrochloride	N-depropylpropafenone	Oxidation - N-Dealkylation	Propafenone hydrochloride	[175]
MR002882	Propafenone hydrochloride	(S)-N-Despropylpropafenone	Oxidation - N-Dealkylation	Propafenone hydrochloride	[242]
MR005194	Propiverine	P-4 (N-oxide)	Unclear - Unclear	Propiverine	[1496]
MR013648	PT2385	PT2385 M10	Oxidation - Hydroxylation	PT2385	[834]
MR013646	PT2385	PT2385 M2	Oxidation - Hydroxylation	PT2385	[834]
MR005431	PT2977	Unclear	Unclear - Unclear	PT2977	[1497]
MR012497	PTC299	O-Desmethyl emvododstat	Unclear - Unclear	PTC299	[887]
MR006986	Q-100155	9-O-demethylemetine	Oxidation - Demethylation	Q-100155	[1498]
MR006987	Q-100155	10-O-demethylemetine	Oxidation - Demethylation	Q-100155	[1498]
MR002785	2-Oxoquazepam	3-hydroxy-2-oxoquazepam	Oxidation - Hydroxylation	Quazepam	[1499]
MR002786	2-Oxoquazepam	N-Desalkyl-2-oxoquazepam	Unclear - Unclear	Quazepam	[1499]
MR002788	Quazepam	2-Oxoquazepam	Hydrolysis - Hydrolysis	Quazepam	[1499]
MR002204	Quetiapine fumarate	7-hydroxyquetiapine	Oxidation - Hydroxylation	Quetiapine fumarate	[1500], [320]
MR002203	Quetiapine fumarate	N-desalkylquetiapine	Unclear - Unclear	Quetiapine fumarate	[1500], [320]
MR002205	Quetiapine fumarate	Quetiapine sulfoxide	Oxidation - Sulfoxidation	Quetiapine fumarate	[1500]
MR002206	Quetiapine fumarate	O-desalkylquetiapine	Oxidation - N-Dealkylation	Quetiapine fumarate	[1500]
MR010018	Quinine sulfate	Quinine sulfate Metabolite M3	Oxidation - Demethylation	Quinine sulfate	[1501]
MR010016	Quinine sulfate	Quinine sulfate Metabolite M1	Oxidation - Hydroxylation	Quinine sulfate	[1501]
MR010020	Quinine sulfate	Quinine sulfate Metabolite M2	Multi-steps Reaction - DemethylationHydroxylation	Quinine sulfate	[1501]
MR010021	Quinine sulfate	3-hydroxyquinine	Unclear - Unclear	Quinine sulfate	[1502], [1503], [1504]
MR006424	R-1124	Netupitant N-Oxide	Oxidation - Oxidationn	R-1124	[1505]
MR006425	R-1124	N\demethylated netupitant	Oxidation - Demethylation	R-1124	[1505]
MR006426	R-1124	Monohydroxy netupitant	Oxidation - Hydrolyzationn	R-1124	[1505]
MR010028	Rabeprazole sodium	Rabeprazole?sulfone	Unclear - Unclear	Rabeprazole sodium	[1506]
MR010172	Mono-hydroxyralfinamide	2-[4-hydroxybenzylamino]propanamide NW-1199	Unclear - Unclear	Ralfinamide	[1507]
MR010171	Ralfinamide	Mono-hydroxyralfinamide	Unclear - Unclear	Ralfinamide	[1507]
MR010497	Ramatroban	Ramatroban Metabolite M1	Conjugation - Acylation	Ramatroban	[812]
MR010498	Ramatroban Metabolite M1	Ramatroban Metabolite M2	Conjugation - Acylation	Ramatroban	[812]
MR009498	Ranolazine	RS-88390 (CVT-2514)	Oxidation - O-demethylation	Ranolazine	[1508], [1509]
MR009500	Ranolazine	CVT-2534	Oxidation - N-dealkylation	Ranolazine	[1508]
MR009504	Ranolazine	CVT-2551	Oxidation - Hydroxylation	Ranolazine	[1508]
MR009506	Ranolazine	CVT-2738	Oxidation - N-dealkylation	Ranolazine	[1508], [1510]
MR009508	Ranolazine	CVT-2512	Conjugation - O-arylation	Ranolazine	[1508]
MR009509	Ranolazine	CVT-3369	Hydrolysis - Hydrolysis	Ranolazine	[1508]
MR005214	Reboxetine	Reboxetine metabolite A	Oxidation - Hydrolyzationn	Reboxetine	[1511], [635]
MR005216	Reboxetine	Reboxetine metabolite B	Oxidation - Hydrolyzationn	Reboxetine	[1511], [635]
MR005218	Reboxetine	Reboxetine metabolite C	Oxidation - O-dealkylation	Reboxetine	[1511], [635]
MR005220	Reboxetine	Reboxetine metabolite D	Oxidation - Oxidationn	Reboxetine	[1511], [635]
MR005221	Reboxetine	Reboxetine metabolite E	Oxidation - Oxidationn	Reboxetine	[1511], [635]
MR005222	Reboxetine	Reboxetine metabolite I	Unclear - Unclear	Reboxetine	[1511], [635]
MR005223	Reboxetine	Reboxetine metabolite L	Unclear - Unclear	Reboxetine	[1511], [635]
MR005224	Reboxetine	Reboxetine metabolite M	Unclear - Unclear	Reboxetine	[1511], [635]
MR005225	Reboxetine	Reboxetine metabolite N	Unclear - Unclear	Reboxetine	[1511], [635]
MR005226	Reboxetine	Reboxetine metabolite O	Unclear - Unclear	Reboxetine	[1511], [635]
MR009519	Regorafenib	Regorafenib M3	Oxidation - Hydroxylation	Regorafenib	[1512]
MR009514	Regorafenib	Regorafenib M2	Oxidation - N-oxidation	Regorafenib	[1513], [1512]
MR009515	Regorafenib M2	Regorafenib M1	Oxidation - Methylhydroxylation	Regorafenib	[1512]
MR013218	Remdesivir	Remdesivir M1	Unclear - Unclear	Remdesivir	[131]
MR008491	Remogliflozin	GSK279782	Unclear - Unclear	Remogliflozin etabonate	[844]
MR008493	Remogliflozin	GSK333081	Unclear - Unclear	Remogliflozin etabonate	[844]
MR013049	Repaglinide	Repaglinide M2	Unclear - Unclear	Repaglinide	[1514], [1515]
MR013051	Repaglinide	Hydroxyrepaglinide	Oxidation - Hydroxylation	Repaglinide	[1514]
MR013052	Repaglinide	Repaglinide M1	Oxidation - Oxidation	Repaglinide	[1514], [1515]
MR013053	Repaglinide	Repaglinide M5	Unclear - Unclear	Repaglinide	[1516]
MR013055	Repaglinide	Repaglinide M0-OH	Oxidation - Hydroxylation	Repaglinide	[1516]
MR013057	Rifabutin	25-O-deacetylrifabutin	Oxidation - Deacetylation	Rifabutin	[177]
MR010856	Rifampin	25-desacetylrifampicin	Unclear - Unclear	Rifampin	[397]
MR010857	Rifampin	3-formylrifampicin SV	Unclear - Unclear	Rifampin	[397]
MR010858	Rifampin	3-formyl-25-desacetylrifampicin	Unclear - Unclear	Rifampin	[397]
MR013474	Rifaximin	Unclear	Unclear - Unclear	Rifaximin	[565]
MR009532	Rilpivirine hydrochloride	Rilpivirine M2	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[1517]
MR009534	Rilpivirine hydrochloride	Rilpivirine M4	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[1517]
MR009536	Rilpivirine hydrochloride	Rilpivirine M1	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[1517]
MR009537	Rilpivirine hydrochloride	Rilpivirine M3	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[1517]
MR005593	Risdiplam	Risdiplam M1 metabolite	Oxidation - N-hydroxylation	Risdiplam	[570]
MR009550	Ritonavir	N-Desmethylritonavir	Oxidation - N-demethylation	Ritonavir	[24]
MR009550	Ritonavir	Hydroxy Ritonavir	Other reaction - Hydoxylation	Ritonavir	[24]
MR009551	Ritonavir	Ritonavir metabolite M1	Unclear - Unclear	Ritonavir	[24]
MR009552	Ritonavir	Ritonavir metabolite M11	Unclear - Unclear	Ritonavir	[24]
MR007663	RO-408757	Unclear	Unclear - Unclear	RO-408757	[982]
MR004609	RO-5190591	RO-5190591 Metabolite M1	Unclear - Unclear	RO-5190591	[1518]
MR006437	RO-7-0207	(2S,3S,4S,5R)-6-[1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid	Unclear - Unclear	RO-7-0207	[780]
MR013062	Rofecoxib	5-OH-rofecoxib	Other reaction - Hydoxylation	Rofecoxib	[24]
MR009562	Roflumilast	Roflumilast N-oxide	Oxidation - N-oxidation	Roflumilast	[571], [1519]
MR006595	Rolapitant hydrochloride	Rolapitant metabolite M19	Oxidation - Hydrolyzationn	Rolapitant hydrochloride	[1520]
MR006596	Romidepsin	Romidepsin metabolite M1	Reduction - Reduction	Romidepsin	[1521]
MR010075	RPR-106541	R-sulfoxide diastereomers	Unclear - Unclear	RPR-106541	[1522]
MR010076	RPR-106541	S-sulfoxide diastereomers	Unclear - Unclear	RPR-106541	[1522]
MR002210	Rucaparib	Rucaparib M323 metabolite	Oxidation - Oxidation	Rucaparib	[255]
MR002211	Rucaparib	Rucaparib M324 metabolite	Oxidation - Oxidation	Rucaparib	[255], [1523]
MR002212	Rucaparib	Rucaparib M309 metabolite	Oxidation - N-Demethylation	Rucaparib	[255]
MR002213	Rucaparib	Rucaparib M337b metabolite	Oxidation - Oxidation	Rucaparib	[255]
MR005247	Rupatadine	Desloratadine	Unclear - Unclear	Rupatadine	[1524]
MR005248	Rupatadine	3-hydroxydesloratadine	Unclear - Unclear	Rupatadine	[1524]
MR008879	Ruxolitinib	Ruxolitinib M16 metabolite	Oxidation - 3-hydroxylation	Ruxolitinib	[1525], [1526]
MR008881	Ruxolitinib	Ruxolitinib M18 metabolite	Oxidation - 2-hydroxylation	Ruxolitinib	[1525], [1526]
MR008882	Ruxolitinib	Ruxolitinib M49 metabolite	Unclear - Unclear	Ruxolitinib	[1525], [1526]
MR008880	Ruxolitinib M16 metabolite	Ruxolitinib M9 metabolite	Other reaction - Ketone formation	Ruxolitinib	[399]
MR002214	Ruxolitinib M16 metabolite	Ruxolitinib metabolite M9	Unclear - Unclear	Ruxolitinib phosphate	[1525]
MR002215	Ruxolitinib phosphate	Ruxolitinib M16 metabolite	Oxidation - 3-Hydroxylation	Ruxolitinib phosphate	[1525]
MR002216	Ruxolitinib phosphate	Ruxolitinib M18 metabolite	Oxidation - 2-Hydroxylation	Ruxolitinib phosphate	[1525]
MR002217	Ruxolitinib phosphate	Ruxolitinib M49 metabolite	Unclear - Unclear	Ruxolitinib phosphate	[1525]
MR010681	Safinamide	Safinamide Metabolite M1	Unclear - Unclear	Safinamide	[402]
MR003338	Safinamide mesylate	Safinamide mesylate carboxylic acid	Oxidation - Oxidation	Safinamide mesylate	[403], [404]
MR003340	Safinamide mesylate	Safinamide mesylate	Oxidation - Dealkylation	Safinamide mesylate	[403]
MR003342	Safinamide mesylate	O-debenzylated safinamide	Oxidation - Dealkylation	Safinamide mesylate	[403], [404]
MR002219	Salbutamol	Salbutamol Oxidative metabolites	Oxidation - Oxidative Deamination	Salbutamol	[18]
MR002221	Salmeterol xinafoate	Alpha-hydroxysalmeterol	Oxidation - Hydroxylation	Salmeterol xinafoate	[1527], [1528], [1529]
MR008515	SAM-531	Desmethylcerlapirdine	Oxidation - Demethylation	SAM-531	[873]
MR002885	Saquinavir mesylate	M2 di-hydroxylated metabolite	Oxidation - Hydroxylation	Saquinavir mesylate	[325], [187], [1530]
MR002886	Saquinavir mesylate	(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide	Oxidation - Hydroxylation	Saquinavir mesylate	[1531]
MR002887	Saquinavir mesylate	(2S)-N-[(2S,3R)-4-[(3S,4aR,8aS)-3-(tert-butylcarbamoyl)-6-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide	Oxidation - Hydroxylation	Saquinavir mesylate	[1531]
MR002888	Saquinavir mesylate	(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-7-hydroxy-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide	Oxidation - Hydroxylation	Saquinavir mesylate	[1531]
MR012409	Saracatinib	Saracatinib M1	Unclear - Unclear	Saracatinib	[852]
MR010187	Savolitinib	Savolitinib Metabolite M5	Unclear - Unclear	Savolitinib	[1532]
MR002223	Saxagliptin hydrochloride	5-hydroxy saxagliptin	Oxidation - Hydroxylation	Saxagliptin hydrochloride	[574]
MR006148	SB-1317	Dehydro lercanidipine	Oxidation - Oxidationn	SB-1317	[1533]
MR006440	SB-939	SB-939 Metabolite M1	Oxidation - N-deethylation	SB-939	[735]
MR006458	SCH-417690	O-Desmethylvicriviroc	Oxidation - O-demethylation	SCH-417690	[24]
MR006460	SCH-417690	Vicriviroc N-oxide	Oxidation - N-oxidation	SCH-417690	[24]
MR006461	SCH-417690	N-Desalkylvicriviroc	Unclear - Unclear	SCH-417690	[24]
MR006462	SCH-417690	N,N-Desalkylvicriviroc	Unclear - Unclear	SCH-417690	[24]
MR006459	SCH-417690	Vicriviroc hydroxylamine	Unclear - Unclear	SCH-417690	[24]
MR006463	SCH-417690	21,22-HDoHE	Unclear - Unclear	SCH-417690	[24]
MR002224	Secnidazole	Hydroxymethyl metabolite of secnidazole	Oxidation - Oxidation	Secnidazole	[480], [1534]
MR010844	Desmethyl selegiline	Amphetamine	Unclear - Unclear	Selegiline	[481]
MR002237	ACT-333679	Hydroxylated and dealkylated products	Oxidation - Oxidation	Selexipag	[483]
MR002894	Selinexor	.	Unclear - Unclear	Selinexor	[1535]
MR005635	Selpercatinib	Unclear	Unclear - Unclear	Selpercatinib	[575]
MR005254	4-hydroxy-serindole	Dehydrosertindole	Oxidation - Oxidationn	Sertindole	[1536]
MR005250	5-hydroxy-serindole	Dehydrosertindole	Oxidation - Oxidationn	Sertindole	[1536]
MR005252	Dehydrosertindole	Norsertindole	Oxidation - N-dealkylation	Sertindole	[1536]
MR005252	Dehydrosertindole	Norsertindole	Oxidation - N-dealkylation	Sertindole	[1536]
MR005259	Sertindole	Norsertindole	Oxidation - N-dealkylation	Sertindole	[1536], [1537]
MR002244	Desmethylsertraline	Alpha-hydroxy sertraline ketone	Oxidation - N-Hydroxylation	Sertraline hydrochloride	[1538]
MR002247	Sertraline hydrochloride	Desmethylsertraline	Oxidation - N-Demethylation	Sertraline hydrochloride	[1539], [1540], [1541], [1542]
MR006464	SHP-620	VP 44469	Oxidation - N-dealkylation	SHP-620	[733]
MR002250	Sibutramine	Sibutramine metabolite M1	Oxidation - Demethylation	Sibutramine	[484], [1543]
MR002251	Sibutramine	Sibutramine metabolite M2	Oxidation - Demethylation	Sibutramine	[484], [1543]
MR013895	Sildenafil	N-desmethyl Sildenafil	Unclear - Unclear	Sildenafil	[782], [1544], [580]
MR002252	Sildenafil citrate	Desmethylsildenafil	Oxidation - N-Demethylation	Sildenafil citrate	[808], [1545], [589]
MR002253	Sildenafil citrate	N-dealkyl Sildenafil	Oxidation - N-Dealkylation	Sildenafil citrate	[24]
MR002254	KMD-3241	KMD-3295	Oxidation - Oxidation	Silodosin	[1546]
MR002895	Simeprevir sodium	Oxidative metabolites	Oxidation - Oxidation	Simeprevir sodium	[578]
MR013434	Simvastatin	6'-beta-Hydroxysimvastatin	Oxidation - Aliphatic hydroxylation	Simvastatin	[242]
MR013433	Simvastatin	Simvastatin hydroxy acid	Oxidation - 3'-hydroxylation	Simvastatin	[256]
MR013435	Simvastatin	Pravastatin 3,5-dihydrodiol	Oxidation - Aliphatic hydroxylation	Simvastatin	[242]
MR013436	Simvastatin	6-Exomethylenesimvastatin	Oxidation - Dehydrogenation	Simvastatin	[1547]
MR013893	Sinomenine	N-demethyl-sinomenine	Unclear - Unclear	Sinomenine	[966]
MR013894	Sinomenine	Sinomenine-N-oxide	Unclear - Unclear	Sinomenine	[966]
MR002272	Siponimod	Siponimod metabolite M1	Oxidation - Hydroxylation	Siponimod	[72]
MR006808	Sirolimus	41-O-demethylrapamycin	Oxidation - 41-O-Demethylation	Sirolimus	[1548]
MR006809	Sirolimus	39-O-Desmethylsirolimus	Oxidation - O-dealkylation	Sirolimus	[242]
MR006810	Sirolimus	16-O-Desmethylsirolimus	Oxidation - O-dealkylation	Sirolimus	[242]
MR006811	Sirolimus	12-OH-sirolimus	Oxidation - Aliphatic hydroxylation	Sirolimus	[242]
MR006812	Sirolimus	11-OH-sirolimus	Oxidation - Aliphatic hydroxylation	Sirolimus	[242]
MR006813	Sirolimus	25-OH-sirolimus	Oxidation - Aliphatic hydroxylation	Sirolimus	[242]
MR006814	Sirolimus	24-OH-sirolimus	Oxidation - Aliphatic hydroxylation	Sirolimus	[242]
MR006815	Sirolimus	46-OH-sirolimus	Oxidation - Aliphatic hydroxylation	Sirolimus	[242]
MR006817	Sitagliptin	Sitagliptin M6 Metabolite	Oxidation - Carbamoylation	Sitagliptin	[1549]
MR006819	Sitagliptin	Sitagliptin M1 Metabolite	Conjugation - Sulfation	Sitagliptin	[1549]
MR006820	Sitagliptin	Sitagliptin M2 and M5 Metabolites	Other reaction - Cyclization	Sitagliptin	[1549]
MR006826	Solifenacin succinate	4R-hydroxy solifenacin	Oxidation - Hydrolyzationn	Solifenacin succinate	[326]
MR006830	Sonidegib phosphate	Sonidegib metabolite M25	Multi-steps Reaction - Oxidationn; hydrolysis	Sonidegib phosphate	[407]
MR006831	Sonidegib phosphate	Sonidegib metabolite M48	Multi-steps Reaction - Oxidationn; hydrolysis	Sonidegib phosphate	[407]
MR006832	Sonidegib phosphate	Sonidegib metabolite M16	Multi-steps Reaction - Oxidationn; hydrolysis	Sonidegib phosphate	[407]
MR006834	Sorafenib	Pyridine N-oxide glucuronide	Multi-steps Reaction - Oxidationn; glucuronidation	Sorafenib	[384], [408]
MR006833	Sorafenib	Pyridostigmine	Oxidation - Oxidationn	Sorafenib	[384]
MR013539	Sotorasib	Sotorasib Metabolite M24	Oxidation - Oxidation	Sotorasib	[1550], [1551]
MR004046	SSR-97193	Mono-N-demethyl ferroquine	Unclear - Unclear	SSR-97193	[845]
MR006841	Stiripentol	Stiripentol metabolite II	Multi-steps Reaction - Oxidationn cleavage; demethylenation	Stiripentol	[1552]
MR008425	STX 64	STX 64 metabolite M13	Oxidation - Hydroxylation	STX 64	[921]
MR008436	STX 64	STX 64 metabolite M14	Oxidation - Hydroxylation	STX 64	[921]
MR006844	Sufentanil	Desmethylsufentanil	Oxidation - Oxidationn	Sufentanil	[1553]
MR006846	Sulfadiazine	Sulfadiazine hydroxylamine	Multi-steps Reaction - Hydrolyzationn; sulfadiazine acetylation	Sulfadiazine	[1554]
MR002280	Sulfamethoxazole	Sulfamethoxazole N4-hydroxylamine	Oxidation - N-Hydroxylation	Sulfamethoxazole	[24], [1555], [327]
MR003414	Sulfinpyrazone	Sulfinpyrazone sulfone	Oxidation - Oxidation	Sulfinpyrazone	[1556]
MR008084	Sulindac	Sulindac sulfone	Oxidation - Oxidation	Sulindac	[486]
MR008647	Sunitinib malate	Sunitinib malate Metabolite M8	Reduction - Reduction	Sunitinib malate	[1557], [73]
MR008644	Sunitinib malate	SU12662	Oxidation - Deethylation	Sunitinib malate	[1558]
MR011579	SUVN-G3031	SUVN-G3031 Metabolite MA	Unclear - Unclear	SUVN-G3031	[745]
MR011582	SUVN-G3031	SUVN-G3034 Metabolite MD	Oxidation - Dealkylation	SUVN-G3031	[745]
MR002313	Suvorexant	hydroxyl-suvorexant	Oxidation - Hydoxylation	Suvorexant	[259], [1559], [1560]
MR002899	Tacrine hydrochloride	7-hydroxytacrine	Oxidation - Hydroxylation	Tacrine hydrochloride	[44]
MR002317	13-demethyl tacrolimus	13,31-didemethyl tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002318	13-demethyl tacrolimus	13,15-didemethyl tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002324	Tacrolimus	31-O-Demethyltacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002325	Tacrolimus	13-O-Desmethyltacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002326	Tacrolimus	15-O-Desmethyltacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002319	Tacrolimus	13-demethyl tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002320	Tacrolimus	31-demethyl tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002321	Tacrolimus	15-demethyl tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002322	Tacrolimus	12-hydroxy tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002323	Tacrolimus	15,31-didemethyl tacrolimus	Oxidation - Deamination	Tacrolimus	[1561]
MR002329	Tadalafil	Tadalafil catechol	Oxidation - Oxidation	Tadalafil	[1562], [580]
MR012520	TAK-063	TAK-063 MI	Unclear - Unclear	TAK-063	[890]
MR011529	TAK-272	TAK-272 Metabolite M1	Unclear - Unclear	TAK-272	[891]
MR009360	TAK-802	TAK-802 Metabolite M-III	Unclear - Unclear	TAK-802	[962]
MR009358	TAK-802	TAK-802 Metabolite M-I	Unclear - Unclear	TAK-802	[962]
MR009357	TAK-802 Metabolite M-IV	TAK-802 Metabolite M-II	Unclear - Unclear	TAK-802	[962]
MR006472	TAK-875	TAK-875 Metabolite M-I	Unclear - Unclear	TAK-875	[746]
MR006475	TAK-875	Fasiglifam-G	Conjugation - Conjugation	TAK-875	[746]
MR003511	N-Desmethyltamoxifen	N,N-didesmethyltamoxifen	Unclear - Unclear	Tamoxifen citrate	[1563]
MR003510	Tamoxifen citrate	N-Desmethyltamoxifen	Oxidation - N-Dealkylation	Tamoxifen citrate	[1564], [1565], [1566], [1567], [1568]
MR003526	Tamoxifen citrate	4-hydroxytamoxifen	Oxidation - 4-Hydroxylation	Tamoxifen citrate	[1564], [1565], [1566], [1569]
MR003423	Tamsulosin	Tamsulosin M-1 metabolite	Oxidation - Deacetylation	Tamsulosin	[1570], [1571]
MR003427	Tamsulosin	Tamsulosin AM-1 metabolite	Oxidation - Oxidative Deamination	Tamsulosin	[1570], [1571]
MR008816	Tandospirone	1\(2\pyrimidinyl)\piperazine (1\PP)	Oxidation - Oxidative cleavage	Tandospirone	[1572], [328]
MR008818	Tandospirone	Tandospirone metabolite Ma	Unclear - Unclear	Tandospirone	[328]
MR008820	Tandospirone	Tandospirone metabolite M2	Oxidation - Hydroxylation	Tandospirone	[328]
MR008822	Tandospirone	Tandospirone metabolite M4	Oxidation - Hydroxylation	Tandospirone	[328]
MR002342	Tasimelteon	Inosine	Oxidation - Hydroxylation	Tasimelteon	[329]
MR002341	Tasimelteon	Tasimelteon metabolite M14	Oxidation - Hydroxylation	Tasimelteon	[329]
MR011394	Tasquinimod	Quinoline hydroxylation	Unclear - Unclear	Tasquinimod	[1573]
MR011395	Tasquinimod	Quinoline-N-demethylation	Unclear - Unclear	Tasquinimod	[1573]
MR011396	Tasquinimod	Carboxamide-N-demethylation	Unclear - Unclear	Tasquinimod	[1573]
MR011397	Tasquinimod	Quinoline-O-demethylation	Unclear - Unclear	Tasquinimod	[1573]
MR010219	Taxol	p-3-hydroxypaclitaxel	Unclear - Unclear	Taxol	[410]
MR011041	Taxol	p-3'-hydroxypaclitaxel	Unclear - Unclear	Taxol	[410]
MR008625	Tazemetostat	Tazemetostat Desethyl Metabolite (EPZ-6930)	Unclear - Unclear	Tazemetostat	[487]
MR006477	TD-758	TD-758 Metabolite II	Oxidation - Oxidationn; N-dealkylation	TD-758	[1574]
MR002364	Telaprevir	.	Unclear - Unclear	Telaprevir	[1575]
MR002374	Telithromycin	RU 76584	Oxidation - Oxidation	Telithromycin	[1576], [1577]
MR002373	Telithromycin	RU 72365	Oxidation - Demethylation	Telithromycin	[1576], [1577]
MR002376	O-conjugate of temazepam	Temazepam metabolite M1	Oxidation - Demethylation	Temazepam	[1578], [488]
MR002378	Temazepam	Oxazepam	Oxidation - Demethylation	Temazepam	[1579], [1578]
MR002390	Sirolimus	.	Unclear - Unclear	Temsirolimus	[1580]
MR002389	Temsirolimus	Sirolimus	Hydrolysis - Hydrolysis	Temsirolimus	[1580]
MR002391	Tenapanor	Tenapanor metabolite M1	Unclear - Unclear	Tenapanor	[1581]
MR002393	Teniposide	Teniposide catechol derivative	Oxidation - O-Demethylation	Teniposide	[1582]
MR002393	Teniposide	Teniposide catechol	Unclear - Unclear	Teniposide	[1583]
MR002397	Teniposide	O-demethylated Teniposide	Unclear - Unclear	Teniposide	[1583]
MR005628	Tepotinib	Tepotinib M506 metabolite	Oxidation - Oxidationn	Tepotinib	[136]
MR002399	Hydroxyterbinafine	N-Desmethylhydroxyterbinafine	Oxidation - N-Demethylation	Terbinafine hydrochloride	[1584], [1585]
MR002406	Terbinafine dihydrodiol derivative (1)	N-Desmethylterbinafine dihydrodiol derivative (1)	Oxidation - N-Demethylation	Terbinafine hydrochloride	[1584]
MR002407	Terbinafine dihydrodiol derivative (2)	N-Desmethylterbinafine dihydrodiol derivative (2)	Oxidation - N-Demethylation	Terbinafine hydrochloride	[1584]
MR002409	Terbinafine hydrochloride	N-Desmethylterbinafine	Oxidation - N-Demethylation	Terbinafine hydrochloride	[1584]
MR002410	Terbinafine hydrochloride	1-Naphthaldehyde	Oxidation - Deamination	Terbinafine hydrochloride	[1584]
MR006164	Terfenadine	Terfenadine alcohol	Oxidation - Hydrolyzationn	Terfenadine	[1586]
MR006166	Terfenadine	Azacyclonol	Oxidation - N-dealkylation	Terfenadine	[1586]
MR006165	Terfenadine alcohol	Fexofenadine	Oxidation - Oxidationn	Terfenadine	[1586]
MR008496	Tesofensine	Tesofensine metabolite M1	Oxidation - N-desalkylation	Tesofensine	[893]
MR006174	Thiamylal	Thiamylal carboxylic acid	Oxidation - Oxidationn	Thiamylal	[691], [1587]
MR004957	Thioridazine	Thioridazine 2-sulfoxide	Oxidation - S-oxidation	Thioridazine	[332]
MR004959	Thioridazine	N-desmethylthioridazine	Oxidation - N-dealkylation	Thioridazine	[332]
MR004960	Thioridazine	Thioridazine 5-sulfoxide	Oxidation - S-oxidation	Thioridazine	[332]
MR005782	Tiagabine	5-oxo-tiagabine	Oxidation - Oxidationn	Tiagabine	[1588]
MR006182	Tianeptine	Unclear	Unclear - Unclear	Tianeptine	[667]
MR004973	Ticagrelor	AR-C124910XX	Unclear - Unclear	Ticagrelor	[138], [1589]
MR004986	Thienodihydropyridinium	Thienopyridinium	Unclear - Unclear	Ticlopidine	[24]
MR004985	Thienodihydropyridinium	Ticlopidine lactam analog (M8)	Unclear - Unclear	Ticlopidine	[24]
MR004987	Ticlopidine	Ticlopidine S-oxide	Unclear - Unclear	Ticlopidine	[24]
MR004984	Ticlopidine	Thienodihydropyridinium	Oxidation - Dehydrogenation	Ticlopidine	[24]
MR004982	Ticlopidine	2-Oxoticlopidine	Unclear - Unclear	Ticlopidine	[24]
MR004993	Ticlopidine	7-Hydroxyticlopidine	Unclear - Unclear	Ticlopidine	[1590]
MR014207	Tilidine	Nortilidine	Oxidation - N-Dealkylation	Tilidine	[1591]
MR004995	M1 metabolite, timolol	Timolol maleate Metabolite M4	Unclear - Unclear	Timolol maleate	[411]
MR004996	M1 metabolite, timolol	Timolol maleate Metabolite M3	Unclear - Unclear	Timolol maleate	[411]
MR004997	Timolol maleate	Timolol maleate Metabolite M2	Unclear - Unclear	Timolol maleate	[411]
MR004994	Timolol maleate	M1 metabolite, timolol	Oxidation - Hydrolyzationn	Timolol maleate	[411], [1592]
MR010765	Tiotropium	Dithienylglycolic Acid	Unclear - Unclear	Tiotropium	[1593], [492]
MR010766	Tiotropium	N-methylscopine	Unclear - Unclear	Tiotropium	[1593], [492]
MR005003	Tipranavir	Tipranavir Metabolite	Oxidation - Monohydroxylation	Tipranavir	[1594]
MR005002	Tipranavir	Tipranavir Metabolite	Oxidation - Monohydroxylation	Tipranavir	[1594]
MR005004	Tipranavir	Tipranavir Metabolite	Oxidation - Monohydroxylation	Tipranavir	[1594]
MR005005	Tipranavir	Tipranavir Metabolite	Oxidation - Depropylation	Tipranavir	[1594]
MR005006	Tipranavir	Tipranavir Metabolite	Oxidation - Dehydrogenation	Tipranavir	[1594]
MR011610	Tivantinib	Tivantinib Metabolite M10	Oxidation - Oxidation	Tivantinib	[716]
MR011603	Tivantinib	Tivantinib Metabolite M4	Unclear - Unclear	Tivantinib	[716]
MR011606	Tivantinib Metabolite M4	Tivantinib Metabolite M11	Oxidation - Oxidation	Tivantinib	[716]
MR011609	Tivantinib Metabolite M5	Tivantinib Metabolite M12	Oxidation - Oxidation	Tivantinib	[716]
MR011602	Tivantinib Metabolite M8	Tivantinib Metabolite M9	Oxidation - Oxidation	Tivantinib	[716]
MR004053	Tocopherol	13'-hydroxychromanol	Oxidation - Hydrolyzationn	Tocopherol	[1595]
MR006780	Tolterodine tartrate	N-Dealkylated tolterodine	Oxidation - N-dealkylation	Tolterodine tartrate	[24]
MR002420	Toremifene citrate	N-demethyl-toremifene	Unclear - Unclear	Toremifene citrate	[1596]
MR003378	N-Desmethyltramadol	N,N-didesmethyltramadol	Oxidation - O-Demethylation	Tramadol hydrochloride	[384]
MR003381	Tramadol hydrochloride	N-Desmethyltramadol	Oxidation - N-Demethylation	Tramadol hydrochloride	[1597], [1598]
MR002442	Trazodone hydrochloride	Triazolopyridinone epoxide	Unclear - Unclear	Trazodone hydrochloride	[183]
MR002444	Trazodone hydrochloride	M-chlorophenylpiperazine	Oxidation - N-Dealkylation	Trazodone hydrochloride	[1599]
MR009636	Tretinoin	18-OH-RA	Oxidation - Hydroxylation	Tretinoin	[75], [1600], [229]
MR009626	Tretinoin	4-Hydroxyretinoic acid	Oxidation - 4-hydroxylation	Tretinoin	[75], [229]
MR009629	Tretinoin	5,6-epoxy-RA	Oxidation - Ring epoxidation	Tretinoin	[1600], [1600], [75]
MR009631	Tretinoin	13-cis RA	Other reaction - Isomerization	Tretinoin	[229], [1600]
MR009634	Tretinoin	9-cis RA	Other reaction - Isomerization	Tretinoin	[229], [1600]
MR002449	Triamcinolone diacetate	6-beta-hydroxy-triamcinolone	Oxidation - 6-Beta-Hydroxylation	Triamcinolone diacetate	[1601], [1602], [291]
MR003285	Triazolam	4-hydroxytriazolame	Oxidation - 4-Hydroxylation	Triazolam	[1603], [1604]
MR003287	Triazolam	Alpha-HT	Oxidation - 1'-Hydroxylation	Triazolam	[1603], [1604]
MR002909	TCBZ-SX	Triclabendazole sulfone metabolite	Oxidation - Oxidation	Triclabendazole	[1605], [1606]
MR002452	Trifarotene	.	Unclear - Unclear	Trifarotene	[1607]
MR002911	Trimethadione	Dimethadione	Oxidation - N-Demethylation	Trimethadione	[1608], [587]
MR002460	Trimethoprim	Calpha-OH-TMP	Oxidation - C-Oxidation	Trimethoprim	[1609]
MR002457	Trimethoprim	1-NO-TMP	Oxidation - N-Oxidation	Trimethoprim	[1609]
MR002459	Trimethoprim	4-Desmethyl-TMP	Oxidation - O-Demethylation	Trimethoprim	[1609]
MR002461	Trimethoprim	Calpha-NAC-TMP	Oxidation - C-Oxidation	Trimethoprim	[1609]
MR002466	Troglitazone	Troglitazone Quinone	Oxidation - Oxidation	Troglitazone	[1610], [1611]
MR002467	Troleandomycin	Cytochrome P-450-troleandomycin	Oxidation - Demethylation	Troleandomycin	[1612]
MR006223	Tropisetron	Tropisetron N-Oxide	Oxidation - Oxidationn	Tropisetron	[281], [1613]
MR006150	TRV-130	Oxy-oliceridine	Oxidation - Oxidationn	TRV-130	[913]
MR006152	TRV-130	TRV0109662	Oxidation - N-dealkylation	TRV-130	[913]
MR008174	Tucatinib	Tucatinib metabolite M23	Oxidation - Oxidation	Tucatinib	[139]
MR008163	Tucatinib	Tucatinib metabolite M20	Oxidation - Oxidation	Tucatinib	[139]
MR006479	TV-5600	5-chloro-N-ethyl-4-hydroxy-N-(4-hydroxyphenyl)-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide	Oxidation - Aromatic hydroxylation	TV-5600	[1614]
MR006480	TV-5600	5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide	Oxidation - N-dealkylation	TV-5600	[1614]
MR006481	TV-5600	5-chloro-N-ethyl-4-hydroxy-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide	Oxidation - N-dealkylation	TV-5600	[1614]
MR006482	TV-5600	5-chloro-N-ethyl-4,8-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide	Oxidation - Aromatic hydroxylation	TV-5600	[1614]
MR006483	TV-5600	5-chloro-N-ethyl-4,7-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide	Oxidation - Aromatic hydroxylation	TV-5600	[1614]
MR006484	TV-5600	5-chloro-N-ethyl-4,6-dihydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide	Oxidation - Aromatic hydroxylation	TV-5600	[1614]
MR012792	UK-453,061	UK-453,061 Metabolite M17	Oxidation - Mono-oxidation	UK-453,061	[815]
MR002469	PGL4002	PGL-4004	Oxidation - Di-N-Demethylation	Ulipristal	[1615]
MR002471	Ulipristal	PGL4002	Oxidation - Mono-N-Demethylation	Ulipristal	[1615]
MR002472	Upadacitinib	.	Conjugation - Glucuronidation	Upadacitinib	[1616]
MR003302	Valdecoxib	Valdecoxib metabolite M1	Oxidation - Methyl-Hydroxylation	Valdecoxib	[1459], [24]
MR003300	Valdecoxib metabolite M9	Valdecoxib metabolite M9-G	Unclear - Unclear	Valdecoxib	[1459]
MR002502	Vandetanib	N-desmethyl vandetanib	Oxidation - N-Demethylation	Vandetanib	[1617], [1618], [1619]
MR002504	Vardenafil hydrochloride	N-desethyl vardenafil	Oxidation - N-Deethylation	Vardenafil hydrochloride	[1620], [1621], [808]
MR002505	Velpatasvir	Desmethyl-velpatasvir	Oxidation - O-Demethylation	Velpatasvir	[1622]
MR002508	Vemurafenib	Hydroxyvemurafenib	Oxidation - Hydroxylation	Vemurafenib	[1623]
MR008135	Venetoclax	Venetoclax metaboliteM27	Oxidation - Oxidation	Venetoclax	[526]
MR005638	Desvenlafaxine	N,O-Didesmethylvenlafaxine	Oxidation - N-demethylation	Venlafaxine hydrochloride	[1624], [1625], [1626]
MR005643	N-Desmethylvenlafaxine	N,O-Didesmethylvenlafaxine	Oxidation - O-demethylation	Venlafaxine hydrochloride	[1624], [1625], [1626]
MR005642	Venlafaxine hydrochloride	N-Desmethylvenlafaxine	Oxidation - N-demethylation	Venlafaxine hydrochloride	[1624], [1625], [1626]
MR010528	D-617	D-620	Unclear - Unclear	Verapamil	[24]
MR010530	D-702	D-620	Unclear - Unclear	Verapamil	[24]
MR010523	Verapamil	Norverapamil	Unclear - Unclear	Verapamil	[24]
MR005651	O-Desmethylverapamil (D-702)	Verapamil metabolite D-620	Oxidation - N-dealkylation	Verapamil hydrochloride	[24]
MR005647	Verapamil hydrochloride	Norverapamil	Oxidation - N-demethylation	Verapamil hydrochloride	[24]
MR005646	Verapamil metabolite D-617	Verapamil metabolite D-620	Oxidation - N-dealkylation	Verapamil hydrochloride	[24]
MR010458	Verubulin	MPI-0440627	Oxidation - O-demethylation	Verubulin	[874]
MR013238	Vilazodone hydrochloride	Vilazodone metabolite M10	Oxidation - Oxidation deamination	Vilazodone hydrochloride	[338], [1627], [1628]
MR005653	Vinblastine sulfate	Desacetylvinblastine	Unclear - Unclear	Vinblastine sulfate	[1629]
MR005654	Vincristine sulfate	Vincristine metabolite M1	Oxidation - Oxidationn	Vincristine sulfate	[1630]
MR005659	Vismodegib	Vismodegib metabolite M1	Unclear - Unclear	Vismodegib	[1631], [1632], [1633]
MR013079	Vonoprazan	N-demethylated TAK-438	Oxidation - N-demethylation	Vonoprazan	[657], [656]
MR013073	Vonoprazan	Vonoprazan M-	Unclear - Unclear	Vonoprazan	[1634], [656]
MR013080	Vonoprazan	Vonoprazan M-	Unclear - Unclear	Vonoprazan	[1634], [656]
MR005663	Vorapaxar sulfate	Vorapaxar sulfate metabolite M20	Oxidation - Hydrolyzationn	Vorapaxar sulfate	[1635]
MR005665	Vorapaxar sulfate	Amine metabolite M19	Other reaction - Carbamate cleavage	Vorapaxar sulfate	[1635]
MR005664	Vorapaxar sulfate metabolite M20	Amine metabolite M19	Unclear - Unclear	Vorapaxar sulfate	[1635]
MR013245	Voriconazole	Voriconazole N-Oxide Metabolite	Oxidation - Oxidationn	Voriconazole	[1636], [415]
MR013250	Voriconazole	4-Hydroxyvoriconazole	Oxidation - Hydrolyzationn	Voriconazole	[1636], [415]
MR005674	Vortioxetine hydrobromide	Vortioxetine Metabolite 4a	Oxidation - Oxidationn	Vortioxetine hydrobromide	[339], [1637]
MR005675	Voxelotor	Unclear	Oxidation - Oxidationn	Voxelotor	[1638]
MR013252	Voxilaprevir	Unclear	Unclear - Unclear	Voxilaprevir	[595]
MR013252	Voxilaprevir	Unclear	Unclear - Unclear	Voxilaprevir	[595]
MR006486	VX-661	Tezacaftor metabolite M1	Oxidation - Hydrolyzationn	VX-661	[747]
MR006487	VX-661	Tezacaftor metabolite M2	Oxidation - Hydrolyzationn	VX-661	[747]
MR006488	VX-661	Tezacaftor metabolite M5	Oxidation - Hydrolyzationn	VX-661	[747]
MR010388	VX-680	VRT-7500074	Oxidation - N-oxidation	VX-680	[875]
MR010389	VX-680	VRT-171335	Oxidation - N-desmethylation	VX-680	[875]
MR013253	Warfarin sodium	R-10(R)-Hydroxywarfarin	Oxidation - 10-hydroxylation	Warfarin sodium	[1639], [250]
MR013256	Warfarin sodium	R-10(S)-Hydroxywarfarin	Oxidation - 10-hydroxylation	Warfarin sodium	[1639], [250]
MR006491	WSM-3978G	Monohydroxyperhexiline	Oxidation - Hydrolyzationn	WSM-3978G	[755]
MR006492	WSM-3978G	Trans-hydroxyperhexilline	Oxidation - Aliphatic hydroxylation	WSM-3978G	[755]
MR006490	WSM-3978G	Cis-Hydroxy Perhexiline	Oxidation - Hydrolyzationn	WSM-3978G	[755]
MR006493	WY-1485	NLA-715	Oxidation - Hydrolyzationn	WY-1485	[1640], [18]
MR006495	Apli-da	Apli-da/h	Oxidation - Hydrolyzationn	Y-100032	[736]
MR006494	Y-100032	Apli-da	Oxidation - C-dealkylation	Y-100032	[736]
MR006496	Y-100032	Apli-h	Oxidation - Hydrolyzationn	Y-100032	[736]
MR012201	YM-17E	YM-17E M1	Unclear - Unclear	YM-17E	[971]
MR012495	YM-758	YM-394111	Oxidation - O-demethylation	YM-758	[856]
MR012496	YM-758	YM-394112	Oxidation - O-demethylation	YM-758	[856]
MR006071	Z-4828	L-ifosfamide	Oxidation - Aliphatic hydroxylation	Z-4828	[1268]
MR006072	Z-4828	Ifosfamide	Oxidation - N-dealkylation	Z-4828	[1268]
MR006073	Z-4828	L-cyclophosphamide	Oxidation - N-dealkylation	Z-4828	[1268]
MR013282	Zafirlukast	Zafirlukast metabolite M5	Unclear - Unclear	Zafirlukast	[24], [1641]
MR013286	Zafirlukast	Zafirlukast metabolite M6	Unclear - Unclear	Zafirlukast	[24], [1641]
MR013292	5-Oxo-zaleplon	N-desethyl-5-oxo-ZAL (M1)	Oxidation - N-dealkylation	Zaleplon	[1642], [416], [1643]
MR013293	Zaleplon	N-Desesethylzaleplon	Oxidation - N-dealkylation	Zaleplon	[1642], [416], [1643]
MR005676	Zidovudine	3'-Aminothymidine	Reduction - Reduction	Zidovudine	[18], [1644]
MR013297	Dehydroxyzyleuton	Dehydroxyzileuton sulfoxide metabolite	Oxidation - Sulfoxidation	Zileuton	[24], [44]
MR013300	Zileuton	Zileuton sulfoxide	Oxidation - Sulfoxidation	Zileuton	[24], [44]
MR005688	Ziprasidone	Ziprasidone Sulfoxide	Oxidation - Oxidationn	Ziprasidone	[1645], [1646]
MR006153	ZK-299	Unclear	Oxidation - Oxidationn	ZK-299	[1647]
MR006074	ZK-31224	N"-monodeethylterguride	Unclear - Unclear	ZK-31224	[1113], [876]
MR006075	ZK-31224	6-norterguride	Unclear - Unclear	ZK-31224	[1113], [876]
MR005696	Zolpidem tartrate	Methoxyzolpidem derivative (M3)	Oxidation - Methyl-hydroxylation	Zolpidem tartrate	[24], [1648]
MR005702	Zolpidem tartrate	Methoxyzolpidem	Oxidation - Aliphatic hydroxylation	Zolpidem tartrate	[24], [1648]
MR005698	Zolpidem tartrate	Methoxyzolpidem derivative (M4)	Oxidation - Methyl-hydroxylation; oxidation	Zolpidem tartrate	[24], [1648]
MR005700	Zolpidem tartrate	7-Hydroxy zolpidem	Oxidation - Aliphatic hydroxylation	Zolpidem tartrate	[1649]
MR005701	Zolpidem tartrate	8-Hydroxy zolpidem	Oxidation - Aliphatic hydroxylation	Zolpidem tartrate	[1649]
MR005703	Zonisamide	2-sulfamoylacetylphenol	Reduction - Reduction	Zonisamide	[1650]
MR009649	Zopiclone	Zopiclone N-oxide	Oxidation - N-oxidation	Zopiclone	[24], [1651]
MR009651	Zopiclone	N-desmethylzopiclone	Oxidation - N-demethylation	Zopiclone	[24], [1651]
MR013081	Zotepine	Norzotepine	Oxidation - N-demethylation	Zotepine	[44], [1652]
MR013084	Zotepine	3-OH-zotepine	Oxidation - Aromatic hydroxylation	Zotepine	[44]
MR013082	Zotepine	Zotepine N-oxide	Oxidation - N-oxidation	Zotepine	[44]


⏷ Show the Full List of 1520 MR(s)

Tissue/Disease-Specific Protein Abundances of This DME
Tissue-specific Protein Abundances in Healthy Individuals		Click to Show/Hide

Download the Tissue-Specific Variation(s) Profile
ICD Disease Classification 01	Infectious/parasitic disease	Click to Show/Hide
ICD-11: 1C1H	Necrotising ulcerative gingivitis	Click to Show/Hide
The Studied Tissue	Gingival tissue
The Specified Disease	Bacterial infection of gingival [ICD-11:1C1H]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.79E-02; Fold-change: -8.65E-02; Z-score: -3.88E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1E30	Influenza	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Influenza [ICD-11:1E30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.14E-01; Fold-change: 1.43E-01; Z-score: 6.67E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1E51	Chronic viral hepatitis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Chronic hepatitis C [ICD-11:1E51.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.61E-01; Fold-change: 9.46E-03; Z-score: 3.66E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1G41	Sepsis with septic shock	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Sepsis with septic shock [ICD-11:1G41]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.10E-04; Fold-change: 6.44E-02; Z-score: 2.85E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA40	Respiratory syncytial virus infection	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Pediatric respiratory syncytial virus infection [ICD-11:CA40.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.52E-01; Fold-change: -1.33E-01; Z-score: -5.91E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA42	Rhinovirus infection	Click to Show/Hide
The Studied Tissue	Nasal epithelium tissue
The Specified Disease	Rhinovirus infection [ICD-11:CA42.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.32E-01; Fold-change: -1.56E-02; Z-score: -1.09E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: KA60	Neonatal sepsis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Neonatal sepsis [ICD-11:KA60]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.57E-01; Fold-change: -3.39E-02; Z-score: -1.45E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 02	Neoplasm	Click to Show/Hide
ICD-11: 2A00	Brain cancer	Click to Show/Hide
The Studied Tissue	Nervous tissue
The Specified Disease	Glioblastopma [ICD-11:2A00.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.54E-05; Fold-change: -6.60E-02; Z-score: -1.90E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Brain stem tissue
The Specified Disease	Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.50E-01; Fold-change: -9.32E-02; Z-score: -1.01E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	White matter tissue
The Specified Disease	Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.15E-08; Fold-change: -6.60E-01; Z-score: -3.96E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Brain stem tissue
The Specified Disease	Neuroectodermal tumour [ICD-11:2A00.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.34E-04; Fold-change: -6.64E-01; Z-score: -1.63E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A20	Myeloproliferative neoplasm	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Myelofibrosis [ICD-11:2A20.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.97E-01; Fold-change: -3.21E-02; Z-score: -2.80E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Whole blood
The Specified Disease	Polycythemia vera [ICD-11:2A20.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.87E-01; Fold-change: -7.38E-02; Z-score: -6.14E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A36	Myelodysplastic syndrome	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Myelodysplastic syndrome [ICD-11:2A36-2A3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.73E-01; Fold-change: -1.99E-02; Z-score: -1.18E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 6.96E-02; Fold-change: -1.22E-01; Z-score: -1.41E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2A81	Diffuse large B-cell lymphoma	Click to Show/Hide
The Studied Tissue	Tonsil tissue
The Specified Disease	Diffuse large B-cell lymphoma [ICD-11:2A81]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.00E-01; Fold-change: 4.53E-02; Z-score: 1.94E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A83	Plasma cell neoplasm	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.51E-01; Fold-change: 8.39E-02; Z-score: 5.00E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Bone marrow
The Specified Disease	Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.93E-04; Fold-change: -6.16E-01; Z-score: -2.64E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2B33	Leukaemia	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Acute myelocytic leukaemia [ICD-11:2B33.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.29E-03; Fold-change: -3.47E-02; Z-score: -1.80E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2B6E	Oral cancer	Click to Show/Hide
The Studied Tissue	Oral tissue
The Specified Disease	Oral cancer [ICD-11:2B6E]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.71E-03; Fold-change: -3.53E-01; Z-score: -9.10E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.44E-04; Fold-change: -2.53E-01; Z-score: -6.49E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B70	Esophageal cancer	Click to Show/Hide
The Studied Tissue	Esophagus
The Specified Disease	Esophagal cancer [ICD-11:2B70]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.05E-01; Fold-change: 1.24E-01; Z-score: 7.63E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: 2B72	Stomach cancer	Click to Show/Hide
The Studied Tissue	Gastric tissue
The Specified Disease	Gastric cancer [ICD-11:2B72]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.97E-02; Fold-change: 1.84E-01; Z-score: 1.84E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.64E-01; Fold-change: -9.02E-02; Z-score: -1.64E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B90	Colon cancer	Click to Show/Hide
The Studied Tissue	Colon tissue
The Specified Disease	Colon cancer [ICD-11:2B90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.19E-03; Fold-change: -7.56E-02; Z-score: -1.51E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.70E-03; Fold-change: -1.08E-01; Z-score: -2.16E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B92	Rectal cancer	Click to Show/Hide
The Studied Tissue	Rectal colon tissue
The Specified Disease	Rectal cancer [ICD-11:2B92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.90E-02; Fold-change: -3.45E-01; Z-score: -1.49E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.10E-01; Fold-change: -3.09E-01; Z-score: -9.49E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C10	Pancreatic cancer	Click to Show/Hide
The Studied Tissue	Pancreas
The Specified Disease	Pancreatic cancer [ICD-11:2C10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.64E-01; Fold-change: -2.20E-01; Z-score: -5.34E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.14E-01; Fold-change: -1.16E-02; Z-score: -8.86E-03
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C12	Liver cancer	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Liver cancer [ICD-11:2C12.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.02E-14; Fold-change: -3.12E+00; Z-score: -2.25E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.09E-84; Fold-change: -2.99E+00; Z-score: -4.75E+00
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 1.26E-05; Fold-change: -3.27E+00; Z-score: -8.99E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual Download DME expression data in the tissue of the other disease section
ICD-11: 2C25	Lung cancer	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Lung cancer [ICD-11:2C25]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.59E-39; Fold-change: -3.76E-01; Z-score: -1.64E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.27E-30; Fold-change: -4.60E-01; Z-score: -1.81E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C30	Skin cancer	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Melanoma [ICD-11:2C30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.19E-08; Fold-change: -5.72E-01; Z-score: -1.61E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Skin
The Specified Disease	Skin cancer [ICD-11:2C30-2C3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.29E-36; Fold-change: -3.75E-01; Z-score: -1.06E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 5.74E-55; Fold-change: -5.47E-01; Z-score: -1.53E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C6Z	Breast cancer	Click to Show/Hide
The Studied Tissue	Breast tissue
The Specified Disease	Breast cancer [ICD-11:2C60-2C6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.87E-03; Fold-change: -6.67E-02; Z-score: -2.12E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 5.49E-04; Fold-change: -1.25E-01; Z-score: -5.25E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C73	Ovarian cancer	Click to Show/Hide
The Studied Tissue	Ovarian tissue
The Specified Disease	Ovarian cancer [ICD-11:2C73]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.96E-01; Fold-change: -3.35E-01; Z-score: -1.10E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 7.51E-01; Fold-change: -7.20E-02; Z-score: -3.51E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C77	Cervical cancer	Click to Show/Hide
The Studied Tissue	Cervical tissue
The Specified Disease	Cervical cancer [ICD-11:2C77]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.13E-04; Fold-change: -2.15E-01; Z-score: -9.34E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C78	Uterine cancer	Click to Show/Hide
The Studied Tissue	Endometrium tissue
The Specified Disease	Uterine cancer [ICD-11:2C78]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.20E-02; Fold-change: -1.08E-01; Z-score: -2.31E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.60E-01; Fold-change: 1.36E-01; Z-score: 6.55E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C82	Prostate cancer	Click to Show/Hide
The Studied Tissue	Prostate
The Specified Disease	Prostate cancer [ICD-11:2C82]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.10E-01; Fold-change: -1.23E-01; Z-score: -2.88E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C90	Renal cancer	Click to Show/Hide
The Studied Tissue	Kidney
The Specified Disease	Renal cancer [ICD-11:2C90-2C91]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.84E-01; Fold-change: -1.61E-01; Z-score: -3.61E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.41E-16; Fold-change: -3.78E-01; Z-score: -1.06E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C92	Ureter cancer	Click to Show/Hide
The Studied Tissue	Urothelium
The Specified Disease	Ureter cancer [ICD-11:2C92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.69E-01; Fold-change: 2.43E-02; Z-score: 7.51E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C94	Bladder cancer	Click to Show/Hide
The Studied Tissue	Bladder tissue
The Specified Disease	Bladder cancer [ICD-11:2C94]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.23E-11; Fold-change: 4.66E-01; Z-score: 5.83E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D02	Retinal cancer	Click to Show/Hide
The Studied Tissue	Uvea
The Specified Disease	Retinoblastoma [ICD-11:2D02.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.95E-02; Fold-change: -1.55E-01; Z-score: -1.24E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D10	Thyroid cancer	Click to Show/Hide
The Studied Tissue	Thyroid
The Specified Disease	Thyroid cancer [ICD-11:2D10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.75E-01; Fold-change: 3.78E-02; Z-score: 1.44E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 9.90E-01; Fold-change: 1.53E-02; Z-score: 7.12E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2D11	Adrenal cancer	Click to Show/Hide
The Studied Tissue	Adrenal cortex
The Specified Disease	Adrenocortical carcinoma [ICD-11:2D11.Z]
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 1.76E-02; Fold-change: -2.70E-01; Z-score: -4.60E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
ICD-11: 2D12	Endocrine gland neoplasm	Click to Show/Hide
The Studied Tissue	Pituitary tissue
The Specified Disease	Pituitary cancer [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.87E-01; Fold-change: -2.28E-01; Z-score: -4.52E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Pituitary tissue
The Specified Disease	Pituitary gonadotrope tumour [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.30E-01; Fold-change: 2.02E-01; Z-score: 5.47E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D42	Head and neck cancer	Click to Show/Hide
The Studied Tissue	Head and neck tissue
The Specified Disease	Head and neck cancer [ICD-11:2D42]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.04E-04; Fold-change: -9.90E-02; Z-score: -3.91E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 03	Blood/blood-forming organ disease	Click to Show/Hide
ICD-11: 3A51	Sickle cell disorder	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Sickle cell disease [ICD-11:3A51.0-3A51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.21E-01; Fold-change: 1.33E-01; Z-score: 8.26E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3A70	Aplastic anaemia	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Shwachman-Diamond syndrome [ICD-11:3A70.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.23E-01; Fold-change: 4.92E-01; Z-score: 1.13E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3B63	Thrombocytosis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Thrombocythemia [ICD-11:3B63]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.50E-03; Fold-change: -5.35E-02; Z-score: -4.77E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3B64	Thrombocytopenia	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Thrombocytopenia [ICD-11:3B64]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.21E-01; Fold-change: -1.09E-01; Z-score: -6.81E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 04	Immune system disease	Click to Show/Hide
ICD-11: 4A00	Immunodeficiency	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Immunodeficiency [ICD-11:4A00-4A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.15E-01; Fold-change: -1.31E-02; Z-score: -9.45E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A40	Lupus erythematosus	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Lupus erythematosus [ICD-11:4A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.35E-05; Fold-change: -1.56E-01; Z-score: -4.11E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A42	Systemic sclerosis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Scleroderma [ICD-11:4A42.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.95E-01; Fold-change: -4.05E-02; Z-score: -2.35E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A43	Systemic autoimmune disease	Click to Show/Hide
The Studied Tissue	Salivary gland tissue
The Specified Disease	Sjogren's syndrome [ICD-11:4A43.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.99E-01; Fold-change: -2.06E-01; Z-score: -1.70E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 9.19E-02; Fold-change: -3.23E-01; Z-score: -1.53E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 4A62	Behcet disease	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Behcet's disease [ICD-11:4A62]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.52E-01; Fold-change: 4.31E-02; Z-score: 3.07E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4B04	Monocyte count disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Autosomal dominant monocytopenia [ICD-11:4B04]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.87E-01; Fold-change: -6.16E-02; Z-score: -5.64E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 05	Endocrine/nutritional/metabolic disease	Click to Show/Hide
ICD-11: 5A11	Type 2 diabetes mellitus	Click to Show/Hide
The Studied Tissue	Omental adipose tissue
The Specified Disease	Obesity related type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.38E-02; Fold-change: -1.12E-01; Z-score: -1.78E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Liver tissue
The Specified Disease	Type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.76E-01; Fold-change: -4.64E-01; Z-score: -9.16E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5A80	Ovarian dysfunction	Click to Show/Hide
The Studied Tissue	Vastus lateralis muscle
The Specified Disease	Polycystic ovary syndrome [ICD-11:5A80.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.86E-01; Fold-change: 7.97E-02; Z-score: 6.52E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C51	Inborn carbohydrate metabolism disorder	Click to Show/Hide
The Studied Tissue	Biceps muscle
The Specified Disease	Pompe disease [ICD-11:5C51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.85E-01; Fold-change: -1.24E-01; Z-score: -8.96E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C56	Lysosomal disease	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Batten disease [ICD-11:5C56.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.89E-01; Fold-change: 1.66E-01; Z-score: 9.51E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C80	Hyperlipoproteinaemia	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.08E-01; Fold-change: -8.08E-02; Z-score: -5.30E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Whole blood
The Specified Disease	Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.24E-05; Fold-change: -3.48E-01; Z-score: -1.34E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 06	Mental/behavioural/neurodevelopmental disorder	Click to Show/Hide
ICD-11: 6A02	Autism spectrum disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Autism [ICD-11:6A02]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.09E-01; Fold-change: -5.31E-02; Z-score: -2.65E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A20	Schizophrenia	Click to Show/Hide
The Studied Tissue	Prefrontal cortex
The Specified Disease	Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.66E-01; Fold-change: 4.25E-02; Z-score: 1.20E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Superior temporal cortex
The Specified Disease	Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.75E-01; Fold-change: 5.15E-02; Z-score: 3.64E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A60	Bipolar disorder	Click to Show/Hide
The Studied Tissue	Prefrontal cortex
The Specified Disease	Bipolar disorder [ICD-11:6A60-6A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.31E-01; Fold-change: -4.19E-02; Z-score: -2.14E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A70	Depressive disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.17E-01; Fold-change: -5.18E-02; Z-score: -2.74E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Hippocampus
The Specified Disease	Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.06E-01; Fold-change: -2.42E-02; Z-score: -1.64E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 08	Nervous system disease	Click to Show/Hide
ICD-11: 8A00	Parkinsonism	Click to Show/Hide
The Studied Tissue	Substantia nigra tissue
The Specified Disease	Parkinson's disease [ICD-11:8A00.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.76E-01; Fold-change: 1.26E-01; Z-score: 8.27E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A01	Choreiform disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Huntington's disease [ICD-11:8A01.10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.43E-01; Fold-change: -2.48E-02; Z-score: -1.78E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A20	Alzheimer disease	Click to Show/Hide
The Studied Tissue	Entorhinal cortex
The Specified Disease	Alzheimer's disease [ICD-11:8A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.04E-02; Fold-change: 6.29E-02; Z-score: 3.54E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A2Y	Neurocognitive impairment	Click to Show/Hide
The Studied Tissue	White matter tissue
The Specified Disease	HIV-associated neurocognitive impairment [ICD-11:8A2Y-8A2Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.40E-02; Fold-change: -1.70E-01; Z-score: -7.22E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A40	Multiple sclerosis	Click to Show/Hide
The Studied Tissue	Plasmacytoid dendritic cells
The Specified Disease	Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.85E-01; Fold-change: 2.24E-02; Z-score: 7.33E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Spinal cord
The Specified Disease	Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 6.29E-02; Fold-change: -1.88E-01; Z-score: -1.32E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: 8A60	Epilepsy	Click to Show/Hide
The Studied Tissue	Peritumoral cortex tissue
The Specified Disease	Epilepsy [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 1.10E-01; Fold-change: 1.59E-01; Z-score: 7.77E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
The Studied Tissue	Whole blood
The Specified Disease	Seizure [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.30E-01; Fold-change: -2.96E-02; Z-score: -1.60E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B01	Subarachnoid haemorrhage	Click to Show/Hide
The Studied Tissue	Intracranial artery
The Specified Disease	Intracranial aneurysm [ICD-11:8B01.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.63E-01; Fold-change: 6.68E-02; Z-score: 3.45E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B11	Cerebral ischaemic stroke	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Cardioembolic stroke [ICD-11:8B11.20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.87E-01; Fold-change: -1.13E-01; Z-score: -5.03E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Peripheral blood
The Specified Disease	Ischemic stroke [ICD-11:8B11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.29E-02; Fold-change: 1.11E-01; Z-score: 6.58E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B60	Motor neuron disease	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.18E-03; Fold-change: 2.30E-01; Z-score: 2.71E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Cervical spinal cord
The Specified Disease	Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.32E-01; Fold-change: 4.74E-02; Z-score: 1.73E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8C70	Muscular dystrophy	Click to Show/Hide
The Studied Tissue	Muscle tissue
The Specified Disease	Myopathy [ICD-11:8C70.6]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.95E-02; Fold-change: -2.34E-01; Z-score: -1.05E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8C75	Distal myopathy	Click to Show/Hide
The Studied Tissue	Muscle tissue
The Specified Disease	Tibial muscular dystrophy [ICD-11:8C75]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.93E-02; Fold-change: -8.20E-02; Z-score: -8.93E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 09	Visual system disease	Click to Show/Hide
ICD-11: 9A96	Anterior uveitis	Click to Show/Hide
The Studied Tissue	Peripheral monocyte
The Specified Disease	Autoimmune uveitis [ICD-11:9A96]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.47E-01; Fold-change: -1.84E-01; Z-score: -9.58E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 11	Circulatory system disease	Click to Show/Hide
ICD-11: BA41	Myocardial infarction	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Myocardial infarction [ICD-11:BA41-BA50]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.97E-01; Fold-change: 5.39E-02; Z-score: 1.24E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: BA80	Coronary artery disease	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Coronary artery disease [ICD-11:BA80-BA8Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.06E-01; Fold-change: -1.48E-01; Z-score: -8.48E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: BB70	Aortic valve stenosis	Click to Show/Hide
The Studied Tissue	Calcified aortic valve
The Specified Disease	Aortic stenosis [ICD-11:BB70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.46E-01; Fold-change: -1.10E-01; Z-score: -1.82E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 12	Respiratory system disease	Click to Show/Hide
ICD-11: 7A40	Central sleep apnoea	Click to Show/Hide
The Studied Tissue	Hyperplastic tonsil
The Specified Disease	Apnea [ICD-11:7A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.97E-01; Fold-change: 2.63E-01; Z-score: 1.40E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA08	Vasomotor or allergic rhinitis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Olive pollen allergy [ICD-11:CA08.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.89E-01; Fold-change: 9.67E-02; Z-score: 4.76E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA0A	Chronic rhinosinusitis	Click to Show/Hide
The Studied Tissue	Sinus mucosa tissue
The Specified Disease	Chronic rhinosinusitis [ICD-11:CA0A]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.50E-01; Fold-change: 1.42E-01; Z-score: 1.16E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA22	Chronic obstructive pulmonary disease	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.13E-01; Fold-change: 4.03E-02; Z-score: 2.50E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Small airway epithelium
The Specified Disease	Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.21E-02; Fold-change: 8.17E-02; Z-score: 4.35E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA23	Asthma	Click to Show/Hide
The Studied Tissue	Nasal and bronchial airway
The Specified Disease	Asthma [ICD-11:CA23]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.90E-01; Fold-change: 2.35E-02; Z-score: 7.88E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CB03	Idiopathic interstitial pneumonitis	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Idiopathic pulmonary fibrosis [ICD-11:CB03.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.36E-01; Fold-change: -2.34E-01; Z-score: -1.17E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 13	Digestive system disease	Click to Show/Hide
ICD-11: DA0C	Periodontal disease	Click to Show/Hide
The Studied Tissue	Gingival tissue
The Specified Disease	Periodontal disease [ICD-11:DA0C]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.21E-02; Fold-change: -1.18E-01; Z-score: -4.76E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: DA42	Gastritis	Click to Show/Hide
The Studied Tissue	Gastric antrum tissue
The Specified Disease	Eosinophilic gastritis [ICD-11:DA42.2]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.82E-01; Fold-change: -2.64E-01; Z-score: -4.06E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: DB92	Non-alcoholic fatty liver disease	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Non-alcoholic fatty liver disease [ICD-11:DB92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.18E-01; Fold-change: -6.23E-02; Z-score: -1.75E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: DB99	Hepatic failure	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Liver failure [ICD-11:DB99.7-DB99.8]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.05E-04; Fold-change: -3.19E+00; Z-score: -2.66E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: DD71	Ulcerative colitis	Click to Show/Hide
The Studied Tissue	Colon mucosal tissue
The Specified Disease	Ulcerative colitis [ICD-11:DD71]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.75E-01; Fold-change: -2.15E-02; Z-score: -1.01E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
ICD-11: DD91	Irritable bowel syndrome	Click to Show/Hide
The Studied Tissue	Rectal colon tissue
The Specified Disease	Irritable bowel syndrome [ICD-11:DD91.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.40E-01; Fold-change: -2.17E-02; Z-score: -4.03E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 14	Skin disease	Click to Show/Hide
ICD-11: EA80	Atopic eczema	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Atopic dermatitis [ICD-11:EA80]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.52E-04; Fold-change: 9.69E-02; Z-score: 7.57E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: EA90	Psoriasis	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Psoriasis [ICD-11:EA90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.67E-01; Fold-change: -3.83E-03; Z-score: -1.24E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.52E-19; Fold-change: -4.66E-01; Z-score: -1.22E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: ED63	Acquired hypomelanotic disorder	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Vitiligo [ICD-11:ED63.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.70E-01; Fold-change: 2.10E-01; Z-score: 5.81E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: ED70	Alopecia or hair loss	Click to Show/Hide
The Studied Tissue	Skin from scalp
The Specified Disease	Alopecia [ICD-11:ED70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.73E-01; Fold-change: -3.42E-03; Z-score: -9.10E-03
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: EK0Z	Contact dermatitis	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Sensitive skin [ICD-11:EK0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.32E-02; Fold-change: -3.50E-01; Z-score: -1.37E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 15	Musculoskeletal system/connective tissue disease	Click to Show/Hide
ICD-11: FA00	Osteoarthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Arthropathy [ICD-11:FA00-FA5Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.22E-01; Fold-change: 6.75E-02; Z-score: 4.19E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Synovial tissue
The Specified Disease	Osteoarthritis [ICD-11:FA00-FA0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.33E-01; Fold-change: 1.48E-01; Z-score: 3.59E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA20	Rheumatoid arthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Childhood onset rheumatic disease [ICD-11:FA20.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.83E-01; Fold-change: -1.32E-02; Z-score: -4.74E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Synovial tissue
The Specified Disease	Rheumatoid arthritis [ICD-11:FA20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.81E-01; Fold-change: 2.72E-01; Z-score: 6.95E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA24	Juvenile idiopathic arthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Juvenile idiopathic arthritis [ICD-11:FA24]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.39E-03; Fold-change: 1.17E-01; Z-score: 4.33E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA92	Inflammatory spondyloarthritis	Click to Show/Hide
The Studied Tissue	Pheripheral blood
The Specified Disease	Ankylosing spondylitis [ICD-11:FA92.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.78E-01; Fold-change: -5.92E-02; Z-score: -3.47E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FB83	Low bone mass disorder	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Osteoporosis [ICD-11:FB83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.60E-02; Fold-change: 1.58E-01; Z-score: 1.36E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 16	Genitourinary system disease	Click to Show/Hide
ICD-11: GA10	Endometriosis	Click to Show/Hide
The Studied Tissue	Endometrium tissue
The Specified Disease	Endometriosis [ICD-11:GA10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.50E-01; Fold-change: 8.27E-02; Z-score: 3.14E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: GC00	Cystitis	Click to Show/Hide
The Studied Tissue	Bladder tissue
The Specified Disease	Interstitial cystitis [ICD-11:GC00.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.87E-01; Fold-change: -4.14E-02; Z-score: -5.17E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 19	Condition originating in perinatal period	Click to Show/Hide
ICD-11: KA21	Short gestation disorder	Click to Show/Hide
The Studied Tissue	Myometrium
The Specified Disease	Preterm birth [ICD-11:KA21.4Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.76E-01; Fold-change: -2.60E-02; Z-score: -3.37E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 20	Developmental anomaly	Click to Show/Hide
ICD-11: LD2C	Overgrowth syndrome	Click to Show/Hide
The Studied Tissue	Adipose tissue
The Specified Disease	Simpson golabi behmel syndrome [ICD-11:LD2C]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.80E-01; Fold-change: -9.44E-03; Z-score: -8.86E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: LD2D	Phakomatoses/hamartoneoplastic syndrome	Click to Show/Hide
The Studied Tissue	Perituberal tissue
The Specified Disease	Tuberous sclerosis complex [ICD-11:LD2D.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.01E-01; Fold-change: 6.22E-02; Z-score: 5.20E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual

References
1	Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
2	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
3	DrugBank(Pharmacology-Metabolism)Bupropion
4	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
5	Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans
6	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
7	Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol. 2001 Apr;41(4):452-4.
8	Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans
9	Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects
10	Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
11	FDA label of Idelalisib. The 2020 official website of the U.S. Food and Drug Administration.
12	Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
13	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
14	Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110.
15	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
16	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695.
17	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
18	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
19	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
20	PubChem:Pimavanserin
21	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
22	Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite
23	Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study
24	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25	Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator
26	Enhanced elimination of betamethasone in dichorionic twin pregnancies
27	Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
28	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
29	Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40(3):207-26.
30	Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
31	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
32	Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
33	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
34	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
35	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
36	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
37	Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
38	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
39	Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
40	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
41	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
42	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
43	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
44	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
45	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
46	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
47	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
48	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
49	Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
50	Clinical pharmacokinetics and pharmacodynamics of linagliptin Clin Pharmacokinet. 2012 Jul 1;51(7):411-27. doi: 10.2165/11630900-000000000-00000.
51	The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans Drug Metab Dispos. 2010 Apr;38(4):667-78. doi: 10.1124/dmd.109.031476.
52	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother. 2007 Apr;41(4):653-8.
53	Drug Interactions Flockhart Table
54	Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61.
55	Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.
56	Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol Drug Metab Dispos. 2021 Oct;49(10):882-891. doi: 10.1124/dmd.120.000350.
57	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
58	Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction. Pharmacol Rep. 2019 Apr;71(2):201-205.
59	CYP3A418B and CYP3A53 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci. 2015 Aug 30;76:238-44.
60	Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 Jul;151(6):737-48.
61	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
62	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
63	Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
64	Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants
65	In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method Front Pharmacol. 2021 Feb 5;11:626897. doi: 10.3389/fphar.2020.626897.
66	Drug interactions with irbesartan. Clin Pharmacokinet. 2001;40(8):605-14.
67	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
68	Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
69	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
70	CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans
71	Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10.
72	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
73	Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
74	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
75	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
76	Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16.
77	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504.
78	Brentuximab vedotin.
79	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
80	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
81	The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol. 2001 Dec;21(6):549-55.
82	The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996 Jun;277(3):1659-64.
83	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
84	Conjugated oestrogens/bazedoxifene. Aust Prescr. 2017 Jun;40(3):114-115.
85	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
86	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
87	Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr;23(2):137-44.
88	Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1057-69.
89	[Enzalutamide in castration resistant prostate cancer.]
90	Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.
91	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
92	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
93	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
94	Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015 Jul;27(2):115-45.
95	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
96	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
97	In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
98	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
99	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
100	Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003 Dec;44(12):1521-8.
101	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
102	Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017 Aug;45(8):900-907.
103	The pharmacology and clinical pharmacokinetics of apomorphine SL BJU Int. 2001 Oct;88 Suppl 3:18-21. doi: 10.1046/j.1464-4096.2001.00124.x.
104	Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308-16.
105	Comparative kinetics of metabolism of beclomethasone propionate esters in human lung homogenates and plasma
106	Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
107	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites
108	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
109	Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos. 2019 Feb;47(2):135-144.
110	CYP3A Specifically Catalyzes 1-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity
111	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
112	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
113	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
114	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
115	Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
116	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
117	FDA label of Levocetirizine dihydrochloride. The 2020 official website of the U.S. Food and Drug Administration.
118	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
119	Is meperidine the drug that just won't die? J Pediatr Pharmacol Ther. 2011 Jul;16(3):167-9.
120	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
121	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
122	FDA Approved Drug Products: TAGRISSO (osimertinib) tablets for oral use
123	The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
124	Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589) Drug Metab Dispos. 2012 May;40(5):1041-50. doi: 10.1124/dmd.111.043620.
125	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27.
126	Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans
127	DrugBank(Pharmacology-Metabolism):Ponesimod
128	Quinine induced simvastatin toxicity through cytochrome inhibition - a case report. BMC Geriatr. 2016 Oct 1;16(1):168.
129	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
130	Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring
131	Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
132	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
133	Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele
134	Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 Apr;7(6):639-51.
135	Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
136	Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
137	Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation
138	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
139	Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
140	Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6.
141	Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31.
142	DailyMed : Alitretinoin
143	Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450
144	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
145	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
146	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
147	Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep. 2007 May-Jun;59(3):296-305.
148	Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16.
149	Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar;73(3):209-22.
150	Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20.
151	Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 2002 Nov;32(11):937-47.
152	Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. Reprod Toxicol. 2013 Jun;37:24-30.
153	Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol. 1991 Nov;40(5):859-67.
154	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A41B and 3A53 for 25 fentanyl cases J Anal Toxicol. 2005 Oct;29(7):590-8. doi: 10.1093/jat/29.7.590.
155	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
156	Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018 May;11(3):251-260.
157	CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr;19(4):680-8.
158	Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. Biochem Pharmacol. 1987 Jan 15;36(2):237-43.
159	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
160	ClinicalTrials.gov (NCT02456883) Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors.
161	Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
162	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
163	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13.
164	Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects
165	DrugBank(Pharmacology-Metabolism):Lasofoxifene
166	Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study. Biomedica. 2012 Oct-Dec;32(4):570-7.
167	In?vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
168	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
169	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
170	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
171	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
172	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65.
173	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999 Apr;65(4):377-81.
174	Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015 Feb;55(2):168-78.
175	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
176	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
177	Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
178	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
179	PubChem:SR141716A
180	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice
181	Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells
182	Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
183	Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20.
184	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478-87.
185	Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
186	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
187	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
188	The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther. 1999 Oct;66(4):408-14.
189	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44.
190	FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
191	DrugBank(Pharmacology-Metabolism):Baricitinib
192	Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522.
193	DrugBank(Pharmacology-Metabolism):Betrixaban
194	Brigatinib: First Global Approval Drugs. 2017 Jul;77(10):1131-1135. doi: 10.1007/s40265-017-0776-3.
195	Metabolite Profiling and Reaction Phenotyping for the in Vitro Assessment of the Bioactivation of Bromfenac ? Chem Res Toxicol. 2020 Jan 21;33(1):249-257. doi: 10.1021/acs.chemrestox.9b00268.
196	Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):926-31.
197	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
198	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
199	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
200	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
201	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
202	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
203	Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016 Apr;37(4):555-60.
204	Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
205	Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228.
206	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
207	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
208	Desvenlafaxine succinate for major depressive disorder
209	Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood
210	Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8.
211	Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91.
212	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
213	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
214	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
215	Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45.
216	Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
217	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
218	Evidence for the Metabolic Activation of Deferasirox In Vitro and In Vivo
219	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
220	O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11.
221	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
222	Effects of fluvastatin on the pharmacokinetics of eepaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by fluvastatin. Korean J Physiol Pharmacol. 2013 Jun;17(3):245-51.
223	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
224	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
225	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
226	Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4
227	Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
228	The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004 May;75(5):464-75.
229	Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids
230	Isocratic high-performance liquid chromatographic method for the separation of isradipine and its main metabolites. Application to in vitro metabolization by h3A4/OR cells J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):359-66. doi: 10.1016/s0378-4347(97)00048-0.
231	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
232	Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998 Mar;28(3):313-21.
233	Pharmacokinetics, absorption, metabolism, and excretion of [(14)C]ivosidenib (AG-120) in healthy male subjects
234	Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies
235	Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015 May 18;28(5):872-85.
236	In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab Dispos. 2003 Oct;31(10):1240-50. doi: 10.1124/dmd.31.10.1240.
237	Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549.
238	Absorption, Metabolism, Distribution, and Excretion of Letermovir Curr Drug Metab. 2021;22(10):784-794. doi: 10.2174/1389200222666210223112826.
239	Resin haemoperfusion in levomepromazine poisoning: evaluation of effect on plasma drug and metabolite levels
240	Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017 May;56(5):493-503.
241	Chemical stability-indicating HPLC study of fixed-dosage combination containing metoprolol tartrate and hydrochlorothiazide.
242	Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
243	Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7.
244	Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7.
245	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
246	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57.
247	FDA label of Pexidartinib. The 2020 official website of the U.S. Food and Drug Administration.
248	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40.
249	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
250	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635.
251	DrugBank(Pharmacology-Metabolism):Propoxyphene Hydrochloride
252	10th North American ISSX meeting. October 24-28, 2000. Indianapolis, Indiana, USA. Abstracts. Drug Metab Rev. 2000;32 Suppl 2:137-340.
253	Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484-7.
254	Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology. 1995 Jan;82(1):214-20.
255	Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors Invest New Drugs. 2020 Jun;38(3):765-775. doi: 10.1007/s10637-019-00815-2.
256	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
257	DrugBank(Pharmacology-Metabolism):Simvastatin
258	CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
259	Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5.
260	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
261	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
262	FDA label of Zanubrutinib. The 2020 official website of the U.S. Food and Drug Administration.
263	In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
264	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010 Sep;66(9):955.
265	In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica. 2018 Jun;48(6):546-554.
266	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
267	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
268	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
269	Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
270	Studies on Drug Interactions between CYP3A4 Inhibitors and Glucocorticoids.
271	No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
272	Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010 Jan-Feb;19(1):4-16.
273	Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.
274	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8.
275	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
276	Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
277	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
278	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
279	Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76.
280	Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
281	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
282	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
283	Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-1483.
284	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
285	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
286	The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):495S-499S.
287	In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314.
288	Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23.
289	Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.
290	LABEL:INGOLIMOD capsule
291	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
292	Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013 Jul;4(4):263-8.
293	Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from In vitro and phase I clinical studies. Drugs R D. 2016 Mar;16(1):81-92.
294	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
295	Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics. 2004;22(6):389-411.
296	Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84.
297	Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147.
298	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
299	Ivabradine: new drug. Best avoided in stable angina. Prescrire Int. 2007 Apr;16(88):53-6.
300	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
301	Clinical profile of levobupivacaine in regional anesthesia: A systematic review. J Anaesthesiol Clin Pharmacol. 2013 Oct;29(4):530-9.
302	Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan
303	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
304	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
305	Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients
306	Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
307	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
308	Ema.europa:Nalmefene
309	Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5.
310	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
311	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
312	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
313	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
314	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
315	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
316	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
317	Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
318	An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)
319	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
320	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
321	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
322	The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
323	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
324	In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997 Jul;25(7):840-4.
325	Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct;29(10):1175-81.
326	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
327	The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol. 1998 May;38(5):463-6.
328	Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes
329	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
330	Managing drug-drug interactions with boceprevir and telaprevir. Clin Liver Dis (Hoboken). 2012 Apr 26;1(2):36-40.
331	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
332	Extraction of structure-activity relationship information from high-throughput screening data Curr Med Chem. 2009;16(31):4049-57. doi: 10.2174/092986709789378189.
333	Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002 Jun;49(6):461-7.
334	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
335	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
336	Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43.
337	Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone
338	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
339	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
340	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012 May;68(5):681-8.
341	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
342	Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23.
343	No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
344	In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58.
345	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
346	FDA label:Avapritinib
347	Avapritinib: First Approval
348	Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2 Chem Res Toxicol. 2021 Apr 19;34(4):1169-1174. doi: 10.1021/acs.chemrestox.1c00036.
349	Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65.
350	Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T. 2015 Jul;40(7):451-62.
351	DrugBank(Pharmacology-Metabolism):Chlordiazepoxide
352	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
353	Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells
354	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
355	Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41.
356	A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement Drug Metab Dispos. 2015 Apr;43(4):523-33. doi: 10.1124/dmd.114.062620.
357	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
358	Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32.
359	Omeprazole-associated digoxin toxicity. South Med J. 2007 Apr;100(4):400-2.
360	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
361	LC-MS/MS determination of dutasteride and its major metabolites in human plasma
362	Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
363	Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01810-18.
364	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005 May;35(5):455-65.
365	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
366	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
367	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
368	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
369	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
370	PubChem:Grepafloxacin
371	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
372	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
373	Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
374	Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
375	Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clin Pharmacokinet. 2005;44(7):731-51.
376	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review Curr Neuropharmacol. 2016;14(2):191-9. doi: 10.2174/1570159x14666151117122458.
377	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
378	Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
379	DrugBank(Pharmacology-Metabolism):Macimorelin
380	Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8.
381	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
382	Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 2000 Jul;68(1):44-57.
383	Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017 May;45(5):540-555.
384	Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
385	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8.
386	DrugBank(Pharmacology-Metabolism):Mycophenolic acid
387	Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos. 2002 Dec;30(12):1504-11.
388	Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci. 2005 Jan;97(1):83-90.
389	Drug-interaction between paclitaxel and goshajinkigan extract and its constituents
390	Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers Biopharm Drug Dispos. 2004 Nov;25(8):329-37. doi: 10.1002/bdd.410.
391	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
392	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
393	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 Dec;29(6):687-710.
394	Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. Biochemistry. 2002 Feb 26;41(8):2712-8.
395	Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization Xenobiotica. 2003 Jan;33(1):27-41. doi: 10.1080/0049825021000017957.
396	Ema.europa:Pitolisant
397	Metabolism and interactions of antileprosy drugs
398	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
399	DrugBank(Pharmacology-Metabolism):Ruxolitinib
400	Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
401	Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27.
402	Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects
403	Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-16.
404	DailyMed : Safinamide mesylate
405	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
406	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
407	Sonidegib: first global approval. Drugs. 2015 Sep;75(13):1559-66.
408	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
409	PubChem:Tapinarof
410	The Quantification of Paclitaxel and Its Two Major Metabolites in Biological Samples by HPLC-MS/MS and Its Application in a Pharmacokinetic and Tumor Distribution Study in Xenograft Nude Mouse
411	Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007 Jul;35(7):1135-41.
412	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
413	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
414	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
415	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
416	Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002 Oct;32(10):835-47.
417	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
418	Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS J Pharm Biomed Anal. 2021 Sep 5;203:114225. doi: 10.1016/j.jpba.2021.114225.
419	Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
420	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
421	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
422	Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
423	DrugBank : Atenolol
424	Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
425	Lithium Intoxication in the Elderly: A Possible Interaction between Azilsartan, Fluvoxamine, and Lithium
426	Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
427	Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8.
428	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
429	Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
430	Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112.
431	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
432	Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
433	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
434	In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87.
435	DrugBank(Pharmacology-Metabolism):Cyproterone
436	Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006 Dec 28;49(26):7711-20.
437	Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
438	Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52.
439	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016 Oct;46(10):868-74.
440	FDA Label of Elvitegravir. The 2020 official website of the U.S. Food and Drug Administration.
441	Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63.
442	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
443	Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
444	Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
445	News and information in drug research: Ethynodiol diacetate.
446	Flibanserin: first global approval. Drugs. 2015 Oct;75(15):1815-22.
447	The disposition and metabolism of [14C]fluconazole in humans Drug Metab Dispos. 1991 Jul-Aug;19(4):764-7.
448	Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.
449	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
450	Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57.
451	DrugBank(Pharmacology-Metabolism):Icatibant
452	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
453	Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53.
454	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
455	Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.
456	DrugBank(Pharmacology-Metabolism):Levomethadyl Acetate
457	Differential N-demethylation of l-alpha-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4
458	Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2016 Jan;56(1):47-55.
459	Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4;11(11):1351-3.
460	EMC: Lotemax 0.5% w/v Eye Drops, Suspension.
461	Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. Infection. 2004 Oct;32(5):299-302.
462	Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000 Oct;52(10):1265-9.
463	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct;48(10):973-983.
464	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
465	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma
466	In vitro metabolism of 14C-moxidectin by hepatic microsomes from various species. Vet Res Commun. 2001 Jul;25(5):345-54.
467	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
468	Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
469	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
470	Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng. 2000 Apr;2(2):115-25.
471	Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects
472	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33.
473	FDA Label of Qsymia. The 2020 official website of the U.S. Food and Drug Administration.
474	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
475	FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
476	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
477	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
478	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
479	Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30.
480	In vitro metabolic profile and drug-drug interaction assessment of secnidazole, a high-dose 5-nitroimidazole antibiotic for the treatment of bacterial vaginosis Pharmacol Res Perspect. 2020 Aug;8(4):e00634. doi: 10.1002/prp2.634.
481	Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations
482	P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87.
483	FDA LABEL:elexipag
484	Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78.
485	Product characteristics of Diacomit.
486	Studies on the metabolism and biological activity of the epimers of sulindac
487	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
488	Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.
489	The In vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. J Pharmacol Exp Ther. 1997 Dec;283(3):1168-76.
490	Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):301-19.
491	FDA label of Tinidazole. The 2020 official website of the U.S. Food and Drug Administration.
492	Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.
493	Tolvaptan: a new therapeutic agent. Rev Recent Clin Trials. 2011 May;6(2):177-88.
494	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
495	The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476-83.
496	FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
497	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
498	Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
499	LABEL:Avacopan
500	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
501	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
502	Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
503	Product monograph: LUMIGAN RC (Bimatoprost).
504	Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108.
505	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
506	Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters Curr Drug Metab. 2020;21(14):1127-1135. doi: 10.2174/1389200221999201208211537.
507	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
508	Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9.
509	Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.
510	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
511	Risk of stroke, gangrene from ergot drug interactions
512	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
513	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
514	Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531.
515	FDA:Enasidenib
516	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
517	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
518	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
519	Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J Med Chem. 1982 Oct;25(10):1174-9.
520	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
521	NCIthesaurus: Fluprednisolone
522	The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64.
523	Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control
524	DrugBank(Pharmacology-Metabolism):Fosinopril
525	Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006 Sep;40(9):1572-83.
526	Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
527	Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
528	NCIthesaurus: Halcinonide
529	Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 Nov;72(5):514-23.
530	Stereoselective method development and validation for determination of concentrations of amphetamine-type stimulants and metabolites in human urine using a simultaneous extraction-chiral derivatization approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jan 1;879(1):8-16.
531	Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459.
532	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
533	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
534	Cross-species comparisons of the pharmacokinetics of ibudilast
535	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
536	Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015 Nov;35(11):1037-51.
537	Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946.
538	FDA label:Lenacapavir
539	DrugBank(Pharmacology-Metabolism):Lenacapavir
540	Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75.
541	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
542	Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration
543	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
544	Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. Eur J Pharm Sci. 2017 Aug 30;106:20-33.
545	Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.
546	DrugBank(Pharmacology-Metabolism):Methysergide
547	DrugBank(Pharmacology-Metabolism):Mitapivat
548	Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
549	Metabolite identification, reaction phenotyping, and retrospective drug-drug interaction predictions of 17-deacetylnorgestimate, the active component of the oral contraceptive norgestimate. Drug Metab Dispos. 2017 Jun;45(6):676-685.
550	Cytochrome P-450 activities in human and rat brain microsomes. Brain Res. 2000 Feb 14;855(2):235-43.
551	PubChem:Omidenepag isopropyl
552	DrugBank(Pharmacology-Metabolism):Orlistat
553	A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010 Winter;12(1):12-9.
554	The Effect of Respiratory Protective Surgical Mask on Physiological Markers of Endurance Performance in a Recreational Runner
555	Evaluation of drug-drug interactions of pemigatinib in healthy participants
556	Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function
557	Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
558	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
559	Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74.
560	Survey of computed tomography doses and establishment of national diagnostic reference levels in the R
561	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006 Sep-Oct;63(5):381-5.
562	HEP Drug interaction: daclatasvir and abacavir.
563	Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9.
564	Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9.
565	U. S. FDA Label -Rifaximin
566	PubChem:Rimegepant
567	Effects of rimegepant 75?mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants
568	Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011 Jan;39(1):151-9.
569	Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
570	Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children
571	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
572	Pharmacokinetic interactions of rolapitant with cytochrome P450 3A substrates in healthy subjects. J Clin Pharmacol. 2019 Apr;59(4):488-499.
573	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
574	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
575	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
576	Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
577	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
578	Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015 May-Jun;23(2):92-6.
579	Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997 Jun 1;53(11):1613-9.
580	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
581	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
582	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
583	Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos. 2017 Dec;45(12):1266-1275.
584	In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6
585	Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5.
586	Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2014;2014:140083.
587	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
588	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica. 1996 Nov;26(11):1143-53.
589	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
590	Product characteristics of Epclusa.
591	Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects
592	Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
593	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
594	Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013 Jul;136:54-8.
595	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration
596	DrugBank(Pharmacology-Metabolism):Voxilaprevir
597	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
598	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
599	DrugBank(Pharmacology-Metabolism):Alfuzosin
600	U. S. FDA Label -Alfuzosin
601	Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002 Apr;58(1):19-27.
602	Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999 Sep;16(9):1352-9.
603	Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25.
604	Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6.
605	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
606	A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8.
607	DrugBank(Pharmacology-Metabolism):Ergoloid mesylate
608	Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
609	Eribulin, a microtubule inhibitor for metastatic breast cancer. Oncology (Williston Park). 2011 Feb;25(2 Suppl Nurse Ed):46-8.
610	The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030.
611	DrugBank(Pharmacology-Metabolism):IPI-145
612	A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. 2002 Winter;9(4):191-8.
613	[Macrolides and ketolides]
614	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
615	Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
616	Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
617	DrugBank(Pharmacology-Metabolism):NERATINIB MALEATE
618	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
619	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
620	Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5
621	P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol Pharm. 2019 Sep 3;16(9):3842-3852.
622	Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450
623	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
624	Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
625	Umbralisib: First Approval
626	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
627	PubChem:Upadacitinib
628	PubChem:Voclosporin
629	Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside
630	In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica. 2002 Nov;32(11):949-62.
631	CYP2D plays a major role in berberine metabolism in liver of mice and humans
632	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
633	The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos. 2000 Oct;28(10):1231-7.
634	Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. Biomed Res Int. 2020 Aug 6;2020:1563874. doi: 10.1155/2020/1563874.
635	Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.
636	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
637	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
638	Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol. 2005 Aug;60(2):172-5.
639	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
640	Prescribrt's digital referenve - Ethinyl estradiol/norethindrone; mestranol/norethindrone - Drug Summary
641	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
642	Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
643	Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica. 1997 Sep;27(9):885-900.
644	Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in?vitro models of hepatic metabolism
645	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
646	Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans
647	Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol. 2003 Oct;43(10):1091-100.
648	No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine
649	Characterization of human urinary metabolites of the antimalarial piperaquine
650	Metabolite identification of the antimalarial piperaquine in vivo using liquid chromatography-high-resolution mass spectrometry in combination with multiple data-mining tools in tandem
651	In vitro metabolism of piperaquine is primarily mediated by CYP3A4
652	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
653	Assessment of the stereoselective metabolism of methaqualone in man by capillary electrophoresis. Electrophoresis. 2003 Aug;24(15):2598-607.
654	Product monograph: Mictoryl (Propiverine hydrochloride modified-release capsules).
655	Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. Ann Pharmacother. 2006 Apr;40(4):767-70.
656	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
657	Assessments of CYP?inhibition?based drug-drug interaction between vonoprazan and poziotinib in?vitro and in?vivo
658	New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. Curr Opin Investig Drugs. 2002 Jul;3(7):1073-80.
659	CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20.
660	Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
661	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
662	Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate Drug Metab Dispos. 2018 Sep;46(9):1320-1328. doi: 10.1124/dmd.118.081182.
663	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
664	The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol. 2001 Feb;51(2):147-52.
665	Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos. 1999 Aug;27(8):860-5.
666	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
667	Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant? J Psychiatr Pract. 2004 Sep;10(5):323-30.
668	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
669	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
670	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87.
671	Cytochrome P450 3A4 and benzodiazepines. Seishin Shinkeigaku Zasshi. 2003;105(5):631-42.
672	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Br J Clin Pharmacol. 2000 Oct;50(4):333-7.
673	Adverse drug interactions: a handbook for prescribers. Taylor and Francis group.2010.
674	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
675	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
676	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (DRUG:D01145)
677	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
678	CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5.
679	Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
680	Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019 Feb;176(3):466-477.
681	FDA label of Elbasvir and grazoprevir. The 2020 official website of the U.S. Food and Drug Administration.
682	Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab Dispos. 2003 Jan;31(1):122-32.
683	Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160.
684	Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride Drug Metab Dispos. 2012 Sep;40(9):1723-35. doi: 10.1124/dmd.112.045120.
685	Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. Drug Metab Pharmacokinet. 2008;23(6):428-33.;
686	Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos. 2008 Feb;36(2):435-41.
687	In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):747-52.
688	Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001.
689	Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug Metab Dispos. 2016 Aug;44(8):1372-80.
690	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
691	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
692	Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811.
693	Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004 Aug;76(2):139-53.
694	Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos. 2006 Jan;34(1):145-51.
695	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
696	Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics
697	Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens
698	Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010 Mar;38(3):474-83.
699	Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives
700	Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents
701	Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
702	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
703	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
704	Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019;20(2):147-154.
705	In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97.
706	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
707	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
708	Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters
709	FDA label of Sacubitril and valsartan. The 2020 official website of the U.S. Food and Drug Administration.
710	Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
711	Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present
712	Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
713	Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone
714	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
715	Pharmacokinetics, Disposition, and Biotransformation of [(14)C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose
716	Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib
717	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
718	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
719	DrugBank(Pharmacology-Metabolism):Chlorpromazine
720	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin. 2009 Apr;25(4):891-902.
721	Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr;4(2):95-103.
722	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
723	DrugBank(Pharmacology-Metabolism):Mavacamten
724	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
725	DrugBank(Pharmacology-Metabolism):Nestorone
726	Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos. 2000 Mar;28(3):315-22.
727	Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011 Mar;26(2):111-7.
728	Studies on the metabolic fate of M17055, a novel diuretic (4): species difference in metabolic pathway and identification of human CYP isoform responsible for the metabolism of M17055
729	Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans
730	Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Drug Des Devel Ther. 2015 Mar 2;9:737-43.
731	Human hepatic metabolism of the anti-osteoporosis drug eldecalcitol involves sterol C4-methyl oxidase. Pharmacol Res Perspect. 2015 Mar;3(2):e00120.
732	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28.
733	Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults
734	Metabolism and Disposition of [(14)C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors
735	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
736	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
737	Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587-94.
738	Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib
739	Metabolism of 5-methoxypsoralen by Saccharomyces cerevisiae. Photochem Photobiol. 1991 Nov;54(5):689-95.
740	Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814.
741	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
742	Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib
743	Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans
744	A Comprehensive Overview of Globally Approved JAK Inhibitors
745	Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H(3)R) inverse agonist in clinical development for the treatment of narcolepsy
746	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
747	Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats
748	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
749	FDA label of Polatuzumab vedotin-piiq. The 2020 official website of the U.S. Food and Drug Administration.
750	Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica. 2000 Jun;30(6):565-74.
751	An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
752	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
753	Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica. 2008 Apr;38(4):353-67.
754	Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019 Apr;59(4):472-487.
755	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
756	A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
757	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
758	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
759	Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin Cancer Res. 2001 Oct;7(10):3056-64.
760	In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
761	Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol Sin. 2003 Mar;24(3):263-8.
762	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
763	Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs
764	Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment. Front Immunol. 2019 Jul 30;10:1801.
765	Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. AAPS J. 2013 Apr;15(2):498-504.
766	Studies on pharmacokinetic drug interaction potential of vinpocetine. Medicines (Basel). 2015 Jun 5;2(2):93-105.
767	Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573-86.
768	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
769	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
770	Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans
771	Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol. 2006 May;61(5):533-7.
772	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
773	Ganaxolone
774	Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr. 2007 Dec;2(3):249-56.
775	Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs. 2013 Jun;31(3):653-60.
776	DrugBank(Pharmacology-Metabolism):Mirvetuximab soravtansine
777	DrugBank(Pharmacology-Metabolism):MRTX849
778	Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res. 2002 May;49(3):247-54.
779	DrugBank(Pharmacology-Metabolism):PT2977
780	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
781	Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr;50(4):1130-5.
782	Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
783	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
784	Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos. 1998 Oct;26(10):970-6.
785	DrugBank(Pharmacology-Metabolism):Ag-221
786	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
787	Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers
788	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
789	Amenamevir: studies of potential CYP3A-mediated pharmacokinetic interactions with midazolam, cyclosporine, and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2018 Nov;7(8):844-859.
790	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
791	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
792	Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 2013;7:105-15.
793	Metabolism of benzalkonium chlorides by human hepatic cytochromes P450. Chem Res Toxicol. 2019 Dec 16;32(12):2466-2478.
794	Product Information of Eumovate.
795	Studies of the pharmacology of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol, a synthetic anti-inflammatory androstene. Int J Clin Exp Med. 2011;4(2):119-35.
796	A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
797	Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions
798	The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
799	PubChem:SCY-078
800	Metabolism, Excretion, and Mass Balance of Solithromycin in Humans
801	Oxidative Deamination of Emixustat by Human Vascular Adhesion Protein-1/Semicarbazide-Sensitive Amine Oxidase
802	Lactobacillus rhamnosus induces CYP3A and changes the pharmacokinetics of verapamil in rats
803	Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism
804	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
805	In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist
806	AMIODARONE AND THYROID DYSFUNCTION
807	Increased serum amiodarone concentration in hypertriglyceridemic patients: Effects of drug distribution to serum lipoproteins
808	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
809	Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies
810	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
811	Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61.
812	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath
813	A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients
814	Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human
815	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
816	CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib
817	Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro
818	Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach
819	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
820	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
821	KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects
822	The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
823	Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite
824	Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs
825	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320-8.
826	Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans
827	Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties
828	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
829	Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
830	Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism
831	Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
832	A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers
833	Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study
834	Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2 Inhibitor PT2385 In Vivo and In Vitro
835	Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients
836	Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
837	Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
838	DrugBank(Pharmacology-Metabolism):AP26113
839	CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183)
840	Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul;34(7):1136-44.
841	Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption
842	Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor
843	Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother. 1999 Mar;43(3):549-56.
844	Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies
845	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
846	Frontiers in CNS Drug Discovery. Edited by Atta-ur Rahman, M. Iqbal Choudhary. Page: 318.
847	Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects
848	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
849	Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638
850	Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs. 2004 Feb;7(2):143-50.
851	Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies
852	Cytochrome P450 Mediated Bioactivation of Saracatinib
853	Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity
854	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
855	Phosphonate O-deethylation of [4-(4-bromo-2-cyano-phenylcarbamoyl) benzyl]-phosphonic acid diethyl ester, a lipoprotein lipase-promoting agent, catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes
856	Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism
857	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
858	Effect of ketoconazole on the pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos. 2013 May;41(5):1035-45.
859	Metabolic pathways of the camptothecin analog AR-67
860	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
861	In vitro assessment of metabolic drugCdrug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
862	Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):403-12.
863	Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos. 1999 Nov;27(11):1254-9.
864	Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
865	Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.
866	Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats
867	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
868	The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos. 2002 Sep;30(9):957-61.
869	Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos. 2008 Nov;36(11):2393-403.
870	Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions. J Clin Pharmacol. 2018 Oct;58(10):1305-1313.
871	Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
872	TB and HIV therapeutics: pharmacology research priorities. AIDS Res Treat. 2012;2012:874083.
873	Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry
874	Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer
875	Effect of human flavin-containing monooxygenase 3 polymorphism on the metabolism of aurora kinase inhibitors
876	Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med. 2002 Apr-Jun;6(2):189-98.
877	Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4.
878	Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors
879	BC-3781: Evaluation of the CYP3A Interaction Potential.
880	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506.
881	The Drug-Drug Interaction Profile of Presatovir
882	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
883	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
884	The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders
885	Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses
886	Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling
887	In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor
888	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019 Jan;85(1):181-193.
889	Comprehensive Medicinal Chemistry III. Page: 569.
890	Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063
891	Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
892	Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D(2)/D(3) receptor antagonist for gastroparesis, towards cytochrome P450s and transporters
893	Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease
894	A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 2007 Jul;193(1):229-33.
895	Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects
896	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
897	Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes
898	Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
899	Pharmacokinetics and ADME Characterization of Intravenous and Oral [(14)C]-Linerixibat in Healthy Male Volunteers
900	Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751.
901	CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo. International Clinical Psychopharmacology, 2006, 21(4):A33.
902	DrugBank(Pharmacology-Metabolism):KD025
903	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
904	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
905	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
906	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
907	Metabolic map and bioactivation of the anti-tumour drug noscapine
908	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
909	Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther. 1996 May;277(2):982-90.
910	Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am J Ther. 1997 Jul-Aug;4(7-8):229-38.
911	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
912	An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab Dispos. 1999 Jul;27(7):776-85.
913	The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects
914	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
915	Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma. Clin Cancer Res. 2018 May 1;24(9):2082-2091.
916	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
917	Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl. 2006 Mar-Apr;27(2):138-50.
918	Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo
919	Lercanidipine in hypertension. Vasc Health Risk Manag. 2005;1(3):173-82.
920	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
921	In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification
922	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
923	Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation
924	Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species
925	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
926	The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients
927	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
928	Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
929	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes
930	In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
931	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
932	In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations
933	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
934	Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. J Clin Pharm Ther. 2019 Oct;44(5):720-725.
935	Sex differences in rat hepatic cytolethality of the protein kinase C inhibitor safingol: role of biotransformation. Toxicol Appl Pharmacol. 1996 Apr;137(2):173-81.
936	Stereoselective disposition of talinolol in man. J Pharm Sci. 2002 Feb;91(2):303-11.
937	Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010 Feb 23;121(7):934-9.
938	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
939	MLN8054 and Alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett. 2015 Apr 22;6(6):630-4.
940	Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans
941	Unexpected interaction between CYP3A4 and BI 11634: is BI 11634 interacting with CYP3A4 similar to nifedipine?
942	Metabolism of F18, a derivative of calanolide A, in human liver microsomes and cytosol. Front Pharmacol. 2017 Jul 19;8:479.
943	Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug
944	MedChemExpress: AZD3839.
945	Possible interaction between topical terbinafine and acenocoumarol. Ann Pharmacother. 2009 Nov;43(11):1911-2.
946	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
947	Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
948	Management of sugar intolerance in children
949	Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
950	In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans
951	Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans
952	In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys
953	A pharmacokinetic interaction study of avitriptan and propranolol
954	Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans
955	Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans
956	Implication of P450-metabolite complex formation in the nonlinear pharmacokinetics and metabolic fate of (+/-)-(1'R,3R)-3-phenyl-1-[(1',2',3',4'-tetrahydro-5',6'-methylene-dioxy-1'-naphthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200) in dogs
957	Metabolism of 1,8-cineole by human cytochrome P450 enzymes: identification of a new hydroxylated metabolite. Biochim Biophys Acta. 2005 Apr 15;1722(3):304-11. doi: 10.1016/j.bbagen.2004.12.019.
958	Performance comparison between multienzymes loaded single and dual electrodes for the simultaneous electrochemical detection of adenosine and metabolites in cancerous cells. Biosens Bioelectron. 2018 Jun 30;109:263-271. doi: 10.1016/j.bios.2018.03.031.
959	Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543
960	In vitro metabolism of 7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite
961	In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland. Mol Cell Endocrinol. 2014 Mar 5;383(1-2):181-92. doi: 10.1016/j.mce.2013.12.012.
962	Main metabolic pathways of TAK-802, a novel drug candidate for voiding dysfunction, in humans: the involvement of carbonyl reduction by 11-hydroxysteroid dehydrogenase 1
963	[Investigation of metabolic kinetics and reaction phenotyping of ligustrazin by using liver microsomes and recombinant human enzymes]
964	Identification of cytochrome P450 isoform involved in the metabolism of YM992, a novel selective serotonin re-uptake inhibitor, in human liver microsomes
965	Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells. Antimicrob Agents Chemother. 2005 May;49(5):2044-9. doi: 10.1128/AAC.49.5.2044-2049.2005.
966	Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide
967	Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor
968	Application of physiologically based pharmacokinetic modeling to understanding the clinical pharmacokinetics of UK-369,003
969	Species-dependent metabolism of a novel selective 7 neuronal acetylcholine receptor agonist ABT-107
970	In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450
971	In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A:cholesterol acyltransferase, by liver microsomes in man
972	Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects
973	Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative
974	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
975	Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos. 2008 Nov;36(11):2185-98.
976	Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica. 2000 Sep;30(9):905-14.
977	In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 2000 Oct;50(4):311-4.
978	In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism
979	Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
980	Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats. J Pharm Pharmacol. 1998 Mar;50(3):275-8.
981	Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54.
982	Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos. 1995 Oct;23(10):1051-7.
983	Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 2003 Jan;10(1):40-8.
984	Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother. 2011 Feb;55(2):722-8.
985	Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20.
986	Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
987	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
988	GW766994 CCR3 receptor antagonist.
989	The mechanism of aphidicolin bioinactivation by rat liver in vitro systems. Xenobiotica. 1990 Mar;20(3):273-87.
990	Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol. 2001 Oct;41(10):1059-63.
991	Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes. Chirality. 2005 Mar;17(3):135-41.
992	Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
993	Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
994	The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
995	Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659. Xenobiotica. 2002 Feb;32(2):109-18.
996	Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation
997	Metabolic activation of aromatic amines by human pancreas. Carcinogenesis. 1997 May;18(5):1085-92.
998	CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol. 1995 Jan;39(1):71-6.
999	Metabolism of butyrylfentanyl in fresh human hepatocytes: chemical synthesis of authentic metabolite standards for definitive identification. Biol Pharm Bull. 2019;42(4):623-630.
1000	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
1001	Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
1002	In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20.
1003	Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001 Feb;51(2):133-42.
1004	Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993 May;43(5):827-32.
1005	Cytochrome P450 4A11 inhibition assays based on characterization of lauric acid metabolites
1006	Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
1007	The naphthol selective estrogen receptor modulator (SERM), LY2066948, is oxidized to an o-quinone analogous to the naphthol equine estrogen, equilenin. Chem Biol Interact. 2012 Mar 5;196(1-2):1-10.
1008	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
1009	6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim Biophys Acta. 1999 Apr 19;1438(1):47-54.
1010	Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18422-7.
1011	Diet Drug Porfimer sodium Safe, Effective, Study Finds.
1012	Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans. Drug Metab Dispos. 1997 Jun;25(6):716-24.
1013	[Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatr Pol. 2011 Jul-Aug;45(4):611-25.
1014	Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sci. 2003 Nov 7;73(25):3201-12.
1015	Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998 Sep;64(3):278-85.
1016	Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26;50(9):1385-9.
1017	P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos. 2001 Mar;29(3):304-12.
1018	CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos. 2011 Jun;39(6):1039-46.
1019	Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes?
1020	New insights in the metabolism of oxybutynin: evidence of N-oxidation of propargylamine moiety and rearrangement to enaminoketone
1021	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer Nature. 2015 Jul 16;523(7560):347-51. doi: 10.1038/nature14406.
1022	Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects
1023	High-performance liquid chromatographic determination of seratrodast and its metabolites in human serum and urine
1024	Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans
1025	Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans Drug Metab Dispos. 2019 Feb;47(2):145-154. doi: 10.1124/dmd.118.084459.
1026	Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors?. J Pharmacol Exp Ther. 2023 Jan;384(1):173-186. doi: 10.1124/jpet.122.001116.
1027	Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1294-1307. doi: 10.1002/cpdd.1153.
1028	Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents FASEB J. 2010 Dec;24(12):4904-16. doi: 10.1096/fj.10-162438.
1029	Rapid detection and quantification of paracetamol and its major metabolites using surface enhanced Raman scattering. Analyst. 2023 Apr 11;148(8):1805-1814. doi: 10.1039/d3an00249g.
1030	Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B J Med Chem. 2008 Feb 14;51(3):666-76. doi: 10.1021/jm7012216.
1031	Nanocrystal Suspensions for Enhancing the Oral Absorption of Albendazole. Nanomaterials (Basel). 2022 Sep 1;12(17):3032. doi: 10.3390/nano12173032.
1032	Multi-residue methodology for quantification of antiparasitics in hen eggs by LC-MS/MS: development, validation and application to 348 samples from Brazil. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2022 Aug;39(8):1412-1423. doi: 10.1080/19440049.2022.2093984.
1033	Improvement of Albendazole Bioavailability with Menbutone Administration in Sheep. Animals (Basel). 2022 Feb 14;12(4):463. doi: 10.3390/ani12040463.
1034	Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY:McGraw-Hill, 2001., p. 1126
1035	Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole J Pharm Pharmacol. 2003 Jun;55(6):757-64. doi: 10.1211/002235703765951357.
1036	Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos. 2005 Mar;33(3):303-11.
1037	Alfentanil pharmacokinetics and metabolism in humans Anesthesiology. 1988 Oct;69(4):527-34. doi: 10.1097/00000542-198810000-00012.
1038	LABEL:LFUZOSIN HYDROCHLORIDE EXTENDED RELEASE- alfuzosin hydrochloride tablet
1039	Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers Drug Metab Dispos. 2007 Aug;35(8):1418-28. doi: 10.1124/dmd.106.013797.
1040	DrugBank(Pharmacology-Metabolism):Almogran
1041	Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemother Pharmacol. 2015 Oct;76(4):751-60.
1042	Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes
1043	Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite
1044	Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009 Jun;49(6):719-24.
1045	Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
1046	Determination of the cardiac drug amiodarone and its N-desethyl metabolite in sludge samples
1047	Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature
1048	Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
1049	Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N)
1050	Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy
1051	CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
1052	Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes Drug Metab Dispos. 2019 May;47(5):453-464. doi: 10.1124/dmd.118.084517.
1053	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
1054	Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
1055	Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica. 2011 Dec;41(12):1063-75.
1056	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
1057	Genetic toxicology and toxicokinetics of arecoline and related areca nut compounds: an updated review
1058	Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691.
1059	Biological conversion of?aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug Results Pharma Sci. 2014 May 2;4:19-25. doi: 10.1016/j.rinphs.2014.04.002.
1060	LABEL:RMODAFINIL tablet
1061	Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether
1062	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4.
1063	CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism Drug Metab Dispos. 2011 Mar;39(3):394-401. doi: 10.1124/dmd.110.036327.
1064	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
1065	Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin
1066	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites
1067	LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application
1068	FDA:Avanafil
1069	In Vitro Kinetic Characterization of Axitinib Metabolism
1070	Vinpocetine, cognition, and epilepsy
1071	Phase I study of orally administered (14)Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
1072	Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man
1073	BC-3781:Evaluation of the CYP3A Interaction Potential.
1074	Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir J Hum Genet. 2020 Jan;65(2):143-153. doi: 10.1038/s10038-019-0685-2.
1075	DrugBank(Pharmacology-Metabolism):Beclomethasone dipropionate
1076	Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers
1077	Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies
1078	Identification of Epoxide-Derived Metabolite(s) of Benzbromarone
1079	The metabolism of berberine and its contribution to the pharmacological effects
1080	LABEL: JUXTAPID- lomitapide mesylate capsule
1081	Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection Drug Metab Dispos. 2006 Mar;34(3):427-39. doi: 10.1124/dmd.105.007617.
1082	Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties
1083	DrugBank(Pharmacology-Metabolism)Asunaprevir
1084	Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans
1085	U. S. FDA Label -BNP-1350
1086	Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor
1087	Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect
1088	DrugBank(Pharmacology-Metabolism)Brentuximab vedotin
1089	Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. Xenobiotica. 2021 May;51(5):590-604. doi: 10.1080/00498254.2021.1890275.
1090	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
1091	[Synthesis of Butyl 6alpha-Fluoro-11beta-hydroxy-16alpha-methyl-3,20-dioxo-1,4-pregnadien-21-oate (Fluocortin Butylester) (author's transl)]
1092	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
1093	Metabolic disposition of 14C-bromfenac in healthy male volunteers J Clin Pharmacol. 1998 Aug;38(8):744-52. doi: 10.1002/j.1552-4604.1998.tb04815.x.
1094	Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism
1095	Fate and disposition of bromocriptine in animals and man. I: structure elucidation of the metabolites
1096	Contribution of cytochrome P450 3A pathway to bromocriptine metabolism and effects of ferrous iron and hypoxia-re-oxygenation on its elimination in the perfused rat liver
1097	Structural elucidation of phase I and II metabolites of bupivacaine in horse urine and fungi of the Cunninghamella species using liquid chromatography/multi-stage mass spectrometry Rapid Commun Mass Spectrom. 2012 Jun 15;26(11):1338-46. doi: 10.1002/rcm.6225.
1098	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
1099	DrugBank(Pharmacology-Metabolism)Buspirone
1100	Metabolism and disposition of buspirone Am J Med. 1986 Mar 31;80(3B):41-51. doi: 10.1016/0002-9343(86)90331-1.
1101	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
1102	Interaction of buspirone and its major metabolites with human organic cation transporters. Fundam Clin Pharmacol. 2023 Feb 26. doi: 10.1111/fcp.12883.
1103	A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors Anticancer Drugs. 2015 Mar;26(3):350-8. doi: 10.1097/CAD.0000000000000185.
1104	Clinical pharmacokinetics of cabergoline Clin Pharmacokinet. 2003;42(7):633-45. doi: 10.2165/00003088-200342070-00003.
1105	Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib Clin Pharmacokinet. 2017 May;56(5):477-491. doi: 10.1007/s40262-016-0461-9.
1106	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
1107	Urine caffeine metabolites are positively associated with cognitive performance in older adults: An analysis of US National Health and Nutrition Examination Survey (NHANES) 2011 to 2014. Nutr Res. 2023 Jan;109:12-25. doi: 10.1016/j.nutres.2022.11.002.
1108	Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99.
1109	Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z.
1110	Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood Epilepsia. 1995 Mar;36(3):241-8. doi: 10.1111/j.1528-1157.1995.tb00991.x.
1111	Metabolism of carvedilol in dogs, rats, and mice Drug Metab Dispos. 1998 Oct;26(10):958-69.
1112	CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine. Arch Toxicol. 2016 Jul;90(7):1737-48.
1113	Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells
1114	Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8.
1115	DrugBank(Pharmacology-Metabolism)Cerivastatin
1116	Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull. 2001 Nov;24(11):1263-6.
1117	Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
1118	Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements Clin Pharmacokinet. 1996 Oct;31(4):257-74. doi: 10.2165/00003088-199631040-00003.
1119	Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance Drug Metab Rev. 2008;40(1):101-47. doi: 10.1080/03602530701836704.
1120	Classics in Chemical Neuroscience: Chlorpromazine ACS Chem Neurosci. 2019 Jan 16;10(1):79-88. doi: 10.1021/acschemneuro.8b00258.
1121	Determination of chlorpromazine and its metabolites in animal-derived foods using QuEChERS-based extraction, EMR-Lipid cleanup, and UHPLC-Q-Orbitrap MS analysis. Food Chem. 2023 Mar 1;403:134298. doi: 10.1016/j.foodchem.2022.134298.
1122	Genotyping studies of Toxoplasma gondii isolates from Africa revealed that the archetypal clonal lineages predominate as in North America and Europe Vet Parasitol. 2008 Aug 17;155(3-4):314-8. doi: 10.1016/j.vetpar.2008.04.021.
1123	In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices Biopharm Drug Dispos. 2006 May;27(4):197-207. doi: 10.1002/bdd.500.
1124	Cyclosporin metabolism in transplant patients
1125	Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography J Pharm Biomed Anal. 2001 Jan;24(3):381-9. doi: 10.1016/s0731-7085(00)00426-x.
1126	Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol Drug Metab Dispos. 2007 Oct;35(10):1730-2. doi: 10.1124/dmd.107.016758.
1127	Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care
1128	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
1129	Analytical methodologies for the enantiodetermination of citalopram and its metabolites
1130	Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride
1131	Aquatic toxicity of the macrolide antibiotic clarithromycin and its metabolites
1132	Kinetics and metabolism of clobazam in animals and man
1133	Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro
1134	Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation
1135	Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation
1136	Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype
1137	Determination of clorazepate and its major metabolites in blood and urine by electron capture gas-liquid chromatography
1138	[Interest in learning (2)]
1139	Biotransformation of cobicistat: metabolic pathways and enzymes. Drug Metab Lett. 2016;10(2):111-23.
1140	Liquid chromatography--tandem mass spectrometry analysis of cocaine and its metabolites from blood, amniotic fluid, placental and fetal tissues: study of the metabolism and distribution of cocaine in pregnant rats
1141	Pharmacogenetics of analgesic drugs
1142	Colchicine-antimicrobial drug interactions: what pharmacists need to know in treating gout
1143	U. S. FDA Label -Conivaptan hydrochloride
1144	Conjugated estrogens and bazedoxifene
1145	Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.
1146	Active cyamemazine metabolites in patients treated with cyamemazine (Tercian?): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET)
1147	The KEGG resource for deciphering the genome
1148	U. S. FDA Label -Cyclobenzaprine
1149	Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism
1150	Uptake, Elimination, and Biotransformation Potential of a Progestagen (Cyproterone Acetate) in Tilapia Exposed at an Environmental Concentration
1151	Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation
1152	In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165.
1153	Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.
1154	Effects of Evodiamine on the Pharmacokinetics of Dapoxetine and Its Metabolite Desmethyl Dapoxetine in Rats
1155	Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine
1156	LC-Q-TOF-MS/MS determination of darunavir and its metabolites in rat serum and urine: application to pharmacokinetics J Pharm Biomed Anal. 2014 Jun;94:92-8. doi: 10.1016/j.jpba.2014.01.035.
1157	Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
1158	Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis J Biomed Res. 2016 Mar;30(2):149-161. doi: 10.7555/JBR.30.20150074.
1159	Resveratrol Inhibits Key Steps of Steroid Metabolism in a Human Estrogen-Receptor Positive Breast Cancer Model: Impact on Cellular Proliferation Front Pharmacol. 2018 Jul 10;9:742. doi: 10.3389/fphar.2018.00742.
1160	Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys Drug Metab Dispos. 1997 Jul;25(7):814-27.
1161	DrugBank(Pharmacology-Metabolism):Desvenlafaxine
1162	DrugBank(Pharmacology-Metabolism)Desvenlafaxine succinate
1163	Dexamethasone metabolism in vitro: species differences J Steroid Biochem Mol Biol. 1997 Jul;62(4):345-52. doi: 10.1016/s0960-0760(97)00038-1.
1164	LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):217-25. doi: 10.1016/j.jchromb.2004.09.040.
1165	Classics in Chemical Neuroscience: Dextromethorphan (DXM). ACS Chem Neurosci. 2023 Jun 21;14(12):2256-2270. doi: 10.1021/acschemneuro.3c00088.
1166	The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol. 1994 Sep;38(3):243-8.
1167	Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People Eur J Drug Metab Pharmacokinet. 2020 Aug;45(4):477-485. doi: 10.1007/s13318-020-00614-8.
1168	Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants. Drugs R D. 2022 Mar;22(1):43-50. doi: 10.1007/s40268-021-00375-y.
1169	Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. J Vet Pharmacol Ther. 2021 Sep;44(5):733-744. doi: 10.1111/jvp.12991.
1170	DrugBank(Pharmacology-Metabolism)Diazepam
1171	Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis Eur J Clin Pharmacol. 1983;25(3):389-94. doi: 10.1007/BF01037953.
1172	Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection J Chromatogr. 1981 Nov 6;217:263-71. doi: 10.1016/s0021-9673(00)88081-4.
1173	DrugBank(Pharmacology-Metabolism)Diclofenac sodium
1174	LABEL: NATAZIA- estradiol valerate and estradiol valerate/dienogest kit
1175	Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A Xenobiotica. 1999 Feb;29(2):171-85. doi: 10.1080/004982599238722.
1176	Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. Drug Metab Dispos. 2002 Jan;30(1):1-3.
1177	Pharmacokinetics and first-pass metabolism of levomepromazine in the rat Acta Pharmacol Toxicol (Copenh). 1982 Feb;50(2):148-54. doi: 10.1111/j.1600-0773.1982.tb00956.x.
1178	The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: an in vitro study Pharmacol Rep. 2014 Dec;66(6):1122-6. doi: 10.1016/j.pharep.2014.07.012.
1179	LABEL:ISOPYRAMIDE PHOSPHATE capsule, gelatin coated
1180	Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9.
1181	Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel Cancer Chemother Pharmacol. 2001 Aug;48(2):115-22. doi: 10.1007/s002800100283.
1182	LABEL:OCETAXEL ANHYDROUS injection
1183	Dofetilide, a novel class III antiarrhythmic agent J Cardiovasc Pharmacol. 1992;20 Suppl 2:S96-105.
1184	Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans
1185	DrugBank(Pharmacology-Metabolism): Doravirine
1186	Doxapram metabolism in human fetal hepatic organ culture
1187	Identification of doxapram metabolites using high pressure ion exchange chromatography and mass spectroscopy
1188	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
1189	Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids
1190	Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions
1191	Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug. Pharmacol Res Perspect. 2014 Jun;2(3):e00044.
1192	DrugBank(Pharmacology-Metabolism):Dronedarone hydrochloride
1193	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes Xenobiotica. 2016 Oct;46(10):868-74. doi: 10.3109/00498254.2015.1134852.
1194	DrugBank(Pharmacology-Metabolism)Estradiol acetate
1195	Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005 Sep 28;227(2):115-24.
1196	Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes
1197	Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans Drug Metab Dispos. 2012 Dec;40(12):2250-5. doi: 10.1124/dmd.112.046888.
1198	Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems. Drug Metab Dispos. 2023 Apr;51(4):521-531. doi: 10.1124/dmd.122.001195.
1199	Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel?Phenotyping Cocktail Differently. Clin Pharmacokinet. 2022 Jul;61(7):1039-1055. doi: 10.1007/s40262-022-01119-0.
1200	Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci. 2021 Oct;110(10):3362-3366. doi: 10.1016/j.xphs.2021.06.028.
1201	Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
1202	#N/A
1203	In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
1204	Disposition, profiling and identification of emixustat and its metabolites in humans
1205	Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
1206	LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation
1207	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
1208	Clinical Pharmacokinetic Studies of Enzalutamide
1209	Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs
1210	Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports
1211	Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies Biomed Chromatogr. 2020 Sep;34(9):e4848. doi: 10.1002/bmc.4848.
1212	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
1213	Ergot alkaloid mycotoxins: physiological effects, metabolism and distribution of the residual toxin in mice Sci Rep. 2020 Jun 16;10(1):9714. doi: 10.1038/s41598-020-66358-2.
1214	In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes Drug Metab Dispos. 2020 Dec;48(12):1350-1363. doi: 10.1124/dmd.120.000171.
1215	Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects Drug Metab Dispos. 2013 Feb;41(2):445-56. doi: 10.1124/dmd.112.049551.
1216	PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics Pharmacogenet Genomics. 2017 Apr;27(4):164-167. doi: 10.1097/FPC.0000000000000270.
1217	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism Clin Pharmacol Ther. 2011 May;89(5):693-701. doi: 10.1038/clpt.2011.25.
1218	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
1219	Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram Drug Metab Dispos. 2001 Aug;29(8):1102-9.
1220	Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole Clin Pharmacokinet. 2001;40(6):411-26. doi: 10.2165/00003088-200140060-00003.
1221	The metabolism of estradiol; oral compared to intravenous administration J Steroid Biochem. 1985 Dec;23(6A):1065-70. doi: 10.1016/0022-4731(85)90068-8.
1222	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
1223	Development of a novel tandem mass spectrometry method for the quantification of eszopiclone without interference from 2-amino-5-chloropyridine and application in a pharmacokinetic study of rat J Pharm Biomed Anal. 2020 Sep 5;188:113363. doi: 10.1016/j.jpba.2020.113363.
1224	Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol Drug Metab Dispos. 2004 Nov;32(11):1299-303. doi: 10.1124/dmd.32.11..
1225	Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk Eur J Intern Med. 2017 Jul;42:54-60. doi: 10.1016/j.ejim.2017.05.019.
1226	Metabolism of 17 alpha-ethinylestradiol by human liver microsomes in vitro: aromatic hydroxylation and irreversible protein binding of metabolites J Clin Endocrinol Metab. 1974 Dec;39(6):1072-80. doi: 10.1210/jcem-39-6-1072.
1227	Chiral aspects of the human metabolism of ethosuximide Biopharm Drug Dispos. 2005 Sep;26(6):225-32. doi: 10.1002/bdd.454.
1228	The metabolism of ethosuximide Eur J Drug Metab Pharmacokinet. 1993 Oct-Dec;18(4):349-53. doi: 10.1007/BF03190184.
1229	Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction. Eur J Med Chem. 2021 Dec 15;226:113890. doi: 10.1016/j.ejmech.2021.113890.
1230	Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
1231	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
1232	Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man
1233	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
1234	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
1235	Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers
1236	Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
1237	Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561-74.
1238	Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients Ther Drug Monit. 2007 Oct;29(5):592-9. doi: 10.1097/FTD.0b013e3181570830.
1239	Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study Ther Drug Monit. 2015 Jun;37(3):296-303. doi: 10.1097/FTD.0000000000000191.
1240	LABEL:EXEMESTANE tablet
1241	Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica. 2000 Jan;30(1):71-80.
1242	Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers
1243	LABEL:INREBIC- fedratinib hydrochloride capsule
1244	Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults. Cancer Chemother Pharmacol. 2022 Oct;90(4):325-334. doi: 10.1007/s00280-022-04464-w.
1245	A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling Pharmaceutics. 2022 Jul 15;14(7):1474. doi: 10.3390/pharmaceutics14071474.
1246	U. S. FDA Label -Fenfluramine
1247	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A41B and 3A53 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
1248	Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl. J Addict Med. 2023 May 17. doi: 10.1097/ADM.0000000000001185.
1249	Predictors of the Rate of Illicit Fentanyl Metabolism in a Cohort of Pregnant Individuals. J Addict Med. 2023 Jan-Feb 01;17(1):85-88. doi: 10.1097/ADM.0000000000001043.
1250	Bupivacaine Metabolite Can Interfere with Norfentanyl Measurement by LC-MS/MS. J Appl Lab Med. 2022 Jun 30;7(4):854-862. doi: 10.1093/jalm/jfac009.
1251	Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron J Clin Pharmacol. 2019 Nov;59(11):1505-1518. doi: 10.1002/jcph.1438.
1252	LABEL:FESOTERODINE FUMARATE tablet, extended release
1253	Finasteride for hair loss: a review J Dermatolog Treat. 2022 Jun;33(4):1938-1946. doi: 10.1080/09546634.2021.1959506.
1254	LABEL:FINASTERIDE tablet
1255	DrugBank(Pharmacology-Metabolism):Finerenone
1256	Flibanserin therapy and CYP2C19 genotype.
1257	LABEL:DDYI- flibanserin tablet, film coated
1258	Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):460-5.
1259	Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica. 1999 Oct;29(10):973-86.
1260	Lack of interaction of buprenorphine with flunitrazepam metabolism
1261	DrugBank(Pharmacology-Metabolism):Fluoxetine hydrochloride
1262	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
1263	Simultaneous identification and quantitation of fluoxetine and its metabolite, norfluoxetine, in biological samples by GC-MS
1264	U. S. FDA Label -Fluprednisolone
1265	Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites
1266	DrugBank(Pharmacology-Metabolism):Fluticasone propionate
1267	Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32.
1268	Metabolism and transport of oxazaphosphorines and the clinical implications Drug Metab Rev. 2005;37(4):611-703. doi: 10.1080/03602530500364023.
1269	Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669.
1270	DrugBank(Pharmacology-Metabolism)Fostamatinib
1271	Esophageal bezoar due to karaya gum granules used as a laxative
1272	Incarceration of the medial collateral ligament in the intercondylar notch following proximal avulsion
1273	A simple and rapid infrared-assisted self enzymolysis extraction method for total flavonoid aglycones extraction from Scutellariae Radix and mechanism exploration
1274	Management of postoperative junctional ectopic tachycardia in pediatric patients: a survey of 30 centers in Germany, Austria, and Switzerland
1275	The metabolism and excretion of galantamine in rats, dogs, and humans Drug Metab Dispos. 2002 May;30(5):553-63. doi: 10.1124/dmd.30.5.553.
1276	Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid
1277	Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
1278	Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition Xenobiotica. 2006 Jan;36(1):29-39. doi: 10.1080/00498250500523253.
1279	An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. Cancer Chemother Pharmacol. 2021 Jan;87(1):43-52. doi: 10.1007/s00280-020-04191-0.
1280	The metabolism of gemfibrozil Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):11-4.
1281	Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557.
1282	Biodegradation of emerging organic pollutant gemfibrozil: Mechanism, kinetics and pathway modelling. Bioresour Technol. 2023 Apr;374:128749. doi: 10.1016/j.biortech.2023.128749.
1283	Metabolic Activation of Gemfibrozil Mediated by Cytochrome P450 Enzymes and Sulfotransferases. Chem Res Toxicol. 2022 Jul 18;35(7):1257-1266. doi: 10.1021/acs.chemrestox.2c00054.
1284	Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon
1285	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
1286	Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons
1287	Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human
1288	Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557-66.
1289	Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy
1290	The metabolism and disposition of GSK2140944 in healthy human subjects
1291	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
1292	Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended-release tablets
1293	Determination of 3-hydroxy-guanfacine in biological fluids by electron-capture gas-liquid chromatography
1294	Pharmacokinetics and metabolism of guanfacine in man: a review
1295	The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects
1296	NCI Thesaurus (NCIt): Halcinonide
1297	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
1298	DrugBank(Pharmacology-Metabolism):Haloperidol decanoate
1299	Update on hydrocodone metabolites in rats and dogs aided with a semi-automatic software for metabolite identification Mass-MetaSite
1300	Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.;
1301	The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects
1302	Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75.
1303	Understanding the pharmacokinetics of anxiolytic drugs
1304	The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation
1305	Pharmacokinetics and metabolism of NO-1886, a lipoprotein lipase-promoting agent, in cynomolgus monkey
1306	Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation
1307	Clinical drug interaction profile of idelalisib in healthy subjects
1308	2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity
1309	Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64.
1310	Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism
1311	Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
1312	In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1
1313	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
1314	Imipramine metabolites in blood of patients during therapy and after overdose
1315	Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine
1316	Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects. Drug Des Devel Ther. 2022 Nov 8;16:3865-3876. doi: 10.2147/DDDT.S387508.
1317	Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans
1318	Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine Eur J Pharmacol. 1994 Apr 21;256(2):185-91. doi: 10.1016/0014-2999(94)90244-5.
1319	Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol. 1997 Apr 25;53(8):1187-95.
1320	Involvement of CYP3A4 and MDR1 in altered metabolism and transport of indinavir in 1,25(OH)(2)D(3)-treated Caco-2 cells. Eur J Pharm Sci. 2023 Apr 1;183:106396. doi: 10.1016/j.ejps.2023.106396.
1321	In vitro metabolism of indiplon and an assessment of its drug interaction potential
1322	VMAT2 Inhibitors in Neuropsychiatric Disorders
1323	Biotransformation of the ipecac alkaloids cephaeline and emetine from ipecac syrup in rats Eur J Drug Metab Pharmacokinet. 2002 Jan-Mar;27(1):29-35. doi: 10.1007/BF03190402.
1324	Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos. 2000 Apr;28(4):423-33.
1325	Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):317-324. doi: 10.1007/s13318-021-00675-3.
1326	Structural insights into catalytical capability for CPT11 hydrolysis and substrate specificity of a novel marine microbial carboxylesterase, E93. Front Microbiol. 2023 Jan 11;13:1081094. doi: 10.3389/fmicb.2022.1081094.
1327	Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Cancer Chemother Pharmacol. 2021 Aug;88(2):247-258. doi: 10.1007/s00280-021-04255-9.
1328	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics Mycoses. 2021 Sep;64(9):1111-1116. doi: 10.1111/myc.13300.
1329	Pharmacokinetics of isosorbide mononitrate Am J Cardiol. 1992 Nov 27;70(17):61G-66G. doi: 10.1016/0002-9149(92)90028-w.
1330	Human biliary metabolites of isotretinoin: identification, quantification, synthesis, and biological activity Xenobiotica. 1990 Feb;20(2):193-207. doi: 10.3109/00498259009047155.
1331	Isotretinoin and its Metabolites Alter mRNA of Multiple Enzyme and Transporter Genes In Vitro, but Downregulation of Organic Anion Transporting Polypeptide Does Not Translate to the Clinic Drug Metab Dispos. 2022 Jul;50(7):1042-1052. doi: 10.1124/dmd.122.000882.
1332	The use of isotretinoin in acne Dermatoendocrinol. 2009 May;1(3):162-9. doi: 10.4161/derm.1.3.9364.
1333	The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline Chem Biol Interact. 2022 Oct 1;366:110123. doi: 10.1016/j.cbi.2022.110123.
1334	An evaluation of lumateperone tosylate for the treatment of schizophrenia
1335	Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos. 2004 Oct;32(10):1121-31.
1336	Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data Clin Pharmacol Ther. 2010 Oct;88(4):499-505. doi: 10.1038/clpt.2010.119.
1337	Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation. J Antimicrob Chemother. 2023 May 3;78(5):1219-1224. doi: 10.1093/jac/dkad072.
1338	Does metabolite matter? Defining target itraconazole and hydroxy-itraconazole serum concentrations for blastomycosis. Mycoses. 2023 May;66(5):412-419. doi: 10.1111/myc.13565.
1339	Influence of Gender, Body Mass Index, and Age on the Pharmacokinetics of Itraconazole in Healthy Subjects: Non-Compartmental Versus Compartmental Analysis. Front Pharmacol. 2022 Jun 15;13:796336. doi: 10.3389/fphar.2022.796336.
1340	Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography--tandem mass spectrometry J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):261-9. doi: 10.1016/s0378-4347(00)00275-9.
1341	PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics Pharmacogenet Genomics. 2017 Jan;27(1):39-42. doi: 10.1097/FPC.0000000000000246.
1342	Identification of the metabolites of ivermectin in humans Pharmacol Res Perspect. 2021 Feb;9(1):e00712. doi: 10.1002/prp2.712.
1343	PubChem : JNJ-54135419
1344	[Metabolism of lomerizine hydrochloride (KB-2796) in rats]
1345	The clinical toxicology of ketamine. Clin Toxicol (Phila). 2023 Jun;61(6):415-428. doi: 10.1080/15563650.2023.2212125.
1346	Pharmacokinetics of Ketamine Transfer Into Human Milk. J Clin Psychopharmacol. 2023 May 23. doi: 10.1097/JCP.0000000000001711.
1347	Chronic exposure to (2?R,6?R)-hydroxynorketamine induces developmental neurotoxicity in hESC-derived cerebral organoids. J Hazard Mater. 2023 Jul 5;453:131379. doi: 10.1016/j.jhazmat.2023.131379.
1348	Urinary diazepam metabolite distribution in a chronic pain population J Anal Toxicol. 2014 Apr;38(3):135-42. doi: 10.1093/jat/bku001.
1349	Revisiting the metabolism of ketoconazole using accurate mass Drug Metab Lett. 2009 Aug;3(3):191-8. doi: 10.2174/187231209789352085.
1350	Label:KLH-2109
1351	DrugBank : KRM-1648
1352	Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004 Nov-Dec;34(11-12):1013-23.
1353	Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration Eur J Drug Metab Pharmacokinet. 2012 Dec;37(4):241-8. doi: 10.1007/s13318-012-0093-x.
1354	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
1355	Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
1356	Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib Drug Metab Dispos. 2011 Jun;39(6):1022-30. doi: 10.1124/dmd.110.037531.
1357	Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure
1358	Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia. Curr Pharmacol Rep. 2022;8(6):418-426. doi: 10.1007/s40495-022-00297-6.
1359	Development, validation, and application of an LC-MS/MS method for the quantification of the novel antibiotic drug lefamulin (Xenleta?) and its main metabolite 2R-hydroxy lefamulin in human plasma. J Pharm Biomed Anal. 2021 Oct 25;205:114293. doi: 10.1016/j.jpba.2021.114293.
1360	The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
1361	Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women Drug Metab Pharmacokinet. 2011;26(5):458-64. doi: 10.2133/dmpk.dmpk-11-rg-007.
1362	N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
1363	The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
1364	[Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study]. Biomedica. 2012 Oct-Dec;32(4):570-7.
1365	The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders Headache. 2018 May;58(5):783-789. doi: 10.1111/head.13298.
1366	Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
1367	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
1368	Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
1369	#N/A
1370	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
1371	Identification of sulfonyl-loxoprofen as novel phase 2 conjugate in rat
1372	DrugBank : LS-248
1373	Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
1374	Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors
1375	In vitro metabolism of perospirone in rat, monkey and human liver microsomes
1376	Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan
1377	Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment
1378	Antimicrobial Resistance, Virulence Factor-Encoding Genes, and Biofilm-Forming Ability of Community-Associated Uropathogenic Escherichia coli in Western Saudi Arabia
1379	Meals, Microbiota and Mental Health in Children and Adolescents (MMM-Study): A protocol for an observational longitudinal case-control study
1380	Corrigendum to: Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition
1381	Transient and resident pathogens: Intra-facility genetic diversity of Listeria monocytogenes and Salmonella from food production environments
1382	IgG and IgM Immunohistochemistry in Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) Liver Explants
1383	In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
1384	A prospective longitudinal study of growth in twin gestations compared with growth in singleton pregnancies. I. The fetal head J Ultrasound Med. 1991 Aug;10(8):439-43. doi: 10.7863/jum.1991.10.8.439.
1385	Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13.
1386	Meperidine and normeperidine levels following meperidine administration during labor. I. Mother
1387	Effects of ethinyl estradiol on pharmacokinetics of meperidine and pentobarbital in the rat
1388	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
1389	Metamizole (Dipyrone) and the Liver: A Review of the Literature J Clin Pharmacol. 2019 Nov;59(11):1433-1442. doi: 10.1002/jcph.1512.
1390	Clinical pharmacokinetics of dipyrone and its metabolites Clin Pharmacokinet. 1995 Mar;28(3):216-34. doi: 10.2165/00003088-199528030-00004.
1391	Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
1392	Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies
1393	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
1394	Disposition and metabolism of metronidazole in patients with liver failure
1395	Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation
1396	Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms
1397	Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions
1398	The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
1399	Midostaurin: an emerging treatment for acute myeloid leukemia patients
1400	Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth
1401	Respirator performance terminology
1402	PAT Program report: background and current status. Proficiency Analytical Testing
1403	Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms
1404	FDA:Mirvetuximab soravtansine
1405	DrugBank(Pharmacology-Metabolism):Modafinil
1406	In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
1407	Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients
1408	Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
1409	Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma
1410	DrugBank(Pharmacology-Metabolism):Adagrasib
1411	DrugBank(Pharmacology-Metabolism):Mycophenolate mofetil
1412	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
1413	Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil J Cardiovasc Pharmacol. 1991 Dec;18(6):918-25. doi: 10.1097/00005344-199112000-00020.
1414	LABEL:Nalmefene
1415	Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects
1416	Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus
1417	DrugBank(Pharmacology-Metabolism):Nefazodone
1418	Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997 Oct;33(4):260-75.
1419	Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19 Drug Metab Dispos. 2004 Dec;32(12):1462-7. doi: 10.1124/dmd.104.001743.
1420	Nestorone? as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies
1421	Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
1422	Disposition and biotransformation of the antiretroviral drug nevirapine in humans Drug Metab Dispos. 1999 Aug;27(8):895-901.
1423	Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions J Antimicrob Chemother. 2014 Feb;69(2):476-82. doi: 10.1093/jac/dkt359.
1424	Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. Biochem Pharmacol. 2022 Oct;204:115243. doi: 10.1016/j.bcp.2022.115243.
1425	U. S. FDA Label -Nevirapine
1426	CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers Pharmacogenomics J. 2004;4(1):34-9. doi: 10.1038/sj.tpj.6500218.
1427	Pharmacokinetics and metabolism of nifedipine Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. doi: 10.1161/01.hyp.5.4_pt_2.ii18.
1428	The first pass metabolism of nifedipine in man Br J Clin Pharmacol. 1984 Dec;18(6):951-4. doi: 10.1111/j.1365-2125.1984.tb02569.x.
1429	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
1430	NORMAN Suspect List Exchange:Nimodipine
1431	Metabolic pro?ling of tyrosine kinase inhibitor nintedanib using metabolomics J Pharm Biomed Anal. 2020 Feb 20;180:113045. doi: 10.1016/j.jpba.2019.113045.
1432	Clinical pharmacokinetics of nisoldipine coat-core Clin Pharmacokinet. 1998 Sep;35(3):191-208. doi: 10.2165/00003088-199835030-00003.
1433	U. S. FDA Label -Nisoldipine
1434	Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro J Steroid Biochem Mol Biol. 1991 Apr;38(4):497-503. doi: 10.1016/0960-0760(91)90338-6.
1435	Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes Clin Pharmacol Ther. 1998 Oct;64(4):384-90. doi: 10.1016/S0009-9236(98)90069-8.
1436	Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation
1437	Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44.
1438	In vitro metabolism of olaparib in liver microsomes by liquid chromatography/electrospray ionization high-resolution mass spectrometry Rapid Commun Mass Spectrom. 2020 Feb 15;34(3):e8575. doi: 10.1002/rcm.8575.
1439	Identification of novel ondansetron metabolites using LC/MS(n) and NMR J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 15;1095:138-141. doi: 10.1016/j.jchromb.2018.07.013.
1440	Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults
1441	In Vitro Metabolism of Oprozomib, an Oral Proteasome Inhibitor: Role of Epoxide Hydrolases and Cytochrome P450s
1442	Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm Drug Dispos. 2003 Mar;24(2):87-94.
1443	Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203.
1444	Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Invest New Drugs. 2023 Feb;41(1):122-133. doi: 10.1007/s10637-023-01328-9.
1445	Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study. Front Pharmacol. 2022 Jul 22;13:928983. doi: 10.3389/fphar.2022.928983.
1446	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
1447	Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging. 1995 Mar;6(3):243-62. doi: 10.2165/00002512-199506030-00007.
1448	Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica. 2007 Jan;37(1):59-73.
1449	Metabolism and Disposition of Prescription Opioids: A Review
1450	Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clin Pharmacokinet. 2023 May 10. doi: 10.1007/s40262-023-01255-1.
1451	Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J. 2022 Feb;22(1):25-32. doi: 10.1038/s41397-021-00253-5.
1452	DrugBank(Pharmacology-Metabolism)Oxycodone hydrochloride
1453	[International council of nurses: the international voice of the nursing profession] Bol Oficina Sanit Panam. 1979 Aug;87(2):152-5.
1454	Update: influenza activity--United States MMWR Morb Mortal Wkly Rep. 1986 Mar 14;35(10):166-7.
1455	In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites J Pharm Biomed Anal. 2018 Aug 5;157:59-74. doi: 10.1016/j.jpba.2018.05.008.
1456	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
1457	S73 \| METXBIODB \| metabolite Reaction Database from BioTransformer \| DOI:10.5281/zenodo.4056560
1458	Metabolism of systematically given corticosteroids Dermatologica. 1975;151(3):129-34. doi: 10.1159/000251325.
1459	Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human Drug Metab Dispos. 2002 Sep;30(9):1013-21. doi: 10.1124/dmd.30.9.1013.
1460	Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
1461	Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
1462	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642.
1463	Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A
1464	Anti-Parkinson's disease drugs and pharmacogenetic considerations Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):859-74. doi: 10.1517/17425255.2013.789018.
1465	Pharmacokinetics, Metabolite Measurement, and Biomarker Identification of Dermal Exposure to Permethrin Using Accelerator Mass Spectrometry. Toxicol Sci. 2021 Aug 30;183(1):49-59. doi: 10.1093/toxsci/kfab082.
1466	Validation of enantioseparation and quantitation of an active metabolite of abrocitinib in human plasma
1467	DrugBank(Pharmacology-Metabolism)Phenacetin
1468	Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review J Psychiatry Neurosci. 1992 Nov;17(5):206-14.
1469	DrugBank(Pharmacology-Metabolism)Phenobarbital
1470	Determination of phentermine, N-hydroxyphentermine and mephentermine in urine using dilute and shoot liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep 1;1029-1030:22-27. doi: 10.1016/j.jchromb.2016.06.045.
1471	The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites Drug Metab Dispos. 2020 Nov;48(11):1113-1120. doi: 10.1124/dmd.120.000188.
1472	LABEL:IMOZIDE tablet
1473	Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction J Pharm Biomed Anal. 1996 Feb;14(4):465-73. doi: 10.1016/0731-7085(95)01665-1.
1474	Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans
1475	Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41.
1476	FDA Center for Drug Evaluation and Research: Pitolisant Non-clinical Review(s)
1477	Wakix, INN-Pitolisant - European Medicines Agency - Europa EU
1478	Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. doi: 10.1007/s00280-012-2040-6.
1479	Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice Xenobiotica. 2017 Oct;47(10):844-848. doi: 10.1080/00498254.2016.1247218.
1480	Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
1481	Absorption, metabolism, and excretion of [(14)C]ponatinib after a single oral dose in humans Cancer Chemother Pharmacol. 2017 Mar;79(3):507-518. doi: 10.1007/s00280-017-3240-x.
1482	In vitro metabolites characterization of ponatinib in human liver microsomes using ultra-high performance liquid chromatography combined with Q-Exactive-Orbitrap tandem mass spectrometry Biomed Chromatogr. 2020 Jun;34(6):e4819. doi: 10.1002/bmc.4819.
1483	In vitro metabolism and inhibitory effects of pranlukast in human liver microsomes
1484	Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom. 2007;21(2):169-79. doi: 10.1002/rcm.2813.
1485	Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions. Pharmacol Rep. 2023 Apr;75(2):423-441. doi: 10.1007/s43440-023-00447-7.
1486	Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2023 Jan;12(1):21-29. doi: 10.1002/cpdd.1172.
1487	Prazepam metabolism by man Clin Pharmacol Ther. 1970 Nov-Dec;11(6):890-7. doi: 10.1002/cpt1970116890.
1488	Prazepam metabolites in dog urine J Pharm Sci. 1970 Mar;59(3):322-5. doi: 10.1002/jps.2600590309.
1489	In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel Pharmacol Res Perspect. 2020 Aug;8(4):e00618. doi: 10.1002/prp2.618.
1490	Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS J Mass Spectrom. 2015 Mar;50(3):633-42. doi: 10.1002/jms.3571.
1491	FDA:Pretomanid
1492	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
1493	Progesterone Metabolites Produced by Cytochrome P450 3A Modulate Uterine Contractility in a Murine Model Reprod Sci. 2015 Dec;22(12):1577-86. doi: 10.1177/1933719115589414.
1494	Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography-mass spectrometry
1495	Single dose pharmacokinetics of proguanil and its metabolites in pregnancy
1496	The muscarinic receptor antagonist propiverine exhibits (1)-adrenoceptor antagonism in human prostate and porcine trigonum
1497	FDA label:Belzutifan
1498	Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance
1499	In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
1500	Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009 Feb;37(2):254-8.
1501	CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever
1502	Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment
1503	Effects of Plasmodium falciparum infection on the pharmacokinetics of quinine and its metabolites in pregnant and non-pregnant Sudanese women
1504	Rapid quantification of quinine and its major metabolite (3S)-3-hydroxyquinine in diluted urine by UPLC-MS/MS
1505	Netupitant PET imaging and ADME studies in humans
1506	Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction
1507	Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers
1508	Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions
1509	Fatal, Intentional Overdose of Ranolazine: Post-Mortem Distribution of Parent Drug and its Major Metabolite
1510	Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats
1511	Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man
1512	Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects
1513	Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS
1514	Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
1515	Bioanalytical method for in vitro metabolism study of repaglinide using 96-blade thin-film solid-phase microextraction and LC-MS/MS
1516	Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80.
1517	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
1518	Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study
1519	A Single-center, Open-label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N-oxide in Healthy Chinese and Caucasian Volunteers
1520	Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects
1521	Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005 Jan;28(1):124-9.
1522	Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis
1523	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemother Pharmacol. 2021 Aug;88(2):259-270. doi: 10.1007/s00280-021-04278-2.
1524	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):117-24.
1525	Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787.
1526	The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers
1527	Determination of salmeterol, -hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS. Biomed Chromatogr. 2021 Aug;35(8):e5114. doi: 10.1002/bmc.5114.
1528	Pharmacokinetics of salmeterol and its main metabolite -hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. Drug Test Anal. 2021 Apr;13(4):747-761. doi: 10.1002/dta.2978.
1529	The salmeterol anomaly and the need for a urine threshold. Drug Test Anal. 2022 Jun;14(6):997-1003. doi: 10.1002/dta.2810.
1530	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
1531	DrugBank(Pharmacology-Metabolism)Saquinavir mesylate
1532	A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers
1533	Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples
1534	Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis Drugs. 1996 Apr;51(4):621-38. doi: 10.2165/00003495-199651040-00007.
1535	SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13.
1536	Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism
1537	Sertindole : a review of its use in schizophrenia
1538	DrugBank(Pharmacology-Metabolism)Sertraline hydrochloride
1539	Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
1540	Pharmacogenetic Testing and Therapeutic Drug Monitoring Of Sertraline at a Residential Treatment Center for Children and Adolescents: A Pilot Study. Innov Pharm. 2022 Dec 26;13(4):10.24926/iip.v13i4.5035. doi: 10.24926/iip.v13i4.5035.
1541	Sertraline. 2022 May 15. Drugs and Lactation Database (LactMed?) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006C.
1542	Neonicotinoids and pharmaceuticals in hair of the Red fox (Vulpes vulpes) from the Cavallino-Treporti peninsula, Italy. Environ Res. 2023 Jul 1;228:115837. doi: 10.1016/j.envres.2023.115837.
1543	Metabolic analysis of the illegal analogues of anti-obesity drugs using LC-Q-TOF-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jan 15;1163:122502. doi: 10.1016/j.jchromb.2020.122502.
1544	In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000 Apr;28(4):392-7.
1545	Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x.
1546	In vivo metabolic investigation of silodosin using UHPLC-QTOF-MS/MS and in silico toxicological screening of its metabolites J Mass Spectrom. 2016 Oct;51(10):867-882. doi: 10.1002/jms.3795.
1547	Simvastatin Tablet, Film-Coated
1548	FDA Approved Drug Products: RAPAMUNE (sirolimus) for oral use
1549	Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
1550	Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Sotorasib in Rats and Dogs: Interspecies Differences in Absorption, Protein Conjugation and Metabolism
1551	Absorption, metabolism and excretion of [(14)C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate
1552	Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity
1553	Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996 Jan;82(1):167-72.
1554	Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
1555	Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
1556	Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos. 2001 May;29(5):701-11.
1557	Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans
1558	Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
1559	CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens Forensic Sci Int. 2020 Jul;312:110307. doi: 10.1016/j.forsciint.2020.110307.
1560	In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans Xenobiotica. 2016 Oct;46(10):882-95. doi: 10.3109/00498254.2015.1129565.
1561	Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics Drug Metab Pharmacokinet. 2007 Oct;22(5):328-35. doi: 10.2133/dmpk.22.328.
1562	Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats Pharmaceutics. 2019 Jul 20;11(7):354. doi: 10.3390/pharmaceutics11070354.
1563	PharmGKB:Tamoxifen citrate
1564	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
1565	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
1566	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
1567	Identification and biological activity of tamoxifen metabolites in human serum Biochem Pharmacol. 1983 Jul 1;32(13):2045-52. doi: 10.1016/0006-2952(83)90425-2.
1568	PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.
1569	The tamoxifen dilemma. Carcinogenesis. 1999 Jul;20(7):1153-60.
1570	Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans Drug Metab Dispos. 1998 Mar;26(3):240-5.
1571	Absorption, metabolism and excretion of tamsulosin hydrochloride in man Xenobiotica. 1996 Jun;26(6):637-45. doi: 10.3109/00498259609046739.
1572	Simultaneous determination of tandospirone and its active metabolite, 1-[2-pyrimidyl]-piperazine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study
1573	Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment
1574	Biotransformation of terodiline. III. Opposed stereoselectivity in the benzylic and aromatic hydroxylations in rat liver microsomes
1575	NCIVEK- telaprevir tablet, film coated Vertex Pharmaceuticals Incorporated
1576	Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915-34.
1577	Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
1578	Pharmacokinetics and metabolism of temazepam in man and several animal species Br J Clin Pharmacol. 1979;8(1):23S-29S. doi: 10.1111/j.1365-2125.1979.tb00451.x.
1579	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
1580	American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD. (2010), p. 2511
1581	LABEL:BSRELA- tenapanor hydrochloride tablet
1582	DrugBank(Pharmacology-Metabolism)Teniposide
1583	PubChem:Teniposide
1584	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
1585	A multi-residue chiral liquid chromatography coupled with tandem mass spectrometry method for analysis of antifungal agents and their metabolites in aqueous environmental matrices. Anal Methods. 2021 Jun 14;13(22):2466-2477. doi: 10.1039/d1ay00556a.
1586	Analysis of hydroxylated and N-dealkylated metabolites of terfenadine in microsomal incubates by liquid chromatography--mass spectrometry
1587	Don't stay home without it
1588	LABEL:TIAGABINE HYDROCHLORIDE tablet, film coated
1589	Metabolism of ticagrelor in patients with acute coronary syndromes
1590	DrugBank(Pharmacology-Metabolism):Ticlopidine
1591	Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine
1592	Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
1593	Quantitative determination of pentazocine in plasma and of pentazocine and metabolites in urine
1594	Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8.
1595	Complexity of vitamin E metabolism
1596	Toremifene in postmenopausal breast cancer. Efficacy, safety and cost Drugs Aging. 1997 Oct;11(4):261-70. doi: 10.2165/00002512-199711040-00002.
1597	Trends in Tramadol: Pharmacology, Metabolism, and Misuse Anesth Analg. 2017 Jan;124(1):44-51. doi: 10.1213/ANE.0000000000001683.
1598	Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. J Pharm Biomed Anal. 2021 Sep 5;203:114171. doi: 10.1016/j.jpba.2021.114171.
1599	Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats Int J Neuropsychopharmacol. 1999 Mar;2(1):17-23. doi: 10.1017/S1461145799001303.
1600	Retinoic acid metabolism and mechanism of action: a review
1601	A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration J Clin Pharmacol. 2000 Jul;40(7):770-80. doi: 10.1177/00912700022009413.
1602	Metabolic fate of a synthetic corticosteroid (triamcinolone) in the dog J Biol Chem. 1961 Apr;236:1038-42.
1603	Triazolam disposition Clin Pharmacol Ther. 1981 Jan;29(1):81-93. doi: 10.1038/clpt.1981.14.
1604	Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos. 2001 Jan;29(1):70-5.
1605	Total determination of triclabendazole and its metabolites in bovine tissues using liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:54-59. doi: 10.1016/j.jchromb.2019.01.021.
1606	Egaten FDA label
1607	LABEL:KLIEF- trifarotene cream
1608	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
1609	In Vitro Hepatic Oxidative Biotransformation of Trimethoprim Drug Metab Dispos. 2015 Sep;43(9):1372-80. doi: 10.1124/dmd.115.065193.
1610	Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
1611	Intestinal motility and its disorders Scand J Urol Nephrol Suppl. 1992;142:18-21.
1612	Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione J Pharmacol Exp Ther. 1983 Mar;224(3):685-91.
1613	Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans
1614	Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos. 2005 Jun;33(6):866-72.
1615	Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity Drug Metab Rev. 2021 Aug;53(3):375-383. doi: 10.1080/03602532.2021.1917599.
1616	LABEL:INVOQ- upadacitinib tablet, extended release
1617	Pharmacokinetics of vandetanib: three phase I studies in healthy subjects Clin Ther. 2012 Jan;34(1):221-37. doi: 10.1016/j.clinthera.2011.11.011.
1618	Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro Chem Biol Interact. 2021 Dec 1;350:109700. doi: 10.1016/j.cbi.2021.109700.
1619	Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation Int J Mol Sci. 2019 Jul 10;20(14):3392. doi: 10.3390/ijms20143392.
1620	Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events Int J Impot Res. 2004 Jun;16 Suppl 1:S34-7. doi: 10.1038/sj.ijir.3901213.
1621	High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma J Chromatogr A. 2011 Nov 4;1218(44):7996-8001. doi: 10.1016/j.chroma.2011.09.001.
1622	A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Oct 1;1208:123399. doi: 10.1016/j.jchromb.2022.123399.
1623	Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state Biomed Chromatogr. 2016 Aug;30(8):1234-9. doi: 10.1002/bmc.3672.
1624	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
1625	Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996 Feb;41(2):149-56.
1626	Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers
1627	Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays
1628	DETERMINATION OF VENLAFAXINE, VILAZODONE AND THEIR MAIN ACTIVE METABOLITES IN HUMAN SERUM BY HPLC-DAD AND HPLC-MS
1629	Pharmacokinetics and metabolism of vinblastine in humans
1630	Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006 Aug;34(8):1317-27.
1631	A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
1632	Absorption, distribution, metabolism, and excretion of [1?C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening
1633	Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor
1634	Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
1635	Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist
1636	The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
1637	Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
1638	FDA Approved Drug Products:Oxbryta (voxelotor) tablets
1639	Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.
1640	BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification
1641	Metabolism and excretion of zafirlukast in dogs, rats, and mice
1642	Variability of Zaleplon 5-Oxidase Activity in Mice and Humans, and Inhibition by Raloxifene
1643	Separation and identification of zaleplon metabolites in human urine using capillary electrophoresis with laser-induced fluorescence detection and liquid chromatography-mass spectrometry
1644	Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis
1645	Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
1646	[Limits of jaw orthopedic treatment]
1647	Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm. 1997 Dec;25(6):647-72.
1648	Zolpidem urine excretion profiles and cross-reactivity with ELISA(?) kits in subjects using Zolpidem or Ambien(?) CR as a prescription sleep aid
1649	Qualitative analysis of 7- and 8-hydroxyzolpidem and discovery of novel zolpidem metabolites in postmortem urine using liquid chromatography-tandem mass spectrometry
1650	Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety
1651	Distribution of zopiclone and main metabolites in hair following a single dose
1652	Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.